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Polycystic Ovary Syndrome (PCOS) is a multifaceted hormonal disorder which affects 5-15% 
of reproductive-aged women worldwide. While classically recognised as an ovarian disorder, 
PCOS is associated with a variety of reproductive, endocrine and metabolic features including 
ovulatory dysfunction, infertility, hyperandrogenism, obesity, and an increased risk of type 2 
diabetes mellitus and cardiovascular disease.  The most consistently present of these is 
hyperandrogenism – supraphysiological levels of androgens such as testosterone (T) and 
dihydrotestosterone (DHT). Typically thought of as male steroid hormones, androgens have 
been shown to play important role in the maintenance of normal female reproductive 
function. Despite the high prevalence of hyperandrogenism amongst patients, the role of 
androgens in the etiology and pathogenesis of PCOS has yet to be determined. The aim of this 
work was to unravel the association between excess androgen exposure and the 
development and advancement of the PCOS phenotype in mouse model of androgen-induced 
PCOS. 
The first study contained within this work (Chapter Three) provides the first comprehensive 
characterization of a range of reproductive, endocrine and metabolic traits associated with 
PCOS in four distinct mouse models: a model of prenatal androgenisation utilising the potent 
non-aromatizable androgen DHT administered during days 16-18 of gestation, and three 
diverse models of postnatal androgen exposure employing a long-term treatment with either 
DHT, the proandrogen dehydroepiandrosterone (DHEA), or letrozole (an aromatase inhibitor) 
for 90 days beginning at 3 weeks of age. Prenatal androgenisation produced some 
reproductive and endocrine traits, but failed to induce the metabolic abnormalities seen in 
PCOS. DHEA treatment did not reproduce any features associated with PCOS while treatment 
with letrozole produced few PCOS-like characteristics and some aberrant changes not typical 
of the syndrome. Additionally, letrozole treatment did not reproduce any metabolic 
attributes of PCOS. On the other hand, postnatal exposure to excess androgen, by way of DHT 
treatment, produced a breadth of reproductive, endocrine and metabolic traits that mimic 
those seen in human PCOS. This study revealed that a treatment regime of long-term 
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postnatal exposure to DHT reproduced the strongest PCOS-like phenotype in our mice and 
provides a robust animal model in which to study the pathogenesis of PCOS.  
The second study (Chapter Four) aimed to explore the involvement of genomic androgen 
receptor (AR)-mediated actions in the development of these PCOS traits. As a prenatally 
androgenised mouse model of PCOS had previously been reported to exhibit impaired 
neuroendocrine hypothalamic feedback of the hypothalamic-pituitary-gonadal (HPG) axis, we 
took this opportunity to utilise mice from our own prenatal model to investigate the 
neuroendocrine regulation of the HPG axis in PCOS in addition to the effects of AR inactivation 
on the PCOS phenotype. PCOS was induced in wild-type (WT) and androgen receptor 
knockout (ARKO) mice using DHT administered on days 16-18 of gestation. A subset of these 
mice were also exposed to 17β-estradiol for 7 days prior to collection, via a subdermal 
implant, to investigate the impaired estradiol negative feedback on the hypothalamus. WT 
mice with DHT-induced PCOS displayed several reproductive abnormalities including aberrant 
cycling and ovulatory dysfunction in addition to adipocyte hypertrophy and hepatic steatosis. 
However, diestrus serum luteinising hormone and follicle stimulating hormone, and estradiol-
induced negative feedback as well as hypothalamic expression of several neuropeptides were 
unaffected by DHT treatment in WT mice. Mice both homozygous and heterozygous for the 
global inactivation of the AR (ARKO), did not display any PCOS traits when exposed to excess 
androgens during prenatal life. This study showed the importance of AR signalling in the 
development of PCOS and revealed that even AR haplosufficiency is adequate to prevent 
induction of PCOS by prenatal hyperandrogenism. 
Finally, the third study (Chapter Five) aimed to shed further light on the AR-mediated 
androgen actions in PCOS with a focus on identifying the tissue-specific targets of these 
actions. Employing our postnatal model of PCOS induction, this study investigates the effects 
of: 1) global loss of AR signalling (ARKO), 2) neuronal knockout (NeurARKO) and 3) granulosa 
cell-specific AR inactivation (GCARKO) on the development of the PCOS phenotype induced 
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by exposure to exogenous DHT. As in our prenatal model, ARKO mice were fully protected 
from all DHT-induced features of PCOS. Neuron-specific AR signaling was required for the 
development of a variety of reproductive and metabolic traits including classic polycystic 
ovaries, dysfunctional ovulation, obesity and dyslipidemia. In contrast, loss of AR signalling in 
granulosa cells did not impede the pathogenesis of PCOS-like features in GCARKO mice. To 
further examine the role of extra-ovarian AR signalling in PCOS, reciprocal ovary transplants 
were carried out in WT and ARKO mice. Results from ARKO hosts with transplanted WT 
ovaries revealed that excess androgen exposure requires functional extra-ovarian, and not 
intra-ovarian, AR signalling in order to produce features of PCOS. This study provides strong 
evidence that neuroendocrine genomic AR signaling is an important mediator in the 
development of PCOS. 
The studies contained within this thesis are the first to provide a comprehensive analysis of a 
mouse model of PCOS encompassing a breadth of reproductive, endocrine and metabolic 
features. This work has identified the optimal model in which to study this complex, 
multifactorial condition which affects a significant number of women worldwide. 
Additionally, our results have shown that the effects of androgens on the pathogenesis of 
PCOS are mediated via the androgen receptor in a dose-dependent manner such that two 
functional copies are required for DHT to reproduce features of PCOS in the mouse. Finally, 
in a crucial study to investigate the locus of androgen actions we have revealed the previously 
overlooked importance of extra-ovarian neuroendocrine androgen action in the origins and 
progression of PCOS, despite it being thought of primarily as an ovarian disorder. Overall, 
these studies have provided valuable insights into both the role of androgens in Polycystic 
Ovary Syndrome and potential new targets for the development of mechanism-based 
treatments of this disorder. 
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1.1 Female Reproductive Physiology Overview 
The following sub-sections will focus on the physiology of reproduction in female humans 
(and other higher primates), unless otherwise specified. 
1.1.1 The Hypothalamic-Pituitary-Gonadal Axis 
The Hypothalamic-Pituitary-Gondal (HPG) axis is the primary driving force in the control of 
reproduction in both females and males. As the name suggests, the HPG axis is comprised of 
the hypothalamus, adenohypophysis (or anterior pituitary) and the gonads – ovaries in the 
female and testes in the male. Put simply, the HPG axis requires that these three organs work 
in harmony with each other to regulate and maintain the hormonal milieu required for 
optimal reproductive function (Figure 1.1).  
1.1.2 Hormonal Control of Reproduction 
1.1.2.1 Gonadotropin-Releasing Hormone 
Gonadotropin-releasing hormone (GnRH) is the primary signal of this hormonal cascade. 
GnRH neurons are predominantly located in the medial septum and pre-optic area (POA) of 
the hypothalamus, but also have a scattered distribution that extends into the medial basal 
hypothalamus in humans. GnRH is released from nerve terminals at the external zone of the 
median eminence into the hypophyseal portal circulation. This is the blood circulation 
between the hypothalamus and the anterior pituitary gland. When GnRH is released into this 
circulation, it acts on gonadotropic cells in the anterior pituitary, and stimulates them to 
release luteinising hormone (LH) and follicle stimulating hormone (FSH) into the bloodstream 
(1). GnRH is released in a pulsatile manner and it is both the frequency of these pulses and 
their amplitude (or concentration) that determines the appropriate release of LH and FSH 
from the pituitary (2). 
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Figure 1.1 The Hypothalamic-Pituitary-Gondal (HPG) Axis 
 
 
Schematic of the Hypothalamic-Pituitary-Gondal (HPG) axis, showing the relationship between the 
hypothalamic hormone GnRH, the gonadotrophic hormones LH and FSH and the ovarian steroids 
progesterone and estrogens. Reproduced from Kong et al (3).  
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1.1.2.2 Follicle Stimulating Hormone 
Follicle stimulating hormone (FSH) is synthesized in and released from the anterior pituitary 
by cells known as the gonadotrophs. These cells have GnRH receptors on their surface 
allowing them to respond to GnRH and activate the proteins required for FSH synthesis (4). 
Interestingly, these cells also express insulin receptors which may cause them to be 
overstimulated by the excess insulin seen in hyperinsulinemia (5,6).  FSH, in turn, acts on the 
ovary to encourage the production of ovarian steroids. More specifically, FSH stimulates the 
granulosa cells within the follicle to convert androgens to estrogens via the activity of the 
enzyme aromatase (2,7).  
FSH acts directly to stimulate the recruitment of quiescent follicles into a pool of growing 
follicles, from which the dominant one will be chosen for ovulation. It seems that FSH plays a 
major role in ‘saving’ these growing follicles from undergoing a programmed, apoptotic death 
(8,9). When these growing follicles reach the large antral stage and begin to produce 
estrogens, namely estradiol, FSH levels will drop as a result of the negative feedback of 
estradiol on the release of GnRH from the hypothalamus. This results in the smaller growing 
follicles undergoing apoptosis as they lack sufficient sensitivity to survive in low-FSH 
conditions (9,10). 
1.1.2.3 Luteinizing Hormone 
Luteinizing Hormone (LH) is synthesized in and released from the same cells responsible for 
FSH secretion – the gonadotrophs of the anterior pituitary (11). The primary role of LH is to 
trigger ovulation of the dominant follicle by way of the LH surge – the phenomenon in which 
the normal state of estrogen negative feedback on the hypothalamus and pituitary is 
switched to become positive feedback, hence triggering a sudden surge of LH to be released 
(2). When the growing follicles are mature and in the final stage before ovulation, the 
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dominant follicle(s) begin to express LH receptors within the granulosa cells to prepare to 
receive the LH surge needed for ovulation to occur (11).  
Although the exact mechanism behind the LH surge remains to be fully understood, two 
leading theories have emerged. One states that once the follicle has fully matured, a rise in 
17a-hydroxyprogesterone inhibits the production of estrogens which leads to a decrease in 
the estrogen-mediated negative feedback of GnRH in the hypothalamus which, in turn, 
stimulates the release of LH from the anterior pituitary (12). Although, a more recent study 
has shown that the elimination of neuroestradiol significantly attenuates LH surges in female 
monkeys, showing that the production of estrogens may need to be maintained in order for 
the LH surge to occur (13). The other is that the LH surge occurs as a result of a positive 
feedback effect of estrogens which must first reach an unknown ‘threshold’ in order to switch 
from its normal negative feedback on GnRH to this positive feedback and cause the surge of 
LH to be released (2,14).  
LH also has a role in the steady conversion of the residual follicle structure into the corpus 
luteum (CL) (15). This process, known as luteinisation, is accelerated by the LH surge. The CL 
is vital to establish a pregnancy due to its ability to produce progesterone (P4) – the critical 
hormone in the development and maintenance of the placenta during pregnancy. 
Additionally, the CL and it’s P4 secretion play a crucial role in preparing the uterine 
endometrium for embryo implantation. Finally, LH has been shown to have a role in 
maintaining the theca cells of the follicle (15) – the cells responsible for the production of 
androgens as precursors for the biosynthesis of estrogens. 
1.1.2.4 Feedback Control of the HPG Axis 
In order to maintain normal levels and secretion patterns of the gonadotropins, and in fact 
the entire HPG axis, a tightly regulated system of negative and positive feedback is employed 
to ensure that optimal fertility is upheld. This system is complex and involves both the 
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gonadotropins themselves to regulate their own production but also the involvement of the 
ovarian steroids that they are charged with stimulating the production of, as well as other 
ovarian factors.  
Inhibins and activins are closely related protein complexes found in both males and females. 
In females, they are predominantly produced by the ovary but can also be synthesised by the 
pituitary gland and the placenta as well as other organs. They have opposing roles in the 
regulation of FSH. Inhibins, whom themselves are positively regulated by FSH, act to suppress 
the secretion of FSH at the level of the pituitary (16,17). It is inhibin B, produced by the 
granulosa cells, that provides the negative feedback regulation of FSH and is the dominant 
form produced during the early and mid-follicular phases of the cycle (18). In the later 
follicular and luteal phases, LH receptor action causes the dominant follicle to switch to 
mostly inhibin A production. Conversely, activins feedback to the pituitary to encourage the 
production of FSH (19). Also in play is follistatin, a globally expressed activin-binding protein. 
While bound to follistatin activin action is ablated, allowing inhibin to suppress FSH secretion 
(19). In addition to inhibins and activin, progesterone also plays a role in regulating the actions 
of the HPG axis. Progesterone is able to directly affect the release of GnRH from the 
hypothalamus, providing negative feedback and acting to inhibit its secretion (20,21). 
Estrogens participate in a complicated system of both negative and positive feedback on the 
hypothalamus. For the most part estrogens, estradiol in particular, feed back to the 
hypothalamus to inhibit the release of GnRH and the subsequent release of LH (21). By 
keeping levels of LH relatively low only a few antral follicles develop and eventually only one 
will be chosen for ovulation. However, just before ovulation, by some as yet unknown 
mechanism – although most likely as a result of estradiol reaching an unidentified threshold 
level, estradiol suddenly flips to positive feedback and encourages a significant release of 
GnRH which in turn triggers the massive release of LH known as the ‘LH surge’ required for 
ovulation to occur (21). 
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1.1.3 Menstrual vs Estrous Cycles 
Menstruation and the menstrual cycle are generally considered to be confined to female 
primates, such as humans and other higher primates (22) while most other female mammals 
experience estrous cycles. Differing between these two forms of reproductive cycle is 
treatment of the endometrial lining in a cycle in which pregnancy does not occur. While there 
are always exceptions within the animal kingdom, generally, estrous cycles result in the 
reabsorption of the endometrium while the menses phase of the menstrual cycle involves the 
shedding of the endometrium. This occurs overtly in humans and many non-human primates 
such as chimpanzees and baboons (when bleeding occurs through the vagina) as opposed to 
covertly such as the resorption seen in the majority of animals experiencing estrous cycling 
(22,23). 
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Figure 1.2 Human Menstrual Cycle 
 
Hormonal profile of the human menstrual cycle with concurrent events occurring in the ovary and 
uterus. Taken from: https://www.quora.com/Is-the-menstrual-cycle-present-in-all-mammals 
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1.1.3.1 Human Menstrual Cycle 
Menstrual cycles in human females are essential for normal, regular reproductive function 
and pregnancy. The onset of menstrual cycles, menarche, occurs most commonly between 
the ages of twelve and fourteen (21). The menstrual cycle begins on the first day of menses 
(referred to as “period”) and subsequently ends the day before menses begins again (Figure 
1.2). In adults, the typical cycle length is 24 to 34 days with the average being 28 days 
(20,21,24).  
The menstrual cycle is highly regulated by hormonal changes with different phases of the 
cycle relying on different ovarian steroid hormones or gonadotropins for proper function. 
Each cycle can be subdivided into three phases based on structural, as well as endocrine, 
changes at both the level of the ovary and the uterus. The uterine cycle begins with menses, 
followed by the proliferative phase. These phases correspond with the follicular phase within 
the ovary (24-26). During this time the uterus prepares for the possibility of implantation by 
rebuilding the functional layer of the endometrium (on top of the basal layer) that was just 
shed during menses (26,27). This process is dependent on the production of estrodiol from 
large antral follicles within the ovary. The functional layer gradually increases in thickness and 
becomes progressively more vascularised. Within the ovary, the follicular phase involves the 
recruitment of immature follicles into the ‘growing pool’ from which the dominant follicle will 
be selected for ovulation. Follicle recruitment and growth relies heavily on FSH, particularly 
in the first week of the follicular phase, to induce the proliferation of granulosa cells (28). The 
dominant follicle produces high levels of estrogens until the LH surge triggers ovulation – the 
second phase of the ovarian cycle. 
Following ovulation, the ovary progresses into the luteal phase as the resultant CL produces 
P4. Meanwhile, the uterus is now in the secretory phase and proliferation of the 
endometrium ceases. P4 from the CL is responsible for making the newly formed functional 
layer of endometrium receptive to implantation by the blastocyst and supporting the newly 
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formed vascular supply (20,25). Should pregnancy not occur, the CL is broken down in a 
process known as luteolysis and all hormones – the ovarian steroids and the gonadotropins – 
return to low levels so that the cycle can begin once more. The unused layer of endometrium 
is shed once more during menses (20,21,25,29). 
Menstrual cycles cease in a natural process of menopause, which usually occurs in a women’s 
50s (21). During this time levels of FSH and estradiol (E2) are often widely varied within 
individual women. The finite supply of oocytes is depleted and without large follicles to 
produce estrogens levels drop dramatically. Consequently, FSH and LH are freed from normal 
negative feedback regulation and levels rise. Without proper cycling of these hormones, 
menstrual cycles cease altogether (20,21,25,28,29).  
1.1.3.2 Murine Estrous Cycle 
In female mice, the vaginal opening is apparent at around 26 days old (30,31), with sexual 
maturity being reached 10-30 days later as indicated by the onset of detectable changes in 
the vaginal epithelium (30,32,33). The murine estrous cycle typically lasts 4-5 days and can be 
divided into four stages (34,35) (Figure 1.3). At proestrus, follicle growth is initiated in smaller 
follicles while antral follicles that began growing during the previous proestrus stage are 
prepared for ovulation (36). High levels of estrogens during this stage prepare the 
endometrium for the possibility of implantation and pregnancy. The following day, the mouse 
moves in to estrus – the state of sexual receptivity (often referred to, in animals, as being “in 
heat”). Surges of FSH and LH finalise the maturation of the large follicles and allow ovulation 
to occur (20,34,35). As a polyovular species, rather than one dominant follicle being chosen 
for ovulation a number of follicles are matured and ovulated. Female mice are able to ovulate 
spontaneously, without the stimulation provided by the presence of a male as is required in 
some estrous animals (32). Ovulation typically take place approximately 18-20 hours post-LH 
surge (20). The proestrus and estrus stages in the mouse are roughly equivalent to the ovarian 
follicular and uterine proliferative stage of the human menstrual cycle. 
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Following ovulation, the metestrus stage is reached. During metestrus the corpora lutea (CLs) 
form from the ovulated follicles and indications of estrogen stimulus (such as mating 
behaviour) recede. The CLs produce P4 which thickens the uterine lining (34). As in humans, 
the CLs function to maintain any pregnancy that is achieved. If mating and pregnancy do not 
occur, the diestrus stage is reached. At this stage the CLs regress and hormone levels remain 
low in preparation for a new cycle to begin one to two days later (34,35). Metestrus and 
diestrus in mice can be compared to the luteal and secretory phases of the human.  
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Figure 1.3 Murine Estrous Cycle 
 
The hormone profile of the estrous cycle in the mouse. White bars represent the 12-hour light period 
while black bars represent the 12-hour dark period. Taken from Miller et al (37). 
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1.1.4 Ovary 
Located lateral to the uterus and attached via the fallopian tube, the human ovary can be 
divided into 2 main regions: the outer ovarian cortex and the inner ovarian medulla. The 
cortex is covered by the tunica albuginea, a fibrous connective tissue layer immediately below 
the ovarian surface epithelium, or ‘germinal epithelium’ although it does not contain any 
germ cells (21,28). Germs cells are rarely found within the ovarian medulla, with follicle 
formation generally thought to be restricted to the ovarian cortex, facilitating ovulation 
through the tunica and the surface epithelium (21,27,38).  
Before the onset of folliculogenesis and the organisation of the ovarian germs cells into 
distinct follicles the oogonia exist within germ cell nests (38), a highly conserved structure 
across multiple species (39). Unlike spermatogonia, oogonia do not undergo development 
while present in these nests instead undertaking the majority of their development either 
before the formation of the germ cell nest or after it’s breakdown (40). Germ cell nest 
breakdown is essential for proper ovarian function and the onset of folliculogenesis. The 
process of nest breakdown not only serves to encapsulate single oocytes into individual 
follicles but also to ‘weed out’ any unhealthy oocytes not suitable for further development 
into follicles (40). The amount of oocytes lost during nest breakdown has been estimated to 
be around one to two thirds of the oogonial population (41,42). Once the complicated process 
of germ cell nest breakdown is complete, the equally complex process of folliculogenesis can 
begin. 
1.1.4.1 Folliculogenesis 
Ovarian follicle formation and growth is a complex and highly regulated process in which the 
oocyte is nourished and prepared for eventual ovulation. An ovarian follicle consists of a 
developing oocyte surrounded by increasing layers of granulosa cells and a fluid-filled antral 
cavity (at the antral follicle stage) enclosed within a basement membrane (Figure 1.4). 
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Surrounding this membrane are concentric layers of theca interna and externa cells, making 
up the follicle. Female mammals, including humans, are born with a finite number of oocytes 
and follicles (43,44). 
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Figure 1.4 Folliculogenesis 
 
Schematic of ovarian follicle development, showing progression from the quiescent primordial follicle through to the corpus luteum as a remnant of an 
ovulated follicle, including theca cell recruitment and antrum formation. BL, basal lamina; O, oocyte; GC, granulosa cell; T, theca; A, antrum; FF, follicular fluid; 
CO, cumulus oophorus; cGC, cumulus granulosa cell; mGC, mural granulosa cell. Adapted from Young and McNeilly (45). 
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1.1.4.1.1 Early Follicular Growth 
In their earliest stage, follicles are referred to as primordial and are quiescent. Primordial 
follicles consist of an immature oocyte surrounded by one layer of flattened, squamous 
granulosa cells. These follicles are not actively growing and are often labelled ‘resting follicles’ 
or referred to as the ‘follicular reserve’ and show no biological activity (44,46).  In a process 
known as initial recruitment these primordial follicles are ‘woken up’ and transition into the 
primary follicle stage as growth is initiated (47). The precise mechanism of this initial follicle 
activation remains unknown however several factors have been implicated in this process, 
including members of the transforming growth factor beta (TGF-β) superfamily including 
bone morphogenic proteins, BMP-4 and BMP (48), while another member of the same family, 
anti-Müllerian hormone (AMH), is said to actually play an antagonistic role by preventing this 
transition (46). Growth and differentiation factor-9 (GDF-9) is an oocyte-specific protein that 
has been shown to play a key role in promoting follicle growth in the early stages (21,46). 
Primary follicles can be distinguished from the primordial predecessors by the transition from 
flattened to cuboidal granulosa cells (GCs). Follicle size is markedly increased in both the 
enlarged size of the oocyte as well as proliferation of the surrounding GCs (49). At this stage 
the oocyte genome becomes active and genes essential for follicle growth and development 
begin to be transcribed (47). This stage marks the appearance of the zona pellucida (ZP), a 
thick glycoprotein layer that surrounds the plasma membrane of the oocyte. The 
glycoproteins needed to make up this layer are secreted by the oocyte with some minor 
contribution from the innermost granulosa cells as well (28,29). Receptors for FSH also 
develop at this stage; however the follicle remains gonadotropin-independent until later 
stages (50). 
As follicle growth and development continues, the follicle attains more layers of GCs as these 
cells proliferate. In mice, once the follicle has more than 1.5 layers of these cells it is referred 
to as a preantral (or secondary) follicle (51). These preantral follicles can be further classified 
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into small and large based on the number of these GC layers. Small preantral follicles have 
1.5 – 2 complete layers whereas large preantral follicles have more than 2 and up to 5 layers 
(51). These growing preantral follicles now recruit theca cells from the surrounding stroma to 
become the initial theca interna layer. As further recruitment occurs, the theca externa layer 
will become apparent (52). An intricate network of capillary vessels forms between these two 
thecal layers and begins to circulate blood to and from the follicle. Oocyte diameter rapidly 
expands during growth at this stage, while still remaining paused at the diplotene stage of 
prophase I of meiosis (53).  
1.1.4.1.2 Antral Follicle Formation 
The formation of a fluid-filled cavity adjacent to the oocyte, called the antrum, designates the 
follicle as an antral follicle. These follicles are also called tertiary or Graafian follicles. These 
follicles have more than 5 layers of GCs and/or the appearance of this follicular fluid within 
the GC layer (51). This fluid is an accumulation of glycoproteins secreted by the granulosa cells 
in response to FSH (52). Both granulosa cells and theca cells continue to undergo mitotic 
proliferation and the volume of the follicle increases as a result. As with preantral follicles, 
antral follicles can be further classified into small and large depending on their appearance. 
Small antral follicles have a few small, scattered pockets of follicular fluid whereas a large 
antral follicle has a single large antral space dominating the follicle (51).  
These follicles now depend on FSH for maintenance and growth and their size is only limited 
by access to FSH (21). In large antral follicles GCs now differentiate into two different subtypes 
– cumulus granulosa cells which surround the oocyte, and mural granulosa cells which enclose 
the single large antral cavity (or antrum) (44). As the follicle continues to grow, receptors for 
LH begin to be expressed on cumulus GCs in preparation for the LH surge which will trigger 
ovulation of the follicle, while the theca cells also express LH receptors (21,54). LH induces 
the production of androgens in these cells, which are then used by GCs as precursors for E2 
biosynthesis (26). Consequently, E2 levels begin to rise in follicles of this type. At this point in 
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development, most of the other follicles they were initially recruited out of the resting pool 
have now regressed in a controlled, apoptotic death (47).  
For those that remain, E2 production causes a negative feedback effect on subsequent FSH 
secretion and levels of FSH begin to fall. In addition to the negative feedback effects of E2, 
FSH concentrations, at this point in the cycle, are at the mercy of both inhibin A and inhibin 
B. High concentrations of inhibin B during the early to mid-follicular phase are responsible for 
this decrease in FSH levels, closing the “FSH window” for antral follicle growth and leading to 
dominant follicle selection (18). Follicles without sufficient FSH receptors are now unable to 
survive and undergo atresia (47). This leaves one follicle (or on rare occasions, two follicles) 
remaining and this is deemed to be the dominant follicle. It has acquired LH receptors by this 
stage and further development is now LH-dependent, ensuring that only the dominant follicle 
continues to grow (55). This is the follicle that will go on to ovulate and is referred to as a 
preovulatory follicle. These follicles can be differentiated from large antral follicles by the 
appearance of the mural granulosa stalk – the cumulus oophorus. This small bridge-like 
cluster of GCs connects the mural GCs to the cumulus GCs and separates the oocyte from the 
granulosa wall of the follicle in preparation for ovulation (28,46). 
1.1.4.2 Ovulation 
Ovulation is a tightly regulated process in which one follicle ruptures from the ovary, expelling 
the oocyte and its cumulus GCs into the fallopian tube in preparation for fertilisation. 
Ovulation is triggered in the dominant follicle by a surge of LH caused by sustained high levels 
of E2 coming from the dominant follicle which reach an as yet unknown threshold in the 
pituitary, initiating the surge (55). This LH surge initiates a cascade of gene transcription and 
translation within the follicle that triggers cumulus cell expansion, luteinisation of mural 
granulosa cells, resumption of oocyte meiosis and finally, factors that will cause the follicle 
wall to rupture and release the mature oocyte (21). A switch within the granulosa from 
producing inhibin B to predominantly inhibin A sees that FSH levels remain low during this 
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phase, allowing LH activity to cause ovulation as well as subsequent luteinisation of the follicle 
(18). It is not until inhibin A levels decline during the late luteal phase that FSH levels will be 
able to rise once again. LH activity also allows the oocyte to resume the first meiotic division, 
which results in the extrusion of the first polar body (46). Until fertilisation occurs the oocyte 
will progress no further than metaphase II of the second meiotic division (24).  
1.1.4.3 Corpus Luteum 
What remains of the ovulated follicle is the corpus luteum (Latin for “yellow body”). Named 
for its yellow appearance on the surface of the human ovary, the CL forms from the remaining 
cells of the follicle in a process of luteinisation (56). Formally granulosa and theca cells, they 
are now referred to as luteal cells and are both morphologically and physiologically distinct 
from their previous states. It was originally thought that CL had no function and was simply a 
scar of the former follicle that would later degenerate into the corpus albicans (Latin for 
“white body”) seen in humans (20). However, is it now widely known that luteal cells are not 
only steroidogenic but essential for the maintenance of the endometrium, mostly through 
the secretion of P4 but also with some contribution of E2 (26). A healthy endometrium is 
essential for successful implantation of the fertilized zygote. The CL will continue to produce 
P4 to maintain the thick endometrial lining until the placenta takes over production at around 
10 weeks gestation in the human (21). If a pregnancy is not achieved and hormonal indications 
of implantation are not received, the CL will cease P4 production and regress (29). This drop 
in P4 relieves the negative feedback it places on GnRH secretion, initiating normal production 
to begin again and a new menstrual or estrous cycle to begin (26).  
1.1.4.4 Follicle Loss and Decline 
The human ovarian reserve reaches its peak at around 20 weeks gestation when 
approximately 7 million germ cells (or oogonia- referred to as oocytes once the process of 
meiosis has begun (56)) are present in the fetal ovary (46,57). This declines rapidly over the 
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remaining gestational period leaving only 1-2 million germ cells within non-growing follicles 
(NGFs) in the ovary at the time of birth. However, only approximately 400,000 of these will 
remain at the time of puberty and further, only around 400 of these oocytes will be ovulated 
during a women’s reproductive lifetime, meaning that the more common fate of ovarian 
follicles and their oocytes is to undergo degeneration (46,56,58). In fact, this equates to just 
1% of all germ cells that developed within the ovary actually making it through to ovulation. 
This controlled, intentional death of follicular structures is known as ovarian follicle atresia 
while the controlled death of germs cells is known as attrition (58). This process is largely 
achieved by the action of granulosa cell death via apoptosis (56). Follicle atresia is regulated 
by LH and FSH as well as paracrine factors such as tumour necrosis factor α (TNFα), insulin-
like growth factor 1 (IGF-I), and interleukin 6 (IL-6) among others (55-58). Several anti-
apoptotic factors have been shown to play a role in trying to inhibit granulosa cell death 
including P4 (56,58,59) as well as E2 and FSH (55), with sufficient exposure to FSH being the 
most critical factor for follicles to avoid an atretic death (58). Follicles in the early stages of 
atresia have been seen to have the apoptotic process initiated in the mural GCs but not the 
cumulus GCs or the oocyte, indicating that it may be GC apoptosis which drives whole follicle 
atresia (10,55,57,60). 
After the permanent conclusion of reproduction function at menopause, the ovary will still 
contain around 1000 oocytes (46) however, without the appropriate signals coming from the 
pituitary, as well as the ovary itself, and the cessation of regular menstrual cycling, these 
oocytes remain immature and unovulated (44). 
1.1.5 Steroidogenesis 
In humans, steroids are classified into 4 main subtypes – androgens, estrogens, progestagens 
and corticosteroids – with the first three subtypes considered the sex steroids responsible for 
reproduction and fertility and the first two specifically being responsible for the 
establishment and maintenance of the primary and secondary sex characteristics in both 
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males and females (27,61). Steroidogenesis is the process by which these steroids are 
biosynthesised from cholesterol and converted into other steroids (61). 
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Figure 1.5 Steroid Pathway 
 
Biosynthesis of steroid hormones from cholesterol. Green boxes indicate progestagens, blue boxes 
indicate androgens, pink boxes indicate estrogens and yellow boxes indicate enzymes. The delta 5 
(D5) pathway to androgens is on the left, while the delta 4 (D4) pathway is on the right.  
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1.1.5.1 Steroid Pathway 
While the human adrenal glands can synthesise cholesterol de novo, the majority of 
cholesterol used for steroid biosynthesis comes from low-density lipoproteins (LDLs) supplied 
by plasma (62-64). As this dietary cholesterol is stored in its esterified form inside lipid 
vesicles, it must first be hydrolysed into free cholesterol to be available for steroidogenic 
conversion (65). The initial step in steroidogenesis – the conversion of cholesterol to 
pregnenolone is the rate-limiting step in the steroidogenic pathway and is mediated via the 
cholesterol side-chain cleavage enzyme (P450scc) (63,65,66). The P450scc enzyme falls into 
the largest of the two groups of steroidogenic enzymes – the cytochrome P450 enzymes 
(CYP), the other group being the hydroxysteroid dehydrogenases (62). This initial conversion 
of cholesterol into the first steroid precursor (as well as first member of the progestagen 
steroid family) is the most critical and can be regulated by LH using the intermediate 
messenger cyclic adenosine monophosphate (cAMP) (62,63). cAMP is able to promote LDL 
cholesterol uptake into steroidogenic cells as well as increase the transport of this cholesterol 
to the site of pregnenolone synthesis within the cell’s mitochondria using the steroid acute 
regulatory protein (StAR) (63). 
Following this initial conversion, pregnenolone can then proceed down any of three 
subsequent steroidogenic pathways. Two of these pathways are involved in the production 
of the progestagens, androgens and estrogens that function as part of the reproductive 
system in both males and females. The third pathway, the adrenal system, is that which 
results in the production of corticosteroids (63,66) and will not be discussed in this work. The 
two pathways involved in reproductive steroidogenesis are the delta 5 (D5) and delta 4 (D4) 
pathways. Within the murine ovary, the D5 is the predominant route of steroidogenesis in 
theca cells while in the granulosa cells, the D4 is predominant (63,65). The D5 pathway, the 
only pathway within the ovaries of primates, involves the metabolism of pregnenolone into 
17α-hydroxypregnenolone and then further into the androgen precursor 
Chapter One 
 24 
dihydroepiandrosterone (DHEA). Both of these conversions are mediated via the enzyme 
cytochrome P450 17α hydroxylase/17,20 lyase (CYP17). CYP17 has both hydroxylase and 
lyase activity with the 17α-hydroxylase component mediating the pregnenolone à 17α-
hydroxypregnenolone conversion and the 17,20 lyase component mediating the 17α-
hydroxypregnenolone à DHEA step of this pathway (62,63,66). Conversely, the D4 pathway 
first involves the conversion of pregnenolone to progesterone via the enzyme 3β-
hydroxysteroid dehydrogenase (3β-HSD) and then to 17α-hydroxyprogesterone and 
androstenedione via the actions of the enzymatic actions of the 17α hydroxylase and 17,20 
lyase components of CYP17, respectively (62,63,66). Both the D5 and D4 pathways lead to 
conversion of progestagens to androgens. It is important to note here that, within the ovary, 
only the theca cells possess the CYP17 enzyme. Therefore, the theca cells are responsible for 
providing precursor androgens to granulosa cells who cannot produce them themselves and 
require these androgens for estrogen biosynthesis (27,62,63).  
In males, the primary sex steroid is testosterone which can be synthesised from both DHEA 
and androstenedione via the actions of 3β-HSD and 17β-hydroxysteroid dehydrogenase (17β-
HSD) or 17β-HSD alone, respectively (66). As with thecal cell steroidogenesis in the ovary, the 
D5 pathway dominates steroid production in Leydig cells (67). Testosterone can be further 
converted into dihydrotestosterone (DHT) a more potent androgen used by the reproductive 
tissues within the male (66,68). As in the ovary, where the steps of the steroidogenic pathway 
are divided between the granulosa and theca cells, androgen biosynthesis in males is 
contained within the Leydig cells, with Sertoli cells are responsible for estrogen biosynthesis, 
under control of FSH (66).  
1.1.5.2 Progestagens 
Named for their primary role in maintaining pregnancy, progestagens are distinct from other 
classes of steroid hormones on the basis of their 21-carbon chain skeleton (69). The most 
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common, and most important, progestagen in the body is progesterone (P4) which binds the 
progesterone receptor (PR). 
1.1.5.2.1 Progesterone 
Progesterone is carried in the bloodstream bound mostly to serum albumin with around 10% 
bound to cortisol-binding globulin (69). In females, the primary sites of P4 synthesis are the 
ovary and, during pregnancy, the placenta (26). Within the ovary, P4 first begins to be 
synthesized by preovulatory follicles. This secretion is key in the transition of the uterine 
endometrium from the proliferative to the secretory phase of the cycle. During this follicular 
phase concentrations of progesterone are normally below 1ng/ml (69). A key role of P4 at this 
stage is to promote follicular growth by acting on the granulosa cells to inhibit apoptosis (70). 
Post-ovulation, P4 plays key roles in both the preparation and maintenance of the 
endometrium as well as blastocyst implantation into this layer of the uterus. The luteinisation 
of the ovulated follicle, facilitated by LH, results in the delivery of cholesterol to the forming 
CL. This is crucial for the production of P4 by the CL, when levels can reach up to 35ng/ml 
(69). It is during this secretory phase of the uterine cycle that the CL’s production of P4 assists 
with uterine receptivity to the blastocyst and supports early pregnancy until the placenta 
takes over as the main producer of P4. In the non-pregnant state, P4 during this phase 
initiates the increased production of estrogens while simultaneously inhibiting the production 
of LH and FSH, the very hormones the CL needs to maintain itself. A loss of responsiveness to 
LH combined with declining concentrations of both gonadotropins leads to the regression of 
the CL, a fall in P4 levels and subsequent menstruation and the start of a new cycle (69,71). 
Due to a lack of CLs within the PCOS ovary caused by a lack of ovulation, P4 levels are often 
low in women with PCOS. 
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1.1.5.3 Androgens 
1.1.5.3.1 Proandrogens 
Proandrogens are compounds that have little to no steroidogenic function of their own, but 
play an essential role in the steroid pathway by acting as precursors for both androgen and 
estrogen biosynthesis (72). These include dihydroepiandrosterone (DHEA) and 
androstenedione (A4). 
1.1.5.3.1.1 Dihydroepiandrosterone 
DHEA, also known as androstenolone, is the most abundant circulating steroid in humans (73) 
and it mostly found in its sulfate ester form DHEA-sulfate (DHEA-S). It is produced by the 
adrenal glands, the gonads and the brain, leading to DHEA often being referred to as a 
neurosteroid (74). In the reproductive tract DHEA serves mostly as a precursor for the 
synthesis of more potent androgens such as testosterone (T) and DHT (Figure 1.5). However, 
DHEA has been shown to have some potential steroidogenic action of its own in acting as an 
agonist of the androgen receptor (AR) (75,76) or by binding the estrogen receptor (ER) (76). 
When using DHEA-S as a marker, approximately 20-30% of PCOS women show an increase in 
adrenal precursor androgen (APA) production. While the role of APA in PCOS is not clear, 
patients demonstrating APA have been shown to exhibit a PCOS-like phenotype (77). 
1.1.5.3.1.2 Androstenedione 
Produced evenly by both the adrenal glands and the gonads, A4 is the common precursor of 
both androgens and estrogens. It is also the predominant steroid produced by the post-
menopausal ovary (78). A4 can either be converted to the estrogen estrone via the actions of 
the enzyme aromatase or to T via the action of 17β-HSD (79,80) (Figure 1.5). Along with DHEA, 
A4 is involved in the onset of adrenarche in adolescents (77). In PCOS, A4 has been suggested 
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as a marker of severity due to the finding that PCOS women with higher A4 levels are more 
likely to maintain the PCOS-phenotype following significant weight loss (79,81).  
1.1.5.3.2 Testosterone 
T is the primary male sex hormone and is synthesized from the conversion of either A4 by 
17β-HSD or from androstenediol by the enzyme 3β-HSD (62,65). While T is responsible for 
male secondary sex characteristics (68), it is not exclusively a male hormone and has been 
shown to play a critical role in female physiology, in particular that of the reproductive 
system, and not solely as a precursor for estrogen biosynthesis. T, which elicits its effects by 
way of the androgen receptor (AR), is transported in the blood by sex hormone-binding 
globulin (SHBG), a protein secreted by the liver in males and by both the liver and placenta in 
females (82-84). A proportion of T goes on to be metabolised to either DHT or E2 while the 
majority of T is actually inactivated for excretion by the renal system (82,85). Production of T 
is primarily regulated by LH and FSH as part of the HPG axis (Figure 1.1). Testosterone feeds 
back to both the hypothalamus and the pituitary in a negative feedback loop to inhibit the 
release of GnRH as well as LH and FSH, respectively (20,21,29,86).  
1.1.5.3.3 Dihydrotestosterone 
DHT is a more potent androgen than T with a greater binding affinity for the AR (82). DHT is 
converted from T by the enzyme 5a-reductase in a reaction that reduces the double bond 
between carbons 4 and 5. This alters the orientation of surrounding structures and the 
geometry of the molecule as a whole which leads to DHT being favoured over T for binding 
with the AR (87-91). DHT has been shown to be 3- to 10-fold more potent than T because of 
this (82). DHT is widely considered a ‘pure’ androgen because it’s activity is mediated 
exclusively via the AR as DHT is unable to undergo conversion to estrogens by the enzyme 
aromatase (86). Experimentally, DHT’s inability to be aromatised is crucial in teasing apart the 
androgenic vs estrogenic effects of administering androgens. As with T in males, DHT is 
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important for the development of secondary sex characteristics such as facial and body hair, 
increased muscle mass and deepening of the voice. DHT is also important during fetal life in 
the development of the external male genitalia (21,24,26,29). Post-puberty, DHT plays a role 
in male-pattern baldness and prostate growth with 5a-reductase inhibitors being used to 
treat benign prostatic hyperplasia (92). 
The importance of DHT in male sexual differentiation and development is illustrated in the 
congenital condition 5a-reductase deficiency (5-ARD). 5-ARD is caused by an autosomal 
recessive mutation in the 5a-reductase type II gene (SRD5A2) (93). The condition causes 
males to be born with pseudohermaphroditism, in which they have internal male sex organs 
(prostate, testes) but fail to develop the typical male secondary sex characteristics (94). 5-
ARD is rare in XY males with a higher prevalence in countries such as the Dominican Republic, 
Turkey and Papua New Guinea. Consanguinity is thought to be contributing factor in the 
occurrence of homozygous SRD5A2 mutants (95). XX females can also be affected by 5-ARD, 
however as DHT is not required for female sexual differentiation in utero symptoms are most 
often mild. Homozygous mutant females can present with reduced body hair and delayed 
menarche with some women also experiencing increased fertility due to an increase in the 
estrogens to DHT ratio (95-98). 
While DHT is a potent androgen that cannot be converted to estrogens via the action of 
aromatase, it must be noted that DHT is able to be reduced to 5α-androstane-3α,17β-diol 
(3a-diol) and 5α-androstane-3β,17β-diol (3β-diol) (62,99,100), the latter of which is capable 
of binding to the ERβ, and therefore acting as an estrogen, with a binding affinity 7% that of 
E2 (101). Conversely 3a-diol is rapidly oxidised back to DHT to function solely as an androgen 
(100). 
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1.1.5.4 Estrogens 
In mammalian ovaries, estrogens are synthesized primarily within the GCs of the follicle. 
However, the biosynthesis of estrogens relies on a multistep process, involving the 
cooperation of both the granulosa and theca cells as well as the involvement of both LH and 
FSH, known as the two-cell, two-gonadotropin model (102) (Figure 1.6). During the FSH-
dependent stage of follicle development FSH stimulates an increase in LH receptors on the 
surface of theca cells. This increase in uptake of LH by the theca cells promotes the cAMP-
dependent LDL cholesterol movement into the cells for the initiation of steroidogenesis (63). 
The theca cell then increases the production of A4 which diffuses across the basement 
membrane to the GCs. Meanwhile on the surface of GCs, FSH positively regulates the 
expression of its own receptor and this rise in cellular FSH concentrations leads to the increase 
in aromatase production via the cAMP pathway. The GC is now ready to convert the incoming 
A4 into estrogens before they diffuse back across the basement membrane and into the 
bloodstream (102-104). 
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Figure 1.6 The Two-Cell, Two-Gonadotropin Model of Estrogen Biosynthesis 
 
 
Schematic of the ovarian biosynthesis of estrogens via the co-operation of the theca and granulosa 
cells, as well as the gonadotropins LH and FSH. Taken from Doshi et al (104). 
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1.1.5.4.1 Estrone (E1) 
Estrone (E1) is the least abundant circulating estrogenic hormone and is produced from the 
enzymatic conversion of androstenedione by aromatase. E1 is mostly produced by the ovaries 
as well as adipose tissue and is widely considered to be a proestrogen – serving mostly as a 
precursor for the more common estrogen E2 and, to a lesser extent, estriol (21,105). While, 
in general, levels of estrogens decline with age many women experience higher E1 levels post-
menopause compared to pre-menopause. This is due, in part, to the fact that P4 secretion 
encourages the release of 17β-HSD, the enzyme required for the conversion of E1 to E2 
(106,107) and P4 levels wane following menopause. This can also be due to an increase in the 
rate of conversion of A4 to E1 post-menopause (106). Because of this, E1 has been implicated 
as a possible marker of increased risk for breast cancer in post-menopausal women (108-112).  
1.1.5.4.2 Estradiol (E2) 
The most important estrogen, E2 is also the most abundant of the estrogenic female 
hormones, so much so that E2 is often referred to as ‘estrogen’. All estrogens, but E2 in 
particular, are responsible for female sexual differentiation in utero and the development and 
maintenance of the female secondary sex characteristics such as breast development, 
widening of the hips, female-pattern fat distribution, as well as the menstrual cycle 
(24,29,86). Primarily, E2 is synthesised within the ovary (113) with contribution from the 
adrenal glands, as well as breast and adipose tissue (114). Within the ovary, it is the granulosa 
cells that convert androgens, received from adjacent theca cells, into E2 via the action of 
aromatase (115,116). E2 levels vary throughout the menstrual cycle, with the lowest levels 
being during menstruation at less than 50pg/ml. E2 steadily rises during the follicular phase, 
peaking just prior to ovulation at around 200pg/ml. A smaller peak is seen during the luteal 
phase before levels fall again proceeding menstruation. In the pregnant state, E2 continues 
to rise until term with the primary source of E2 now being the placenta, having surpassed the 
ovary as the main site of aromatase activity (26,86,117). 
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As with all estrogens, the actions of E2 are mediated by the estrogen receptor (ER), a nuclear 
receptor of which there are 2 forms - ERa and ERb - encoded by the genes ESR1 and ESR2, 
respectively (101,115,118). Within the ovary, ERb is localised to the granulosa cells while ERa 
can be found only in theca cells (113,119). This, combined with the fact that levels of 
aromatase mRNA have been shown to increase in the granulosa cells of the dominant follicle 
leading up to ovulation, has led many to believe that E2 may play an important role in the 
progression of this dominant follicle (113,120). ERa and ERb have been implicated in the 
development and progression of some cancers – in particular breast cancer, referred to as 
“ER-positive”. This is unsurprising considering the role of ER in mammary cell proliferation 
and therefore induction of the cell cycle as well as DNA replication and repair. Due to this, 
many treatments for ER-positive breast cancers involve the use of ER antagonists such as 
tamoxifen (121). 
1.1.6 Key Intraovarian Factors 
1.1.6.1 IGFs 
Insulin-like growth factors I and II (IGFs) are signalling proteins used by cells to communicate 
with their immediate environment. Named for their homology to insulin, IGFs work within a 
complex system, known as the IGF axis, to facilitate cell proliferation, inhibition of apoptosis 
and cell-to-cell communication, all of which are critical for the health and function of 
developing follicles (122). Within the ovary, IGF-II is found in the granulosa cells while IGF-I 
has been localised to the theca-interstitial space (122-126). The IGF axis also contains six high-
affinity IGF-binding proteins (IGFBPs) which are responsible for transport of IGFs as well as 
modulation their interaction with the two IGF receptors. Studies have shown that women 
with PCOS display lower levels of IGFBP-1 (127), which can lead to insufficient antagonisation 
of IGF-I in theca cells, the downstream effect being an overproduction of androgens and the 
propagation of PCOS symptoms. This imbalance can be remedied by use of the combined oral 
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contraceptive pill, which is often a treatment for the androgen-induced features of PCOS 
(123,128). 
1.1.6.2 GDF-9 
Growth differentiation factor-9 (GDF-9) is an oocyte derived member of the transforming 
growth factor-beta (TGF-b) superfamily.  It has been shown that the oocyte plays a key role 
in regulating the development and growth of the follicle in which it is contained (129,130) and 
that GDF-9 is essential for follicular growth and ovulation (131-133) both on its own and in 
co-operation with bone morpho protein-15 (BMP-15, see below) (134). In mice, knockout 
studies have shown that GDF-9 is not required for male fertility but that females lacking GDF-
9 display a loss of follicular progression past the primary stage of development due to the 
inability of granulosa cells to proliferate past this stage (130,135). These females also 
displayed the same type of follicle cyst formation seen in women with PCOS, who have been 
shown to have decreased GDF-9 mRNA expression (130,136). In addition to its role in 
granulosa cell proliferation, GDF-9 has also been shown to play vital roles in preventing 
apoptosis within the cumulus-oocyte complex (137), maturation of the oocyte (138) and 
theca cell function (130). 
1.1.6.3 BMP-15 
Bone morpho protein-15 (BMP-15) is also an oocyte-derived member of the TGF-b 
superfamily, most often studied in conjunction with GDF-9 due to their synergistic 
relationship. As with GDF-9, BMP-15 is not required for male fertility, while BMP-15 deficient 
female mice are subfertile (139), in a phenotype less severe than that of GDF-9 knockouts 
(130). While BMP-15 has also been shown to play crucial roles in folliculogenesis, including 
granulosa cell proliferation and prevention of apoptosis (131,132,134,139,140), it appears 
that the role of BMP-15 is more focused on ovulation and successful fertilisation of the 
oocyte. For example, BMP-15 has been shown to play a role in the provision of glycolysis 
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products to the oocyte from the granulosa cells (130). Women with BMP-15 mutations can 
display premature ovarian failure, underdeveloped ‘streak’ ovaries or little to no ovulation. 
Unlike GDF-9, the BMP-15 gene is located on the X chromosome leading to its implication in 
the reproductive abnormalities seen in patients with Turner’s Syndrome (140). The role of 
BMP-15 in PCOS is yet to be determined. 
Simultaneous knockout of both BMP-15 and GDF-9 produced effects more severe than either 
knockout alone, including additional effects such as an inability for the follicle to undergo 
cumulus expansion in mature antral follicles, and an increase in oocyte size with disorganised 
organelles and spindle formation (139). These knockouts have provided solid evidence that 
BMP-15 and GDF-9 work together in the maintenance of female reproductive function. 
  
Chapter One 
 35 
1.2 Polycystic Ovary Syndrome 
1.2.1 Clinical Diagnosis of PCOS 
In 1935 Irving Stein and Michael Leventhal first described the condition that would become 
known as Polycystic Ovary Syndrome. Originally named Stein-Leventhal Syndrome, the pair 
detailed seven infertile, obese women with amenorrhea, hirsutism and bilateral polycystic 
ovaries (141). PCOS is now considered the most common cause of anovulatory infertility (142) 
and effects 5-15% of reproductive-aged women worldwide, depending on the criteria used 
for diagnosis (143). Currently, there are three different criteria used in the diagnosis of PCOS 
in women. 
1.2.1.1 National Institutes of Health 
The 1990 National Institutes of Health (NIH) Conference recommended that the criteria for 
diagnosis be (in order of importance): 
• Clinical and/or biochemical signs of hyperandrogenism and  
• Chronic anovulation  
• As well as having excluded other hyperandrogenic disorders such as Cushing’s 
syndrome, androgen-secreting tumours and adrenal hyperplasia (144).  
These criteria worked well for many years and paved the way for large clinical trials in PCOS 
women (145), however there became a gradual increase in awareness that the criteria may 
not be broad enough to cover the full scope of presentations of PCOS being seen in the clinics.  
1.2.1.2 Rotterdam Consensus 
And so in 2003, at a joint meeting of the European Society for Human Reproduction and 
Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM), the 
Rotterdam criteria for the diagnosis of PCOS were proposed. According to these standards, 
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after the exclusion of these same similarly presenting disorders, a diagnosis of PCOS is 
appropriate if the patient presents with at least two of: 
• Oligo- or anovulation  
• Clinical and/or biochemical indications of androgen excess or  
• Polycystic ovaries (PCO) (146) (Figure 1.7) 
These criteria included many more patients than the former, for instance those with 
polycystic ovaries and androgen excess but who were still able to have normal ovulatory 
cycles (known as “functional hyperandrogenism”) (147). 
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Figure 1.7 The Polycystic Ovary 
 
 
 
The structure and appearance of the normal ovary compared to the polycystic ovary which contains 
many, fluid-filled cysts (above).  The polycystic ovarian morphology is clearly visible on ultrasound 
(below). Taken from: http://www.mdguidelines.com/polycystic-ovary-syndrome 
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1.2.1.3 Androgen Excess-PCOS Society 
Most recently, in 2006, the Androgen Excess-PCOS Society advises that the patient should 
have: 
• Hyperandrogenism – defined as hirsutism and/or hyperandrogenemia and  
• Ovarian dysfunction – oligo- or anovulation and/or polycystic ovaries and  
• Other hyperandrogenic or similar presenting disorders excluded (148). 
Under these criteria women diagnosed with PCOS can be sub-divided into a wide variety of 
phenotypes allowing researchers to study specific aspects of the syndrome. The Society 
believes that allows for greater use of “phenomics” – the study of phenotypes – used to help 
identify the  cause(s) of complex conditions (148). 
1.2.2 Reproductive Traits of PCOS 
Throughout follicle development and ovulation, the entire process is highly regulated to 
ensure that optimal fertility is maintained. However in PCOS, hyperandrogenism and 
hyperinsulinemia can disturb this tightly controlled process. A common feature of polycystic 
ovaries is the arrest of follicular development at the large antral stage. Because of this, a large 
number of these antral follicles accumulate in the ovary, rather than having one dominant 
follicle selected for ovulation (120). This results in the stereotypical “pearls on a string” 
appearance of these follicles as they amass around the periphery of the ovary. In humans, 
this arrest usually occurs when follicles are approximately 7mm in size, at a stage when they 
normally begin expressing aromatase within the granulosa cells. Excess androgens within the 
intraovarian environment can inhibit the activity of aromatase and therefore inhibit follicular 
growth causing arrest (149). Increased levels of insulin, often seen in PCOS, are able to 
promote premature follicular luteinisation by enhancing the response of granulosa cells to LH 
in those larger follicles whose growth is already arrested (149,150).  
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1.2.2.1 Follicle Number and Health 
The leading cause of subfertility in PCOS is ovulatory dysfunction (151). While the cause of 
this is most likely the arrest of follicular growth before the ovulatory stage is reached, the 
exact mechanism of anovulation in PCOS remains a mystery (142). Despite the fact that PCOS 
ovaries can contain twice as many primordial and preantral follicles than normal ovaries, due 
to the phenomenon of enhanced follicular recruitment (152), these follicles do not go on to 
fully mature and ovulate as they should (142). Clinically, anovulation, the complete loss of 
ovulation, or even oligoovulation (time between two menstrual periods being longer than 35 
days or <10 cycles per year) is most often presented as amenorrhea or oligomenorrhea, a 
disturbance in the natural menstrual cycled defined in the same way (148). However, it should 
be noted that not all women with ovulatory dysfunction have concurrent menstrual 
dysfunction with studies showing that only 60-85% of PCOS patients with oligoovulation 
exhibit menstrual dysfunction while the remainder seem to display normal menstrual cycles 
(148).  
1.2.2.2 Polycystic Ovaries and Ovarian Volume 
Despite appearing in the name of the syndrome, polycystic ovaries are not present in all 
patients with diagnosed PCOS. In fact, polycystic ovaries can be found in up to 20% of the 
general public and as many as 30% of women with diagnosed PCOS do not have polycystic 
ovaries (153). Defined as the presence of 12 or more follicles, in each ovary, measuring 2-
9mm in diameter (146), the idea that polycystic ovaries should be an included diagnosis 
criterion is hotly debated. Polycystic ovaries or ovarian cysts are relatively common during 
early puberty with the incidence declining with age, with cysts less likely to be seen in post-
menopausal women (154). It is the presence of multiple cysts within the ovary that can cause 
an increase in ovarian volume which can be detected via ultrasound. A volume greater than 
10ml warrants investigation (146), and if multiple cysts are also found then a diagnosis of 
PCOS is the most likely. A lack of apparent cysts, however, does not mean that PCOS is not 
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the likely cause. Studies have shown that PCOS women are more likely to show an increase in 
the stroma:whole ovary ratio upon ultrasound (155). 
1.2.3 Endocrine Traits of PCOS 
1.2.3.1 Hyperandrogenism 
As the most consistent feature of PCOS, hyperandrogenism and its associated symptoms have 
been widely characterised (156). Clinically, there are many signs which can indicate high levels 
of male sex hormones in female patients. Acne during puberty is most often due to hormonal 
imbalances experienced during this life transition, however severe acne outside of this age 
can be a sign of hyperandrogenism with several androgens having being linked to severe acne 
such as T, DHT and DHEAS (157). Male-pattern hair loss, or androgenic alopecia, is another 
common presentation of hyperandrogenism as is hirsutism – defined as the presence of 
excess terminal body hair growing in a male pattern, for example on the face or chest (158). 
Hirsutism is evaluated using the Ferriman-Gallwey score with a score greater than 6 being 
indicative of hyperandrogenism (158). Biochemically speaking, hyperandrogenism can be 
defined as an increase in circulating total and free testosterone as well as DHEAS or an 
increase in the free androgen index (FAI) which gives an idea of the amount of androgen 
circulating that is not bound to SHBG and is therefore readily available for use (159).  
1.2.3.2 LH Hypersecretion 
Whether or not LH hypersecretion is a feature of PCOS is debated amongst clinicians and 
researchers. The measurement of gonadotropins, in particular LH, is widely used in the clinic 
during the diagnosis of PCOS with an elevated LH:FSH ratio >2 considered by some to be 
indicative of possible PCOS (160). However this is not part of the diagnostic criteria, with 
researchers having shown that in some populations as little as 50% of women with diagnosed 
PCOS do not display this imbalance in the LH:FSH ratio (160). This increase in LH levels is 
thought to be due to a decreased sensitivity of the GnRH pulse generator to inhibition by the 
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negative feedback effects of E2 and P4 (161,162) leading to increased pulse frequency with a 
subsequent increase in the pulsatile release of LH (161). 
1.2.4 Metabolic Traits of PCOS 
The Metabolic Syndrome is diagnosed by the co-occurrence of three out of the five following 
metabolic conditions: elevated blood pressure; abdominal (central) obesity; elevated serum 
triglycerides; low high density lipoprotein (HDL) cholesterol levels and elevated fasting 
glucose levels (163). This syndrome is also highly associated with insulin resistance and type 
2 diabetes mellitus (T2DM) and has been linked to PCOS (164). 
1.2.4.1 Insulin Resistance 
Insulin resistance and compensatory hyperinsulinemia are common finds amongst the obese 
within the general population, and those suffering from PCOS are no exception (165). 
Unfortunately, this state is able to increase production of ovarian androgens and decrease 
SHBG production which results in androgen excess, the degree of which increases with 
obesity (166). That is not to say that lean women with PCOS are not affected by insulin 
resistance also. It has been reported that insulin resistance is present in around 80% of PCOS 
women, with 75% of lean PCOS women being affected and 95% of overweight women being 
affected, leading to the conclusion that insulin resistance may be intrinsic to PCOS regardless 
of adiposity (166). One modulator of insulin receptor sensitivity is TNF-α, a cell-signalling 
adipokine involved in systemic inflammation (167). Chronic low-grade inflammation is 
present in PCOS and TNF-α levels have been shown to be elevated in many women with PCOS, 
particularly those with abdominal obesity (168), leading to the conclusion that with regards 
to insulin resistance, lean women with PCOS are as metabolically dysfunctional as non-PCOS 
obese women because of their concurrent hyperandrogenism or constant state of 
inflammation (166,168). 
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1.2.4.2 Obesity 
It has been widely noted that PCOS is often associated with obesity (143,146,149). But despite 
the somewhat public perception that all patients with PCOS are overweight or obese there is 
actually substantial variability in the incidence of being either overweight (Body mass index 
(BMI) between 25-30 kg/m2) or obese (BMI between over 30 kg/m2) in PCOS women from 
different populations worldwide, with some populations having as little as 10% of PCOS 
women being overweight but not obese while others having around 37% (143). 
Unsurprisingly, the countries reporting the highest rates of obesity amongst its PCOS women 
are those countries who rate among the top worldwide for the prevalence of obesity in the 
general public – Australia and the United States (169,170). Women with PCO are more likely 
than matched controls to exhibit increased upper body fat distribution with a particular 
increase in visceral fat. 
1.2.4.3 Dyslipidemia and Cardiovascular Risk 
Dyslipidemia, or more specifically hyperlipidemia (an abnormally high amount of lipids in the 
blood), is a serious side effect of obesity and is a strong risk factor for cardiovascular disease 
and stroke due to its encouraging effects on atherosclerosis. While  causes have been 
proposed for primary hyperlipidemia, secondary hyperlipidemia is most often the result of 
chronic elevated insulin levels (164). It has been shown that even in non-diabetic, non-obese 
PCOS patients as young as in their 20’s, circulating levels of triglycerides as wells as non-HDL 
cholesterol were twice as high as matched controls and levels of HDL-cholesterol, or “good 
cholesterol” were 60% lower in PCOS women (171). Higher LDL cholesterol levels have been 
found in women with PCOS even when the patients are neither overweight nor obese (164). 
This dysregulation in lipid utilisation and storage is why PCOS is linked to an increased 
incidence in cardiovascular disease. Impaired glucose tolerance, the metabolic syndrome, 
T2DM and dyslipidemia are all major risk factors for cardiovascular disease and all are 
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associated with PCOS in lean, overweight and obese PCOS women and are all 3 times more 
likely to be seen in these women than in those without PCOS (143).  
1.2.4.4 Hepatic Steatosis 
Hepatic steatosis, or non-alcoholic fatty liver disease (NAFLD), is one of the most common 
causes of chronic liver disease and liver failure in the western world (172). It is characterized 
by the accumulation of lipid within the liver that is not the result of excessive alcohol intake. 
NAFLD can present anywhere on a large spectrum of histological changes ranging from benign 
simple steatosis (nonalcoholic fatty liver) to the most serious cirrhosis of the liver and 
ultimately liver failure (173). It has long been known that NAFLD is associated with insulin 
resistance and central obesity so the link to PCOS seems obvious considering that these two 
metabolic features are so commonly linked with PCOS. Today the incidence of NAFLD in PCOS 
is estimated to be around 40-55% (173). NAFLD may be of particular concern due to the 
increase risk it places the patient in of developing hepatocellular carcinoma (liver cancer) 
once cirrhosis of the liver has set in (172). Due to the often early onset of PCOS in many 
populations, NAFLD needs to be carefully screened for and monitored as patients with NAFLD 
have a 2.6-fold increase in mortality rate compared to the general population (174). 
Treatment of NAFLD in its earliest stages requires diet and lifestyle intervention while the 
later stage non-alcoholic steatohepatitis (NASH) has shown mixed responses to drugs like 
metformin and thiazolidinediones (TZDs) (174). 
1.2.5 Other Co-morbidities and Complications of PCOS 
1.2.5.1 Cancer Risk 
Due to two of the most common traits of PCOS (obesity and anovulation) the risk for 
developing reproductive cancers is significantly higher in these women compared to those 
without PCOS. When large antral follicles fail to ovulate in PCOS, their ability to produce 
estrogens does not diminish, and it is this unopposed production of estrogens that raises the 
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risk of developing cancer, in particular endometrial cancer (175). In addition to these factors, 
the risk of endometrial cancer can also be increased by nulliparity and infertility, hypertension 
and T2DM which are all associated morbidities of PCOS (176). It has been proposed that 
endometrial hyperplasia is a precursor to the development of adenocarcinoma, and the 
increased interval between menstrual periods often seen in PCOS may be associated with 
endometrial hyperplasia (177). The risk of developing endometrial cancer for women with 
PCOS is estimated to be around 3.1 times higher than women without PCOS (175). The lack 
of ovulation in PCOS may also be linked to an increased risk of ovarian cancer, due in part to 
the increased use of drugs intended to induce ovulation in anovulatory PCOS women (175). 
However, the evidence surrounding the link between PCOS and ovarian cancer is highly 
varied. Some studies have suggested that it is infertility on its own that increases the risk 
(178,179), while others suggest that it may be prolonged treatment with clomiphene citrate 
in these women that can increase the chance of developing ovarian cancer (180). Despite this 
earlier data in favour of a link between PCOS and ovarian cancer, more recent studies and 
analyses suggest that the news is more positive and that no strong link exists to suggest that 
women with PCOS are more likely to develop ovarian cancer than those without PCOS 
(181,182). 
1.2.5.2 Pregnancy Complications 
As well as infertility issues that decrease the chances of a woman with PCOS conceiving 
naturally, side effects of the syndrome’s co-morbidities can have severe consequences for 
any pregnancy that the patient is able to achieve. As a syndrome of hormone imbalances, 
PCOS puts the expectant mother at a higher risk for spontaneous miscarriage due to the 
developing fetus’ dependence on stable hormone levels throughout pregnancy, with an early 
miscarriage rate of 30-50% being reported in PCOS women (183). Others believe that 
miscarriage can occur in these women due to defects in the corpus luteum required to 
maintain the uterine lining and therefore the pregnancy (184). It has been shown that defects 
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seen in large antral follicles in PCOS ovaries that go on to ovulate under stimulation can also 
be seen in the resultant corpus luteum and could lead to the inability of that corpus luteum 
to maintain a successful pregnancy. 
Once again, high insulin levels are able to affect the normal function of an ovulating follicle, 
whereby hyperinsulinemia is able to trigger the production of excess LH and testosterone, the 
three of which have been linked to lowered egg quality (185). Due also to high insulin levels 
is the increased rate of gestational diabetes amongst women with PCOS (183,186). It is well 
established that gestational diabetes is associated with pre-term birth, large birth weight and 
difficulty breathing unassisted for the newborn, as well as an increased risk for T2DM later in 
life for the child and also for the mother (186).  Pre-eclampsia is another severe pregnancy 
complication that has a higher incidence in PCOS women (187). Pre-eclampsia is characterised 
by a sudden increase in blood pressure and if left untreated can develop into the much more 
serious eclampsia. Eclampsia can cause organ damage, seizures and increases the chances of 
a stillbirth, as well as being potentially fatal to the mother. Babies born to PCOS mothers have 
a higher incidence of being admitted to the neonatal intensive care unit, perinatal mortality 
and delivery complications requiring a caesarean section (186-188). 
1.2.5.3 Psychological Impact and Quality of Life 
Many of the symptoms typically associated with PCOS such as acne, hirsutism, infertility, 
menstrual dysfunction and obesity can negatively affect quality of life in patients suffering 
from this condition without a cure. While these aspects of PCOS can impact on the physical 
quality of life, a recent focus of the psychological quality of life has shown that PCOS women 
report a significantly lower quality of life in this regard than do controls (169). Despite recent 
pushes by society to accept bodies of all shapes and sizes, obesity is generally the largest 
contributor to reduced quality of life, followed by other appearance-based factors (189). 
Although infertility is a significant cause of depression in some women with PCOS (169), other 
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studies have suggested that this may not be as important a factor in reducing quality of life 
as those that impact negatively on body image and self-esteem (189-191). 
1.2.6 Current Treatments for PCOS 
Due to the complex nature of PCOS and the lack of clear understanding as to what causes it 
and what genes may or may not be involved, a cure or single treatment for PCOS does not 
exist. Thus far the focus has been primarily on the treatment and control of the many 
symptoms and co-morbidities of PCOS. None of the current therapeutic agents are capable 
of reversing all of the multiple indications of PCOS, therefore a combination of therapies plus 
various lifestyle modifications are often necessary in order to control signs of PCOS and allow 
the patients to live a relatively normal life. The focus of these current therapies, be it 
pharmaceutical, surgical, lifestyle or assisted reproductive technologies (ART), is to 
compensate for or correct the hormonal imbalance that underpins the progression of PCOS 
and the presentation of its symptoms.  
1.2.6.1 Pharmaceutical Treatment 
1.2.6.1.1 Clomiphene Citrate 
Clomiphene citrate (CC) remains the top drug of choice for the induction of ovulation and 
restoration of fertility in anovulatory women with PCOS. A variety of factors make CC the ideal 
choice for treating PCOS including its ease of use by patients, low cost compared to alternative 
drugs, clinical safety record with few adverse side effects that require very little monitoring 
of the ovarian response (151). CC acts by competitively inhibiting estrogen receptors within 
the hypothalamus, blocking the negative feedback effects of estrogens on GnRH release and 
therefore the release of LH and FSH and the up-regulation of the HPG axis (192). Most 
important in female users of CC is the release of FSH in order to stimulate the growth of 
follicles for subsequent ovulation. Ovulation rates are reported to be as high as 75-80% in CC 
users (193) with those failing to achieve a pregnancy after 6 ovulatory cycles deemed to be 
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CC-resistant as this is usually sufficient time to determine if the patient will respond or not 
(192). Failure by CC to induce ovulation is more likely in patients who have hyperandrogenism, 
insulin resistance or who are obese (194). For those patients for whom CC has not been 
successful, more invasive surgical procedures are recommended (195). 
1.2.6.1.2 Metformin 
Metformin is primarily an anti-diabetic drug used in the treatment of T2DM.  Capable of 
lowering blood glucose levels by suppressing hepatic gluconeogenesis (the production of 
glucose by the liver – although the precise mechanism remains a mystery) (196), metformin 
has since become a common treatment for the metabolic consequences of PCOS. Metformin 
has been shown to increase the frequency of ovulation, but some dispute that this may be 
due to the concurrent weight loss seen in patients undertaking metformin therapy (197). 
Others are more in favour of the beneficial effects of metformin on anovulation in PCOS 
showing that patients taking metformin are almost 4 times more likely to ovulate than those 
who received a placebo treatment and equivalent weight loss (198). Despite this, others have 
shown that metformin does not increase the live birth rate in women taking this drug 
compared to CC or lifestyle modification (199,200). However, 15-20% of patients who take 
metformin experience gastrointestinal side-effects, leading many to discontinue taking the 
drug (192,194). 
1.2.6.1.3 Combined Clomiphene Citrate + Metformin 
The benefits of using of a combined CC + metformin treatment are hotly debated. Some 
studies have found that the combined treatment has no benefit whatsoever (194,199,200) 
over CC alone, while others disagree stating that CC + metformin results in higher ovulation 
and pregnancy rates than either drug on its own (192). However, it should be noted that those 
studies in favour of a combined therapy have not been able to definitively show that the 
benefit seen in those taking the combined therapy is independent of the weight loss that 
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occurs when metformin is used. It has therefore been suggested that the addition of 
metformin to CC treatment only be advised for those patients with a BMI > 35kg/m2 (151). 
1.2.6.1.4 Other Insulin Sensitizers 
The thiazolidinediones, namely pioglitazone and rosiglitazone, have a similar effect as 
metformin in lowering blood glucose levels. They act by binding to the peroxisome 
proliferator-activated receptor γ (PPAR-γ) in adipose tissue which is usually bound by free 
fatty acids. In this way these drugs are able to initiate downstream synthesis of a number of 
genes responsible for fat storage and gluconeogenesis (201). While these drugs have been 
shown to improve ovulation rates in some PCOS women (202), as well as reducing 
testosterone and glucose and insulin levels (203), the main concern with the use of these is 
the risk of liver toxicity as well as weight gain and negative cardiovascular effects 
(151,202,204).   
1.2.6.1.5 Anti-Androgens and Aromatase Inhibitors 
Low-dose oral contraceptive pills (OCPs) have been used in the treatment of the androgenic 
symptoms of PCOS such as hirsutism, acne and irregular menses. They are able to suppress 
the negative-feedback-controlled release of LH and FSH and therefore try to suppress the 
over-production of androgens which can cause these symptoms (205,206). OCPs are also able 
to decrease hepatic production of SHBG and therefore decrease the amount of circulating 
free T (193,206) and may be able to inhibit binding of DHT to the androgen receptor (206). 
The anti-androgenic properties of compounds found within OCPs, such as cyproterone 
acetate, are known to inhibit 5 α-reductase and subsequently reduce the availability of the 
more potent androgen DHT (207), and reduce ovarian androgen production by suppressing 
the release of gonadotropins (193). Caution should be applied when using anti-androgens 
outside of the OCP, owing to the fact that if proper contraception is not used there is risk of 
feminisation of a male fetus (193). 
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Because aromatase is the primary enzyme responsible for the conversion of androgen 
precursors to estrogens, aromatase inhibitors, such as letrozole and anastrozole, are used to 
reduce circulating estrogen levels. High estrogen levels result in an increase in the negative 
feedback placed on the secretion of FSH from the pituitary. By lowering estrogen levels, this 
feedback can be alleviated and FSH secretory dynamics can try to return to normal (208). 
Earlier studies showed that the use of aromatase inhibitors were able to increase pregnancy 
and delivery rates in women with PCOS (209), however more recent studies have stated the 
comparable results between aromatase inhibitors and CC with regards to pregnancy and live 
birth rates (210,211) but that letrozole treatment achieves a better endometrial response as 
measured by endometrial thickness (212). It should be noted that concerns have been raised 
over the safety of aromatase inhibitors with regards to congenital abnormalities (193) with 
cases of cleft palate and heart defects having been reported in the offspring of letrozole users 
(210). Despite this a recent, large randomised controlled trial containing 750 women has 
concluded that letrozole is not significantly associated with birth defects compared to CC and 
that letrozole actually achieves higher ovulation and live birth rates (213). 
1.2.6.1.6 Exogenous Gonadotropins and GnRH Analogues 
The use of gonadotropins to induce ovulation in PCOS is not new. Studies from the 70s 
showed that with the administration of the hypergonadotrophic substance human 
menopausal gonadotropin (hMG – which often also contains human chorionic gonadotropin 
(hCG)), conception rates were increased in women who had previously failed to respond to 
CC (214). Initially, risk of ovarian hyperstimulation syndrome (OHSS) as well as spontaneous 
first trimester abortion were a common side effect of using such preparations. However, since 
then a better understanding of the physiological mechanisms involved has led to the 
evolution of low-dose gonadotropin therapy with subsequent ultrasound monitoring to 
reduce the risk of OHSS (193). This low dose is designed to be just above the threshold 
required to develop and maintain 1 or 2 follicles without exceeding this threshold so much 
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that OHSS and multiple pregnancy become risks. This is especially important in PCOS women 
who are especially prone to multiple follicle selection and growth (151,193). Ovulation rates 
following low-dose gonadotropin therapy are reported to be around 70% with pregnancy 
rates around 20% (151,193). 
The use of pulsatile GnRH in PCOS women displaying abnormal patterns of release has all but 
been discontinued.  It was initially thought to help women for whom CC and anti-estrogens 
had previously failed to induce ovulation by providing a normal pattern of GnRH in hope of 
leading to normal FSH and LH dynamics (215). However, the efficacy of this treatment regime 
has yet to be decisively established. 
1.2.6.2 Surgical Interventions 
1.2.6.2.1 Ovarian Wedge Resection 
Before the invention of pharmaceutical interventions for the management of PCOS 
symptoms, surgical treatment was the only option. As one of the first of these surgical 
treatments, ovarian wedge resection involved an open laparotomy and the removal of up to 
75% of each ovary (216). The benefit of this treatment was first described by Stein and 
Leventhal (141) who noted that ovulation rates improved following ovarian biopsy. It was 
thought that by removing some of the ovary and returning it to a ‘normal size’ the endocrine 
output of the ovaries would also return to normal. Ninety years later, the success of this 
technique was reported as a pregnancy rate of 58.8% (217). The most common side effect of 
this procedure is pelvic adhesions, reported to be as high as 100% in some cases (216). The 
use of wedge resection has become less and less common with the arrival of drug therapies 
for PCOS and the invention of less invasive, less risky laparoscopic surgical techniques. 
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1.2.6.2.2 Laparoscopic Ovarian Drilling 
Less invasive, laparoscopic ovarian drilling involves the targeted puncture of large follicles or 
cysts within the ovary, either by laser or by electrocautery (diathermy), in order to decrease 
the hypersteroidogenic capacity of the ovary (218). There does not seem to be a difference 
in outcomes between the two drilling methods (219). As little as four punctures has been 
shown to be effective in the management of menstrual irregularity or hyperandrogenism with 
most treating physicians administering between 4 and 10 punctures as more than this has 
been associated with premature ovarian failure (220). The most common side effect of 
ovarian drilling is the development of peri-ovarian adhesions. Although significantly less risky 
than pelvic adhesions the formations of these strictures on the surface of the ovary can 
damage the ovarian surface epithelium and compromise future ovulations and fertility (219). 
Twelve months following ovarian drilling, the cumulative pregnancy rates of these women 
are equal to those who undergo gonadotropin therapy (216). 
1.2.6.3 Assisted Reproductive Technologies (ART) 
1.2.6.3.1 In Vitro Fertilisation (IVF) and Intracytoplasmic Sperm Injection (ICSI) 
In vitro fertilisation (IVF) is the recommended third-line treatment for PCOS-related 
anovulation behind the use of CC and gonadotropin therapy for ovulation induction (151). IVF 
involves the retrieval of the women’s oocytes following natural or induced ovulation for 
fertilisation in vitro. The fertilised oocyte (now called a zygote) is cultured for 2-6 days before 
being transferred to the uterus in the hopes of establishing a successful pregnancy. It is 
common for the IVF process to be driven with artificial ovarian stimulation with several 
protocols having been developed including the use of CC, hMG, FSH, GnRH agonists or 
antagonists or a combination of these (221-223). The primary risk associated with stimulated 
ovulation is the chance of developing OHSS. The main benefit of IVF is the ability to severely 
reduce the incidence of multiple-pregnancy by transferring just one embryo into the uterus. 
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IVF is particularly helpful for those PCOS patients who also have concurrent tubal infertility 
(151) by eliminating the need for the oocytes to travel through the fallopian tubes. The 
success rates of IVF treatment are around 34% of cycles resulting in a pregnancy while 28% 
of cycles result in a live birth. These rates highly depend on the women’s age with women 
under 35 achieving pregnancy rates around 43% and live birth rates around 37% (224). 
The use of Intracytoplasmic sperm injection (ICSI) is popular in cases of concurrent male-
factor infertility and involves the injection of a single sperm into the egg after retrieval. This 
is then followed the by the same culture and transfer procedures as IVF. There has been some 
debate as to whether or not IVF and ICSI are associated with an increase in the incidence of 
birth defects and chronic conditions such as Prader-Willi syndrome and Angelman syndrome. 
Although the mechanism remains unclear, children born using ART are at an increased risk of 
cleft lip (with or without cleft palate), septal heart defects, esophageal atresia and anorectal 
atresia (225) with a recent systematic review and meta-analysis, involving almost 100,000 
ART infants, concluding that these children are 1.4 times more like to be born with birth 
defects than naturally conceived children (226). Others disagree stating that the observed risk 
to ART infants born via IVF is eliminated once parental factors, such as age, race, parity, 
smoking status and diseases in pregnancy, were adjusted for (227). The risk, however, 
remained for infants born via ICSI, however the researchers understand that ICSI is most 
commonly performed in couples for whom male-factor infertility is also an issue and male 
parental factors could not accurately be controlled for in their analysis. IVF and ICSI have also 
been associated with an increase in imprinting disorders such as those above as well as Silver–
Russell syndrome and Beckwith–Wiedemann syndrome, which are both growth disorders 
(228). There is currently no evidence that ART is linked to an increase in childhood cancer 
(229). 
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1.2.6.3.2 In Vitro Maturation (IVM) 
IVM is the process of maturing the ovarian follicle in vitro before subsequent ART processes. 
The benefits of this technique include that it does not require any artificial ovarian 
stimulation, and therefore nearly eliminates the risk of OHSS, as well as rescuing oocytes that 
are otherwise destined to “die” in vivo and possible benefits for women undergoing intensive 
cancer treatment who wish to preserve their fertility (230). Women with PCOS or non-PCOS 
cystic ovaries form the majority of women undergoing IVM due to their increase likelihood 
and severity of OHSS (231), however women with low follicular reserves can also benefit as 
oocytes that are immature after ovarian stimulation are often discarded as they do not result 
in successful pregnancies after ART. IVM allows these collected immature oocytes to be 
matured in the lab, rather than lost, and then used for subsequent cycles of IVF or ICSI (232). 
More recently, IVM has been used for other patients showing no or poor response to IVF such 
as those with empty follicle syndrome, oocyte maturation arrest or idiopathic failure of 
fertilization (233).  
1.2.6.3.3 Outcomes of ART in PCOS Women and Ovarian Hyperstimulation Syndrome 
Recent meta-analyses have shown that women with PCOS achieve similar pregnancy and live 
birth rates as non-PCOS patients seeking ART to conceive (151,187,224,234), even though 
PCOS women have higher cycle cancellation rates (prior to egg collection) due to lacking or 
inadequate response from the ovary leading to a longer stimulation time required or, more 
commonly, the increased risk of developing OHSS (224). At its most severe, OHSS can lead to 
ovarian torsion or rupture which can be life threatening. Women with PCOS have a 10% risk 
of developing OHSS compared with a risk of 0.5–4.0% in the general population undergoing 
IVF (235). Due to this propensity to over-respond to ovarian stimulation, PCOS patients have, 
on average, 3.4 more oocytes collected per retrieval than non-PCOS women (224,234). 
Despite this, fertilization rates are significantly lower in PCOS women (234) leading to the 
somewhat obvious conclusion that oocyte quality is much poorer in women with PCOS. 
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Because of this, the number of fertilized oocytes available for transfer is similar in PCOS and 
non-PCOS women, and the clinical pregnancy and live birth rates are equivalent in each group 
of women (234). 
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Table 1.1 Summary of The Current Treatments for PCOS 
 
Summary of the current treatments employed to treat the various symptoms of PCOS and the 
effectiveness of these treatments on the fertility of PCOS patients. 
  
Type Treatment Current Effectiveness
Ph
ar
m
ac
eu
tic
al
Clomiphene Citrate 75-80% ovulation rate (195)
Metformin Ovulation rates 4x those with equivalent weight loss (198)
Combined Clomiphene
Citrate and Metformin
Higher ovulation, pregnancy and live birth 
rates than either drug alone (192)
Insulin Sensitizers Significantly improved ovulation rates (202)
Anti-Androgens and 
Aromatase Inhibitors
Decreased serum androgen levels and 
improvement of androgenic symptoms 
(193,206)
GnRH and
Gonadotropin Therapy
70% ovulation rate, 20% pregnancy rate 
(151,193)
Su
rg
ica
l Ovarian Wedge Resection Rate of pregnancy approximately 60% (217)
Laparoscopic Ovarian Drilling Cumulative pregnancy rates equal to that of gonadotropin therapy (216)
As
sis
te
d
Re
pr
od
uc
tiv
e 
Te
ch
no
lo
gi
es In Vitro Fertilisation (IVF),
Intracytoplasmic Sperm 
Injection (ICSI) and In Vitro 
Maturation (IVM)
Pregnancy rates similar to that of non-PCOS 
patients – over 30% of treatment cycles (224)
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1.2.7 Proposed Causes of PCOS 
PCOS is inarguably a multifactorial, complex condition with high heterogeneity of clinical 
presentation. The variability of phenotypes and severity of PCOS symptoms are key factors 
contributing to the confusion surrounding the cause(s) of PCOS. Familial clustering adds 
significant weight to the idea that PCOS is a  and heritable condition. However,  studies so far 
have been unable to reach a consensus regarding any PCOS-causing genes. As the most 
common feature present in PCOS women is hyperandrogenism, androgens have naturally 
been implicated in the pathogenesis of PCOS. More recently, it has been proposed that there 
is an interaction between  perturbations that leave certain individuals susceptible to 
hyperandrogenic influences in the environment.  
1.2.7.1 Fetal Origins 
PCOS may arise from exposure during fetal life that can impact the normal development of 
the fetus and lead to dysregulation of normal endocrine function later in life, causing PCOS. 
By evaluating the first-degree relatives of women with NIH-diagnosed PCOS, researchers 
found that, when assessing their premenopausal relatives, 35% of mothers and 40% sisters 
were also found to have PCOS (236). This may also lend itself to the argument that PCOS is a  
disorder. The machinery necessary for androgen production is present in fetal life, as evident 
from the examination of human fetal ovaries (237). Evidence also shows that the fetal ovary 
may be capable of producing androgens with the presence of the CYP17 enzyme as well as 
numerous androgen receptors (238,239), and that ovaries ‘pre-programmed’ to become 
plagued with PCOS may secrete increased amounts of androgens in response to hCG (240). 
Levels of hCG can be higher in pregnant women with PCOS (156). Additionally, maternal 
adrenal proandrogens can act as substrates for fetal ovarian androgen biosynthesis and levels 
of these proandrogens can be increased in conditions such as 21-hydroxylase deficiency or in 
the presence of excess 17,20 lyase enzyme in the mother (156).  
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Animal models have provided the strongest evidence for a fetal origin of PCOS. Prenatally 
androgenised rodents, sheep and non-human primates all display aberrant endocrine 
performance and altered ovarian functionality, such as that seen in PCOS, in adulthood as a 
result of exposure to high levels of androgens in utero (237,241-245). In addition, rodent 
models have also shown that exposure to androgens during key times of early postnatal life, 
equivalent to human childhood and pre- and peripubertal periods, causes disruption of the 
normal functioning of the HPG axis and the development of PCOS-like characteristics in 
adulthood (245).  
While these animal models of hyperandrogenism have provided numerous insights into the 
development of PCOS and its possible cause(s), the source of excess androgens in these 
animals is exogenous. In humans, the source of excess androgens in fetal life is less 
straightforward. It is well known that women with PCOS who display elevated androgen levels 
continue to do so during pregnancy (156,246-248), sometimes to levels sufficient to cause 
virilisation of the mother or female fetus (156). Normally, both maternal and fetal androgens 
are quickly processed into estrogens by the aromatase activity of the placenta (237) with high 
efficiency, even in mothers with androgen secreting tumors (240). However, if the placenta is 
impaired, such as in the case of maternal malnutrition or placental aromatase deficiency, the 
levels of androgens that the fetus is exposed to may rise (156,249,250). Insulin has been 
shown to inhibit the activity of aromatase (251) and hyperinsulinemia is a common 
characteristic of PCOS. Combined with evidence that diabetic women who use insulin during 
their pregnancy are more likely to give birth to larger babies who display PCOS traits such as 
hirsutism, ovarian cysts, theca cell hyperplasia, as well as increased levels of T in the amniotic 
fluid (241,247,252-254), it may be that concurrent hyperinsulinemia and hyperandrogenism 
in pregnant mothers can lead to a hyperandrogenic environment for the developing fetus. 
Theca cell hyperplasia within the fetal ovary, in particular, may contribute to the fetal 
hyperandrogenic environment (156) in pregnancies with normal maternal androgen levels. 
Additionally, mothers with PCOS are more likely to give birth to babies that are smaller than 
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average for their gestational age (246,255), a condition which has been shown to lead to the 
premature onset of puberty, dyslipidemia, hyperinsulinemia and functional 
hyperandrogenism later in life (247,256,257). These findings give rise to the idea that the 
ovary could be “pre-programmed” during fetal life to be susceptible to producing excess 
androgens in later life, in response to cues such as the onset of puberty, or environmental 
stimuli such as obesity (240,241).  
Another possible source of excess androgens during fetal life is that of the female fetus’ male 
twin. Studies in animals have shown that androgens are able to diffuse through fetal 
membranes and into the amniotic fluid (258). It was originally thought that females born of 
an opposite-sex twin pair were 25% less likely to reproduce than those women from same-
sex twin pairs (259), however more modern studies involving multiple populations have since 
shown no difference in the fecundity of females from opposite-sex twin pairs compared to 
those from same-sex twin pairs (258,260). In addition, the prevalence of PCOS in women with 
a male twin has been shown to be no different from those born with a female twin (both 
monozygotic and dizygotic), singleton sisters of twins or even biologically unrelated women 
(258). This suggests that contribution of the male fetus to an androgenic environment in utero 
does not contribute significantly to the development of PCOS in later life.  
While the contribution to androgen levels by the adrenals in PCOS is minor in adults (240), 
there is evidence to suggest that adolescents with congenital adrenal hyperandrogenism 
(CAH) are at an increased risk of developing PCOS and that this risk may have been pre-
programmed during fetal life when excess adrenal androgens contributed to the 
hyperandrogenic environment during key moments in fetal development (156,237). 
Congenital conditions that lead to adrenal hyperandrogenism, such as 21-hydroxylase 
deficiency, 17,20 lyase excess and adrenal virilising tumours, carry with them an increased 
prevalence of PCOS (156,237,240,247), and have been shown to manifest in PCOS symptoms 
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prior to and during puberty (237,240), further strengthening the idea that the morphological 
and functional ovarian features of PCOS are pre-programmed in these individuals.  
The idea that PCOS has its developmental origins in fetal life still has some unconvinced. It is 
true that not all females exposed to the hyperandrogenic PCOS environment in utero go on 
to develop PCOS themselves, leading to the hypothesis that the development of PCOS must 
not be purely due to exposure to this “unfavourable” environment, but must instead have 
other determinants such as genetics or postnatal interactions with the environment (237). 
One such example of this is the proposed interaction of insulin resistance and 
hyperandrogenemia in adult life. Both of these traits have the ability to alter the normal 
functioning of the GABAergic systemic which controls GnRH secretion and therefore 
downstream LH pulse frequency, accounting for the gonadotropin defects seen in PCOS 
(237,261-263). The cause of the metabolic phenotype that would result in both insulin 
resistance and hyperandrogenemia remains elusive, although genetic predispositions may 
once again be implicated as they “confer greater reactivity” to perturbations of the hormonal 
milieu (237).  
1.2.7.2 Possible Male Phenotype of PCOS 
It must also be considered that if PCOS was to be a condition arising purely from in utero 
exposures, then male offspring of PCOS women would likely be affected by an equivalent 
condition. A male phenotype has yet to be formally defined, although many refer to such a 
condition by the original moniker for PCOS, Stein-Leventhal Syndrome. Studies have shown 
that brothers of women with PCOS have an increased prevalence of dyslipidemia and insulin 
resistance, often manifesting in similar ways to their PCOS sisters (264). It is often said early 
androgenic alopecia (AGA) in males, defined as occurring before the age of 30, is the 
phenotypic equivalent of PCOS in females (265). In fact, women with PCOS often suffer from 
AGA while men with early AGA repeatedly display hormone profiles similar to that seen in 
PCOS (266), with these men being more likely to suffer from insulin resistance and other 
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metabolic features of PCOS than those with early AGA but without hormone profiles matching 
those of PCOS women (267). The brothers of PCOS women can also display increased DHEA-
S levels, which has been suggested to be the reproductive phenotype in these men (268). 
Many of the visible symptoms experienced by PCOS are often ignored in men simply because 
they are typically male characteristics, such as hirsutism which has been reported, along with 
early AGA in the first-degree male relatives of PCOS women (269). Other studies have found 
that the first-degree relatives of PCOS women, including brothers, sons and fathers, are more 
likely to have had increased body weight during childhood and increased BMI during 
adulthood (270). Additionally, these men also have increased prevalence of insulin resistance 
and T2DM, independent of body weight, putting them at an increased risk of cardiovascular 
disease and other metabolic complications (270,271).  
Whether this male phenotype of PCOS will be recognised as Stein-Leventhal Syndrome 
remains to be seen, however, what is clear is that this manifestation of PCOS-like 
characteristics in the relatives of PCOS lends significant weight to the theory of a genetic basic 
for PCOS. 
1.2.7.3 Interaction of Environment and Genetics - Epigenetics 
The rise of epigenetics over the last few decades has lead the way for research into how the 
epigenome could potentially play a role in the pathogenesis of PCOS. Off the back of animal 
studies, which showed that fetal exposure to excess androgens could lead to PCOS-like 
symptoms in adulthood when the exposure is no longer present, researchers have proposed 
that the hyperandrogenic environment may perturb the epigenetic programming of the 
developing fetal ovary in utero (272). These changes are what “pre-programme” the ovary to 
become hyperandrogenic in the future. It is postulated that the epigenetic alterations 
inflicted on the fetal ovary are not erased from the germline during fertilisation and the 
resumption of meiosis II and are therefore passed on to the next generation (273), a theory 
that is supported by transgenerational animal models (274,275). One such study, in a DHEA-
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induced PCOS mouse model, showed that the female offspring of PCOS mice experienced 
increased body fat, dyslipidemia and impaired glucose tolerance which was coupled with 
altered expression of several key genes involved in glucolipid metabolism, including 
peroxisome proliferator-activated receptor gamma (PPAR-γ) and CYP17a1 (275). 
Interestingly, although male offspring also displayed increased body weight, albeit during the 
first four weeks of life only, there were no apparent genetic alterations, suggesting that 
epigenetic modifications caused by in utero exposure to hyperandrogenism may be specific 
to females, with males somehow protected from this phenomenon. A study of human 
granulosa cells from hyperandrogenic and nonhyperandrogenic PCOS women undergoing IVF 
showed different methylation levels at the cytosine-phosphate-guanine (CpG) sites of nuclear 
receptor co-repressor 1 (NCOR1) and PPAR-γ, both of which have been shown to interact with 
the androgen receptor (276,277) with PPAR-γ also implicated in glucose homeostasis and the 
pathology of obesity and diabetes (277). Epigenome-wide association studies (EWAS) on both 
blood and ovarian tissue have revealed mixed results with regards to gene methylation status 
of PCOS vs non-PCOS tissues (273,278,279). However, multiple studies have pinpointed a 
number of functional pathways that are differentially methylated in PCOS patients, including 
one implicated in type-I diabetes mellitus (273,279).  
Interestingly, several EWAS studies have revealed that a number of pathways involved in 
autoimmune diseases, such as asthma and thyroid disease, are differential methylated in both 
the whole blood (280,281) and ovarian tissue (279) of PCOS patients, a finding that is 
supported by an increase in the prevalence of autoimmune diseases amongst PCOS women 
(282,283). Together, these suggest that PCOS could possibly have its origins in or be 
associated with autoimmune disease (284), although further research is required to establish 
a firm link between the two.  
DNA methylation studies have also found a difference in the methylation in the insulin 
receptor and LH/hCG receptor genes, particularly when comparing obese and non-obese 
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PCOS patients (285). This is reflected in the expression levels of these receptors in these two 
subsets of PCOS women and implies that epigenetic modifications may be the reason for the 
heterogeneity of symptoms displayed by PCOS patients. This has led many to believe that 
prenatal exposures may be responsible for epigenetic changes at key sites of the genome and 
that these changes may explain the transgenerational propagation of PCOS (286,287). 
1.2.7.4 Genetics 
The complex and multifaceted nature of PCOS and its involvement of both reproductive and 
metabolic abnormalities casts doubt on original ideas that PCOS could possibly be Mendelian 
in nature and inherited in an autosomal dominant fashion (156,288-290). For the same 
reasons, teasing apart the genetic basis for PCOS would require large cohorts with 
appropriate controls and the methodology required to detect any perturbation(s) present at 
the genetic level. While several candidate genes have been put forward as the result of whole 
genome sequencing or genome-wide association studies (GWAS), a genetic cause of PCOS 
remains to be determined, largely due to the lack of replication of positive results (291). The 
heterogeneity of PCOS suggests that multiple factors may work in combination, only adding 
to the difficulty in fully understanding the aetiology of this condition. Additionally, the 
multiple diagnostic criteria for PCOS and the current inability to diagnose PCOS in women 
who are not of reproductive age further complicate studies aiming to uncover the genetics of 
PCOS (292,293).  
1.2.7.4.1 Familial Clustering and Twin Studies 
Familial clustering has long suggested a genetic component to PCOS. Numerous studies of 
PCOS women and their first-degree relatives have attempted to establish a mode of 
inheritance with no avail (294,295). The strongest evidence for heritability in PCOS comes 
from a large Dutch twin-family study (296). This study of females from the Netherlands 
included 1332 monozygotic (MZ) twins and 680 dizygotic (DZ) same-sex twins. MZ, or 
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identical, twins result from one single fertilised egg that divides in two. While the genetics of 
these twins are near identical, some differences can arise due to epigenetic modifications. In 
70% of MZ pregnancies the developing zygote splits after the first four days of development 
and the twins share the same amniotic sac (21,29). Conversely, DZ, or fraternal, twins result 
from two separate fertilised oocytes which both implant and develop in the uterus. DZ twins 
are as genetically similar are regular siblings with almost all DZ pregnancies being diamniotic 
(separate amniotic sacs) (20,21,29). The Dutch study included 474 females from DZ opposite-
sex twin pregnancies as well as 719 singleton sisters. Results showed that while the 
prevalence of PCOS did not differ between MZ or DZ twins, or singleton sisters, there was a 
higher concordance of PCOS between MZ than DZ twins, strongly suggesting that PCOS has 
genetic origins but that it may be the result of an additive effect of multiple genes with 
contribution from environmental factors as well. Additionally, they propose that the 
pathogenesis of PCOS is 72% due to genetic factors and that the leading theory is that these 
factors result in a disruption of the normal ovarian androgenic activity with the environmental 
influence working to disturb the body’s sensitive insulin milieu. It is thought that this altered 
setting is what permits the ovarian hyperandrogenic state to produce the pathophysiological 
features of PCOS (292,296). 
Results from a smaller familial association study also suggest that PCOS is not the result of 
one single autosomal gene defect but rather a combination of environmental and polygenic 
effects as shown in twin pairs where only one twin is affected by PCOS (297). Similar metabolic 
and hormonal profiles in these twins, despite PCO status, endorses the notion that the 
genetics of PCOS are intricate and multifarious and that studies to date have been ill equipped 
to properly tease out a definitive genetic basis for PCOS. Another study showed that almost 
a quarter of the sisters of PCOS women themselves fulfilled the diagnostic criteria for PCOS 
while another quarter displayed functional hyperandrogenism (298). Both of these groups of 
sisters also exhibited elevated T levels. Hyperandrogenism is the most common trait displayed 
by the first-degree relatives of PCOS women, suggesting that this is a genetically inherited 
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trait (236,298,299). Ovarian hyperandrogenism has led many to investigate the genetic 
aspects of this trait such as the CYP steroidogenic enzymes as well other key enzymes involved 
in the biosynthesis of theca cell androgens (300-302). In addition to hyperandrogenism, 
metabolic traits of PCOS have also been shown to cluster in the families of PCOS women, such 
as insulin resistance and the metabolic syndrome (293,303,304), particularly in sisters and 
mothers.  
1.2.7.4.2 Candidate Genes 
Earlier cytogenetic studies of PCOS have not resulted in reproducible results (305), while 
studies of aneuploidy in unfertilised oocytes did not differ in PCOS patients vs normal patients 
undergoing IVF treatment (306). This has lead modern studies to focus on genetic techniques 
capable of detecting differences down to the single nucleotide level in an effort to pinpoint 
individual genes associated with the pathogenesis of PCOS. Association studies have been an 
effective tool with case-control studies, in particular, providing a strong foundation of 
evidence for current studies to focus on (307). GWAS are now considered to be the most 
effective, with their ability to cover a vast number of variants, identified by previous studies, 
at once.  
While the ability to identify genetic variants associated with PCOS only becomes more feasible 
as technology progresses, the critical next step must be to ascertain the biological relevance 
of these variants, with researchers suggesting that targeted gene disruption in cell culture or 
other organisms should be the vital first step (292). 
1.2.7.4.2.1 Genes Involved in Steroidogenesis and Ovarian Function 
Due to hyperandrogenism being the most consistent feature of PCOS, initial studies focused 
heavily on genes involved in androgen biosynthesis and ovarian and adrenal steroidogenesis. 
The CYP family of proteins act to catalyse enzymatic reactions and, in humans, a number of 
these are involved in the steroidogenic pathway. The CYP11a gene codes for the first enzyme, 
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and rate-limiting step, in the pathway – cholesterol side-chain cleavage enzyme. 
Polymorphisms in this gene were originally linked to increased T levels in PCOS (240,308,309). 
However, more recent larger studies have not shown such a link (310-312). Coding for the 
enzyme 17-hydroxylase/17,20-lyase, CYP17 was associated with ovarian hyperandrogenism 
(313,314), however, once again, a subsequent larger study failed to confirm this association 
or its linkage in familial studies of PCOS (315). The final member of the CYP family to be 
associated with PCOS is CYP21. This gene encodes the enzyme 21-hydroxylase, which is most 
commonly associated with cases of CAH (294). The prevalence of mutations in CYP21 was 
thought to be higher in women with PCOS (316,317), however the link between these 
mutations and increased androgen production has not yet been established (318).  
Using whole genome sequencing (WGS) of 80 Caucasian patients with NIH-diagnosed PCOS, 
researchers have found 3 rare variants in the AMH gene (AMH) that were not present in 
controls. Further testing of 643 PCOS cases revealed 21 further variants, of which 18 were 
specific to PCOS (319). Additionally, these variants were always inherited and never de novo 
and all subjects carrying variants were heterozygous. Almost all variants were discovered to 
be in the prodomain region of the AMH protein. As this region is responsible for the post-
translational processing of the protein, it is suggested that these variants may compromise 
AMH bioactivity. If this were to be the case, it could be feasible that this results in the 
diminished inhibition of ovarian T production and hence, hyperandrogenism (319). 
The gene encoding fibrillin-3 (FBN3) was identified early on as a susceptibility loci for PCOS 
with some of the strongest evidence of any potential PCOS-related gene (298,315). Fibrillins 
are essential for production of the elastic fibres found within connective tissues and the 
human genome contains three distinct fibrillin proteins (320). Expression of FBN3 is at its peak 
during fetal life but it still present in adult tissues, particularly in the ovary (307). Fibrillins 
have been shown to regulate expression of the TGF-b superfamily as well as activin and 
inhibin within the ovary (321), while immunohistochemical analysis has revealed a decrease 
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in, or total loss of, FBN3 staining in follicles transitioning from the primordial to primary stage 
of development (322). The microsatellite marker D19S884 was found to have a strong 
transgenerational transmission, although the small sample size prevented significant results 
post-correction (315). However, when the authors repeated their investigation in a larger 
sample size the significance of this marker and its linkage with PCOS was re-established (323). 
The importance of a large sample size, powerful enough to identify linkage of this variant is 
highlighted in smaller studies which have failed to detect such a result (324,325). These initial 
studies reported D19S884 to be found within the insulin receptor gene, although it is now 
known that this marker also resides within the FBN3 gene (321). 
With the knowledge that DHT plays an important role in the pathogenesis of PCOS, 
researchers have investigated the link between the genes encoding the 2 isoforms of 5a-
reductase, SRD5A1 and SRD5A2 respectively, and the development of PCOS. They found that 
haplotypes within both genes were associated with PCOS risk, with most haplotypes resulting 
in increased 5a-reductase activity (326). One variant within the SRD5A2 gene was found to 
have a protective effect against PCOS due to its resulting reduction in 5a-reductase activity. 
Haplotypes with the SRD5A1 but not SRD5A2 gene were found to be associated with hirsutism 
in particular, a finding that is supported by data showing that 5a-reductase activity is 
enhanced in PCOS (327) and in particular those with hirsutism (328). 
1.2.7.4.2.2 Genes Involved in Steroid Hormone Action 
Women with PCOS often display low SHBG levels, resulting in the peripheral tissues being 
exposed to higher levels of free androgens (312). In a study of Greek women, a (TAAAA)n 
polymorphism in the promoter region of the SHBG gene was associated with NIH-diagnosed 
PCOS and resulted in lower SHBG levels in those PCOS women carrying the longer allele of 
more than 8 repeats (329). The association of polymorphism repeat length and SHBG levels 
has also been found in a study of hirsute women, of which half met the criteria for NIH-
diagnosed PCOS (330). Interestingly, a case-study has been published describing severe 
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hyperandrogenemia during pregnancy and the presence of multiple mutations in the coding 
region of the SHBG gene. One such mutation, identified in the patient’s maternally derived 
SHBG allele, was a missense mutation that has also been identified in patients with either 
PCOS, ovarian failure, or idiopathic hirsutism (331).  
1.2.7.4.2.3 Genes Involved in Gonadotropin Release and Action 
A study of 240 Chinese women revealed that previously characterised mutation in the FSH b-
subunit gene (332) was significantly over-represented in women with PCOS compared to 
controls (333), with this mutation leading to higher FSH levels in those homozygous for this 
change which results in the addition of a restriction enzyme site within the gene. A recent 
GWAS study in a European population identified the SNP locus 11p14.1 as being strongly 
associated with PCOS as well as being correlated to LH levels in the PCOS population (334). 
This locus has been mapped to the FSH b-subunit gene (FSHB) and when adjusted for LH levels 
in the PCOS women, the study suggests that the association between PCOS and FSHB was 
mediated by LH and implies that it may be this variation in FSHB expression that contributes 
to the altered gonadotropin secretion seen in PCOS (334). This strong association between 
PCOS and FSHB and its relationship to the LH:FSH ratio in PCOS patients has been replicated 
in another GWAS study of European PCOS women, which also reported the robust association 
between several epidermal growth factors and PCOS (335). Additionally, FSHB has also been 
associated with PCOS in a GWAS performed in a Han-Chinese population, indicating that the 
importance of this gene may not be ethnicity-specific, only lending greater weight to 
significance of this loci and the susceptibility to PCOS that it infers (336).The FSH receptor 
gene (FSHR) has been screened in search of possible variants linked to gonadotropin action 
in PCOS, although no such variants have been identified as yet (315,321,337,338). 
The gene coding for the b-subunit of LH has also been investigated for possible mutant 
variants that can be linked to the pathogenesis of PCOS. A large study of European and North 
American PCOS women (339) showed that the frequency of a structurally dissimilar variant 
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of LH was lower in obese PCOS patients than in non-obese PCOS as well as normal women of 
both weight ranges. The researchers behind the study suggest that this variant may play a 
role in protecting obese women susceptible to PCOS from developing obvious symptoms 
(339). However, studies of other populations of PCOS women, including Korean, Chinese and 
Indian have found variants in the LH b-subunit gene to be rare and were unable to establish 
any conclusive link to PCOS (340,341). Variants in the LH receptor gene, LHCGR, have not been 
associated with the pathogenesis of PCOS (312,315,321). 
Follistatin, encoded by the FST gene, is a protein capable of binding and neutralising members 
of the TGF-b superfamily, with a particular affinity for binding activin (342). Overexpression 
of follistatin in transgenic mice led to lowered serum FSH levels and arrested follicle 
development (343). Activin is known to augment FSH secretion, leading to follistatin’s original 
moniker ‘FSH-suppressing protein’. Due to this property, the FST gene has been investigated 
for links to PCOS. In a study of over 200 families, no significant association between the FST 
gene and PCOS was able to be established (315,344). Similarly, studies of Chinese (345) and 
Spanish (346) women with PCOS have also been unable to establish a link been mutations in 
FST and the development of PCOS.  
1.2.7.4.2.4 Genes Involved in Insulin Secretion and Effect 
A variable number tandem repeat (VNTR) within the insulin gene’s (INS) regulatory element 
has been previously linked to T2DM (347). Multiple small studies have attempted to establish 
a link between this VNTR and PCOS with initial studies providing mixed results (315,348), 
however a large multicohort study demonstrated no evidence for an association between the 
INS VNTR and the development of PCOS (349). Conversely, in a familial linkage study 
Waterworth et al found that 60% of the families in the study were linked to the marker 
D11S922, found distal to the INS gene (350). They also reported that insulin levels were higher 
in families linked to this marker than those without linkage, which is suggestive of a role in 
hyperinsulinemia for this VNTR. 
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While insulin resistance is more often associated with overweight and obese PCOS patients, 
a study of Indian women has shown that a polymorphism in exon 17 of the insulin receptor 
gene (INSR) was associated with PCOS in lean women (351). In this group of patients, the 
genetic variant was also associated with higher fasting insulin levels, lower insulin sensitivity 
and hyperandrogenemia. Differential phosphorylation at specific sites within INSR of PCOS 
women have been reported although the significance of these has yet to be determined 
(352,353). Linkage studies have found an association between PCOS and a genetic marker 
(D19S884) located near to INSR (315,324), although it remains to be seen as to whether this 
marker resides within INSR itself or an as yet known putative PCOS gene. 
A study of Caucasian European women uncovered an association between variants in both 
the IRS1 and INS2 genes and PCOS. These genes encode insulin receptor substrate 1 and 
insulin receptor substrate 2, respectively, which are signalling adaptor proteins that act to 
facilitate the transmission of signals from the insulin receptor to it downstream target 
pathways (354). The study concludes that these variants may play a role in the insulin 
resistance experienced by many women with PCOS. Another study was unable to replicate 
the link between PCOS and IRS1 only, however did show that the IRS2 polymorphism was 
associated with high blood glucose levels in PCOS patients (355). 
The transcription factor 7-like 2 gene (TCF7L2) is, so far, the most noteworthy genetic marker 
correlated with T2DM. This gene is involved in embryogenesis and cell proliferation, as well 
as the development of pancreatic islets (293). Single nucleotide polymorphisms (SNPs) in 
TCF7L2 have been found to be associated with T2DM development (356,357). A study of 
Greek PCOS women revealed a minor overrepresentation of one of these SNPs in these 
women (358) although this could not be confirmed by subsequent studies (359-361). 
Another gene associated with T2DM is that encoding PPAR-γ, a nuclear receptor that 
mediates glucose metabolism. While multiple studies have not found a link between 
polymorphisms in this gene and PCOS, a recent meta-analysis of studies focusing on the PPAR-
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γ2 Pro12Ala variant found a significant association with this variant and a reduced risk for 
PCOS, possibly mediated by an effect on insulin sensitivity (362). Plasminogen activator 
inhibitor-1 (PAI-1) levels are correlated with insulin resistance (363) and have been shown to 
be increased in PCOS (364). A Greek study found that two different genotypes within the PAI-
1 gene (SERPINE1) promoter region were linked to PCOS and that plasma levels of PAI-1 were 
higher in PCOS women (365). The authors suggest that this may be implicated in the insulin 
resistance displayed by many PCOS women. 
Calpain-10, a member of the Calpain family of calcium-dependent proteolytic enzymes, is 
encoded by the CAPN10 gene. While members of the Calpain family are involved in an 
inordinate number of human cell process, Calpain-10 has been linked to a susceptibility to 
T2DM (294). A study spanning multiple ethnic backgrounds and 3 distinct SNPs of the CAPN10 
gene revealed that one haplotype was associated with higher insulin levels in nondiabetic 
African-American PCOS women as well as an approximate 2-fold increased risk for PCOS in 
both Caucasian and African American women (366). A study of Spanish women showed a 
relationship between mutations in CAPN10 and PCOS status, as well as specific alleles linking 
to specific PCOS traits such as hyperandrogenic features and hypercholesterolemia (367). 
Other researchers dispute these findings, showing no association between the CAPN10 gene 
and PCOS (368).  
1.2.7.4.2.5 Other Genes 
Owing to the fact that obesity is so prevalent in PCOS, genes related to obesity are often the 
target of new investigations into potential PCOS-causing genes. The fat mass and obesity-
related protein, encoded by the FTO gene, was identified in a GWAS as being associated with 
obesity traits such as BMI, dietary intake, impaired fasting glucose and the metabolic 
syndrome (369). The association between FTO and obesity remains even after correction for 
the difference in BMI between cases and controls (370). Several recent meta-analyses (371-
373) have established a firm link between SNPs in the FTO gene and obesity, with one in 
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particular finding that the effects of the FTO gene on obesity-related traits are more than 
doubled in women with PCOS (371), suggesting an interaction between the two. 
Known as the “satiety hormone”, leptin has been investigated for possible links to the 
pathogenesis of PCOS due to the leptin-sensitive state often observed in obesity. A small 
study of European women with PCOS did not reveal any mutations in the gene encoding 
leptin, LEP, and the frequency of variants identified in the leptin receptor gene (LEPR) did not 
differ between PCOS and control subjects despite being associated with insulin regulation 
(374). Conversely, a larger and more recent study in Korean PCOS patients has shown that 2 
separate SNPs within the LEPR gene were significantly associated with PCOS and may provide 
an early screening tool for the modulation of cardiovascular disease in these patients (375). 
Adiponectin, postulated to be a beneficial adipokine due to its insulin-sensitizing property and 
antiatherogenic action, is reduced in PCOS (376). Multiple studies have attempted to establish 
a link between polymorphisms in the adiponectin gene (ADIPOQ) and PCOS with conflicting 
results (377-379). While data suggests that mutations in ADIPOQ may not play a causative 
role in PCOS, they may contribute to the severity of the metabolic symptoms of PCOS 
(318,379). 
1.2.7.4.3 Genetic Studies of the Androgen Receptor 
Early on, it was postulated that genes involved in androgen secretion and action may be 
causative of PCOS, with some suggesting that polycystic ovaries in females and early onset 
male pattern baldness in males may be caused by mutations in the same gene affecting 
androgen action (380). Functional hyperandrogenism can be diagnosed in early life, before 
the onset of puberty, and therefore presents as a realistic diagnostic marker for PCOS (302). 
This hinges on the genetic basis for functional hyperandrogenism being linked to PCOS in a 
causative manner, which has become the focus of many genetic studies of PCOS.  
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The AR protein is comprised of 3 functional domains, including the transactivation domain 
which is encoded by exons 1-3 of the AR gene (AR). Initially, a large-scale genetic screen of 
PCOS patients and their families failed to find a link between PCOS and the VNTR trinucleotide 
CAG repeat polymorphism within exon 1 of this X chromosome-located gene (315). In the 
normal population, the number of repeats present varies from 11 to 31, with the most 
common being 20 repeats (381). The length of this repeat has been reported to be inversely 
correlated with receptor activity with longer lengths resulting in reduced AR activity and male 
infertility (382). It is proposed that a decreased number of CAG repeats in AR may explain the 
normal androgen levels seen in some women with PCOS (383). A study of Singaporean women 
with PCOS revealed no difference in the average CAG repeat length in PCOS women vs 
controls, however did show a significant difference in PCOS patents with low vs high T levels 
(383). This suggests a link between the shorter CAG repeat polymorphism and low AR activity 
in PCOS specifically, which resulted in anovulatory infertility in these patients.  
A more recent study of Caucasian Australian women with PCOS showed a significantly higher 
frequency of longer CAG alleles in infertile women with PCOS vs healthy infertile women. This 
was also true of all PCOS women in the study and correlated with higher T levels in these 
PCOS women, despite the lower potential AR activity (384). The researchers suggest that this 
lowered AR activity may result in low androgen levels during early development which could 
then “trigger a mechanism that ultimately results in increased androgen secretion” such as 
that seen in PCOS. While both studies have highlighted the relationship between CAG repeat 
length and T levels, neither have been able to conclusively link this to PCOS. The same was 
true for a large familial study which did not find an association between repeat length and 
PCOS or a significant transgenerational transmission of the polymorphism (315). Conversely, 
Shah et al reported that CAG repeat number was linked to PCOS status with a significant 
decrease in the odds of PCOS as the CAG repeat length increased (385).  
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CAG repeat polymorphisms have also been investigated in girls with precocious pubarche. 
This study found that these girls had shorter CAG repeats lengths when compared to controls 
(386). Additionally, these shorter lengths resulted in higher 17a-hydroxyprogesterone levels, 
known to increase ovarian androgen biosynthesis. These results seem to suggest that shorter 
CAG repeats may increase the risk of precocious pubarche and subsequent ovarian 
hyperandrogenism and PCOS. 
To date, studies of mutations in the AR have focussed mostly on the CAG VNTR polymorphism. 
Results from these studies are only complicated by the phenomenon of X chromosome 
inactivation, a normal process in females in which one of the X chromosomes is 
transcriptionally silenced by being packaged in such a way that it is not accessible to cell’s 
transcription machinery (387). The study by Hickey et al (384) revealed potential differences 
in X-inactivation in women with PCOS, reporting that multiple follicles from PCOS ovaries 
displayed the same single AR allele which could potentially affected the AR-mediated activity 
of the affected follicles and hence the cellular responses to androgens. This could potentially 
provide one explanation for the variation in the presentation of PCOS symptoms in different 
patients. Others have reported that although X-inactivation, by way of differential 
methylation, was not different in PCOS vs controls, in those with non-random inactivation the 
chromosome with the shorter CAG repeat was favourably active in PCOS patients (385). This 
may suggest that X-inactivation plays a role in determining AR bioactivity and hence androgen 
action and the susceptibility to develop PCOS. A study of sisters with PCOS showed that sisters 
with the same PCOS phenotype and the same CAG repeat length genotype displayed the same 
pattern of X-inactivation more often than did sisters with different phenotypes (388). Data 
from these studies combined suggests that the genes on the X chromosome, including but 
not limited to the AR, may be key in driving preferential X-inactivation and the propagation 
of conditions such as PCOS possibly caused by mutations in these genes. 
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A pivotal study into granulosa cell dysfunction in PCOS has revealed the potential role of 
alternative splice variants of the AR in the pathogenesis of PCOS (389). Alternative splicing is 
a normal process during gene expression that results in a single gene coding for more than 
one protein. During this process, selected exons are either included in or removed from the 
mRNA transcript, resulting in a different protein being translated.  Using GCs collected from 
Han-Chinese women during oocyte retrieval for IVF procedures, Wang et al identified two 
alternative splice variants of the AR expressed in a combined 62% of the patients with PCOS 
and never in any of the 120 control women. Additionally, while total AR mRNA levels were 
higher in PCOS women, levels of wild-type AR mRNA were reduced whereas levels of the 
splice variant AR were increased. These variants, one causing an insertion into intron 2 and 
the other a deletion of exon 3, cause in-frame changes to the AR, particularly in the DNA-
binding domain which the authors suggest may alter the bioactivity of the receptor. 
Interestingly, these variants occurred more often in those with higher serum androgen levels 
and were found in patients with higher antral follicle numbers, a common trait of PCOS. While 
culturing the GCs the researchers found that some genes were dysregulated in the cells 
expressing AR splice variants, including genes involved in folliculogenesis, steroidogenesis and 
ovulation (389). These cells carrying splice variants also struggled to regulate the ratio of 
androgens to estrogens by failing to upregulate CYP19A1, the gene encoding aromatase. 
However, evidence already exists to suggest that the deletion variant seen in this study may 
be a downstream effect of PCOS rather than a cause behind it with well documented cases of 
AR exon 3 deletion causing complete androgen insensitivity rather than hyperandrogenism 
(390,391). This suggests that the deletion variant is more like to be an adaptive response to 
the hyperandrogenic PCOS environment, in an attempt to ameliorate the excess androgen 
levels.  
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Table 1.2 Summary of Putative PCOS Genes 
 
Summary of possible PCOS-causing genes and their role in normal physiological function.  
Gene Function(s)
CYP11a Cholesterol side-chain cleavage enzyme – converts cholesterol into pregnenolone in the first, and rate-limiting, step of steroidogenesis (308,309)
CYP17 17-hydroxylase/17,20-lyase – these two enzymes convert progestagens into pro-androgens (313,314)
CYP21 21-hydroxylase – this enzyme plays a role in the conversion of progestagens to mineralocorticoids and glucocorticoids (294)
AMH Anti-Müllerian hormone – has key roles in embryonic sex differentiation, folliculogenesis and inhibiting excessive follicular recruitment thereby maintaining ovarian reserve (319)
FBN3 Fibrillin-3 – essential for the production of elastic fibres in connective tissues (320)
SRD5A1 & 
SRD5A2
The two isoforms of 5a-reductase – the enzyme responsible for the conversion of testosterone 
to dihydrotestosterone (326)
SHBG Sex hormone-binding globulin – a glycoprotein that binds both androgens and estrogens for transport in the bloodstream (329,330)
FSHB Follicle stimulating hormone b-subunit – one of two polypeptide units making up the FSH protein (333)
LHB Luteinizing hormone b-subunit – one of two polypeptide units making up the LH protein (339)
FST Follistatin – protein capable of binding and neutralising members of the TGF-b superfamily, particularly activin (342)
INS & INSR Insulin and insulin receptor – the primary peptide hormone responsible for glucose homeostasis and its transmembrane receptor (350,351)
IRS1 & IRS2 Insulin receptor substrates 1 and 2 – signaling adaptor proteins that help facilitate signal transmission from the insulin receptor (354)
TCF7L2 Transcription factor 7-like 2 – a transcription factor involved in several pathways including cell proliferation and embryogenesis (293)
PPARG Peroxisome proliferator activated receptor gamma – a nuclear receptor that regulates glucose metabolism (362)
SERPINE1 Plasminogen activator inhibitor-1 – a serine protease inhibitor that acts to prevents fibrinolysis (364,365)
CAPN10 Calpain-10 – a member of a family of calcium-dependent proteolytic enzymes involved in a number of cell processes including cell cycle progression and cell death (366,367)
FTO Fat mass and obesity-related protein – associated with traits such as BMI, dietary intake and glucose homeostasis (371)
LEP & LEPR Leptin and leptin receptor – a hormone acting to regulate energy homeostasis by inhibiting hunger and its transmembrane receptor (375)
ADIPOQ Adiponectin – an adipose-secreted adipokine which acts to regulate glucose levels and fatty acid breakdown (318,379)
AR Androgen receptor – a nuclear receptor which facilitates the actions of the androgens testosterone and dihydrotestosterone (384)
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1.2.7.5 Interaction of Environment and Lifestyle 
1.2.7.5.1 Birth Weight and Excess Weight During Adolescence 
As previously discussed, there are increased rates of gestational diabetes amongst women 
with PCOS (183,186) and it is well established that gestational diabetes is associated with 
giving birth to a baby that is large for its gestational age (LGA) (186). A large Danish study of 
over 500,000 females born in a period spanning three decades aimed to study the association 
between birth weight and the diagnosis of PCOS in adulthood (392). The study found that the 
risk of developing PCOS was significantly increased if the women’s birthweight was greater 
than 4.5kg, making them LGA. Women born to mothers diagnosed with gestational diabetes 
were also at an increased of developing PCOS, with the risk for these women increasing as 
birthweight decreased. This is likely due to the fact that babies born small for gestational age 
(SGA) are at an increased risk for cardiovascular disease and the metabolic syndrome as a 
result of an overcompensation during early life in which SGA children tend to gain more BMI 
than those born in the normal weight range (393). A Brazilian study of infants born SGA found 
that the likelihood of developing PCOS was twice that of those born of an appropriate weight 
(394). Additionally, the SGA infants had a higher prevalence of hyperandrogenism as well as 
lower circulating SHBG levels. The developing fetus adapts to the environment that sustains 
it and it has been said that it may be these adaptations that result in conditions such as PCOS 
in later life (395). This is shown in babies born in developing countries where the mother was 
nutritionally deprived during her pregnancy. During development, the fetus’ physiological 
processes have adjusted to this low nutritional intake and when these babies are adopted 
and raised in Western countries, where access to food is not restricted, they are at risk of 
precocious puberty as a consequence of the discordance between the environment that the 
fetus has prepared for and the one it now surrounded by (395). This adaption to cope with 
exposures falling within a certain range influences the future susceptibilities to adult disease 
that are “realised through interaction with the environment” (396). 
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Childhood obesity has been implicated in the pathogenesis of PCOS due to the exacerbation 
of PCOS symptoms in patients known to be overweight during adolescence. As PCOS is a 
condition that manifests at puberty, the peri-pubertal time is a critical window during which 
the severity of the condition can be heavily influenced (397). Data suggests that the 
prevalence of PCOS is elevated 3 to 14.7-fold in post-pubertal adolescents depending on the 
extent of their obesity (398). Peripubertal obesity has also been shown to be associated with 
insulin resistant hyperinsulinism and hyperandrogenism, providing a strong link to the onset 
of PCOS. Findings show that adolescents suffering from obesity are more likely to have higher 
fasting glucose levels as well as insulin resistance (399) and elevated total T levels (400) as a 
consequence of the negative effect of hyperinsulinemia on levels of SHBG (397). Combined, 
these findings suggest that exposures during early life that influence body weight and the 
metabolic profile may play a key role in the development of PCOS during adult life (401). 
1.2.7.5.2 Bisphenol A 
Bisphenol A (BPA) is a common chemical compound used to make a variety of polycarbonate 
plastics and epoxy resins. Most people are exposed to BPA, in one way or another, on a daily 
basis. BPA-based plastics are used in water bottles, household electronics and sports 
equipment while BPA-containing resins are found in the lining of many food and beverage 
containers, aluminium cans and thermal paper such as that used for supermarket receipts 
(402). Studies have found that levels of BPA are significantly higher in patients with PCOS, 
which mirrors increased androgen levels and lowered SHBG concentrations in these women 
(402). This is supported by data from animal studies that showed that prenatal exposure to 
BPA lead to the development of PCOS-like symptoms in adult life (403). As well as its estrogen-
mimicking properties, BPA has been shown to act as a potent SHBG ligand, capable of 
displacing bound androgens and therefore increasing the concentration of free androgens in 
the bloodstream (402). In PCOS patients, particularly high levels of BPA are found within the 
follicular fluid, suggesting that the ovary may be the primary target of this endocrine 
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disrupting compound. This coincides with an increase in theca cell androgen production seen 
in rat models of BPA exposure (404,405). While numerous studies have found that BPA levels 
are increased in PCOS patients they have, to date, been unable to establish a strong causal 
relationship. BPA levels are also correlated with BMI which may confound studies linking BPA 
to the cause of PCOS. Studies have shown that obese patients without PCOS often have 
increased circulating BPA levels implying that the association may be between BPA and 
obesity, however others revealed that within PCOS patients, BPA concentrations do not differ 
between lean and obese patients seemingly contradicting this previous finding (404,406).  
Animal models of BPA exposure have shown that it is plausible that BPA causes permanent 
disruption of the HPG axis which may be transmitted from one generation to the next (407). 
Generations of rats without direct exposure to BPA and other endocrine disrupting chemicals 
displayed symptoms similar to that of human PCOS, suggesting that epigenetic modifications 
were induced in previous generations. The transgenerational effect of BPA in humans remains 
undetermined but it is hypothesised that these epigenetic changes are what make the 
offspring of PCOS more susceptible to developing the syndrome themselves (408). 
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1.3 Animal Models of PCOS 
The expanse of data coming out of GWAS studies into potential PCOS causative genes has laid 
a solid foundation on which future research into the origin of PCOS can build upon. The most 
important of which will be utilising animal models and transgenic technologies to elucidate 
what these putative genes really do in relation in PCOS. While physiological differences do 
exist between humans and todays current standard mammalian models (non-human 
primates, sheep and rodents), the benefits of these models and their contribution to our 
understanding of PCOS cannot be denied.  The obvious ethical constraints surrounding 
research involving human patients make animal models a valuable tool for teasing out specific 
aspects of PCOS for more in depth investigation in large-scale, reproducible studies (409). 
Only in animal models is it possible to evaluate the underlying molecular mechanisms behind 
the clinical manifestations identified in human PCOS. Despite the fact that PCOS, as a 
diagnosable syndrome, is an inherently human disorder and does not occur naturally in the 
animal kingdom (410), the information gathered from the following animal models of PCOS 
has been extremely valuable to our understanding of this condition to date. 
1.3.1 Non-Human Primates 
1.3.1.1 Establishment of The Model and Methods 
The Rhesus monkey (Macaca mulatta) is one of the most widely used non-human primates 
in scientific research due to their close similarity to humans with regards to both anatomy 
and physiology (411) and the discovery that PCOS-like traits can occur naturally in female 
Rhesus monkeys (411). Early work by Treloar et al (412) aimed to replicate, in primates, 
previous work carried out in rats to determine the crucial timing of T treatment in affecting 
reproductive physiology and ovarian morphology. The researchers failed to induce any PCOS-
like changes in adolescent monkeys with a single injection of 35mg/kg T given within 24 hours 
of birth (412), however this did lead to the predominance of prenatally-administered 
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treatments in large animal models such as the Rhesus monkey, highlighting the difference in 
developmental physiology and timing in these mammals compared to that of rodents. 
Following on from this work, T or testosterone propionate (TP) treatment has been the main 
method of inducing PCOS-like phenotypes in Rhesus monkeys (50,413-424). Although T is able 
to be aromatized to E2, researchers have shown that levels of E2 are either reduced in T-
treated as well as DHT-treated monkeys (422,423) or not changed compared to control 
counterparts (50,413,416-419), which they say rules out the likelihood that effects are being 
mediated via E2 and the ER rather than the T treatment itself (422).  
Early researchers aimed to determine the different effects of androgens and estrogens on 
ovarian function by utilising implants of either A4 or E1 (425), revealing that only A4 
treatment resulted in an increase in atretic ovarian follicles and hyperandrogenism, with E1 
treatment only resulting in impaired LH response to E2 benzoate. They made the excellent 
point that the ovulatory cycle of Rhesus monkeys is very similar to that of humans, making 
them the perfect animal model for studying ovulatory and menstrual cycle-specific aspects of 
human PCOS.  
Studies utilising the Rhesus monkey have highlighted the importance of timing when 
administering these treatments and the determination of key developmental windows during 
which androgenisation is most effect. Both pre- and postnatal models offer different insights 
into the mechanisms of actions of these steroids in the pathophysiology of PCOS. Prenatal 
timing varies from as early as day 26 of gestation (416) through to later treatments beginning 
as late as day 118 (415), with the gestational period in Rhesus monkeys being approximately 
164 days. Postnatal treatments vary widely, ranging from new-borns (412) to infants (50), 
adolescents (421) and through to treatments beginning in adulthood (423,425). Finally, mode 
and dose of treatment have also differed since the 1970s. All prenatal models discussed 
utilised an subcutaneous (sc.) injection of the pregnant mother in doses ranging from 5 to 
15mg of TP (413,415-420,424,426). The use of injection treatments in postnatal models is 
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primarily administered proportional to body weight at doses ranging from 20µg-35mg/kg 
(412,422). A4, T, DHT-containing implants have also been used to provide a one-off 
intervention with long-lasting effects (50,421,423,425). 
1.3.1.2 Reproductive Traits 
The initial study by Treloar et al showed that a single injection of 35mg/kg administered within 
24 hours of birth was insufficient to cause changes in menstrual cycling and ovulation or the 
ovarian phenotype (412). A study utilising various sizes of T implants placed sc. (at 1 year of 
age) to achieve a 3 to 4-fold increase in serum T also reported no change in menstrual cycles 
despite some changes to the endocrine profile evident (50). In contrast, a decrease in 
menstrual cycles was observed when 4-12 year-old monkeys were treated with a number of 
10-25mg implants until serum T levels were raised to 115ng/dL (421), while cycles were 
disrupted in those whose mothers were given 5-15mg TP injections beginning at day 26, 40, 
or 100 of gestation for a period of several weeks (415,416). Treatment with A4 appeared to 
increase the incidence of ovulation in monkeys treated during adulthood, however this study 
could not determine if this effect was indeed the result of A4 or an estrogenic effect as a 
consequence of the aromatisation of androgens to estrogens (425). 
The effect of hyperandrogenemia on ovarian morphology has shown to be dependent on the 
timing of treatment administration. The majority of early studies utilising postnatal 
treatments did not find any significant difference in ovary size/weight, overall follicle 
numbers, amount of antral follicles or CL numbers (50,412,421,423). Conversely, one 
postnatal model employing a high-dose T treatment over just 3-10 days in adult monkeys was 
able to show enlarged ovaries, an increase in total follicle number and an increase in the 
number of all follicle types with the exception of large antral follicles (422). Additionally, this 
model also displayed an increase in GC proliferation in follicles past the primary stage as well 
as an increase in theca layer thickness and cell proliferation. An early prenatal treatment with 
TP for 15-35 days beginning on day 40-44 of gestation initially resulted in no change in the 
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number of oocytes retrieved during FSH-stimulated IVF egg retrieval, while still decreasing 
the number of blastocysts that formed per zygote (419). A more recent study of this model, 
however, showed a decrease in the number of oocytes retrieved in early but not late 
(beginning on day 100-115) treatment with TP (417).  
Treatment with 25mg DHT in adult females resulted in a decrease in ovarian weight after 15 
days of treatment (423), while 145µg DHT administered for 5 consecutive days in sexually 
mature monkeys was associated with an increase in total follicle number including all follicle 
stages up to the large antral stage, an increase in GC proliferation and a decrease in small 
antral follicle apoptosis (422).  
Prenatal androgenisation of Rhesus monkeys has resulted in disrupted menstrual cycling and 
poorer outcomes from ART procedures, while postnatal exposure to excess androgens had 
led to a decrease in cycles, enlarged ovaries, an increase in total follicle number as well as an 
increase in GC proliferation.  
1.3.1.3 Endocrine Traits 
While short-term postnatal treatment with T did not produce any significant changes in LH or 
FSH in adult monkeys (423), long-term treatment over several years, beginning at the age of 
1, did appear to result in an increase in LH pulses during the menstrual cycle of 5-year-old 
monkeys and a greater LH response to GnRH in 4-year-old monkeys (50). Prenatal treatment 
with 5-15mg, beginning at various points through gestation, TP has been shown to result in a 
significant increase in LH during both the luteal and follicular phases of the menstrual cycle 
(416). Additionally, these animals also displayed an increase in the LH:FSH ratio due to 
unchanged FSH levels. Repeated studies with this model have shown that if treatment begins 
early in gestation (day 40-44) then an increase in LH results while late starting treatment 
beginning on day 100-115 actually displayed decreased LH levels compared to untreated 
monkeys (417-419), however both of these effects were rescued following administration of 
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recombinant hCG, when LH levels in both early and late treated animals were comparable to 
controls. FSH levels in all treated monkeys remained unchanged in this model.  
Initial studies utilising a postnatal 10-25mg T implant treatment regime reported no change 
in peak serum P4 levels (421), a finding that mirrored the first prenatal studies using TP which 
reported no change in P4 or E2 throughout the luteal and follicular phases (416). This prenatal 
model has been well studied by Dumesic et al, who have consistently showed prenatal 
exposure to high levels of androgens does not appear to have effects on P4 or E2 dynamics, 
at least not those that persist into adulthood (417-419). This has also been reported by Abbott 
et al who showed that a treatment of daily injections of 15mg TP from day 40 to day 80 of 
gestation did not result in any change in E2 or E1 in the infant offspring (413,414). Only a high-
dose treatment of 4mg/kg of body weight (BW) has been shown to be sufficient to result in 
changes to estrogen secretion with these monkeys displayed a significant decrease in E2 
levels following treatment administered during adulthood (422). 
As expected, treatment with exogenous androgens given postnatally has been shown to raise 
androgen levels in female monkeys. Daily injections of T in adult monkeys resulted in 
hyperandrogenemia in these animals although it is not reported if this effect is sustained long-
term (422). The same can be said for the use of a T-containing implant placed during 
adulthood which resulted in increased A4 levels in response to exogenous LH and FSH (423). 
No studies have reported the long-term effects of androgen administration following 
cessation of injections or the removal of the androgen-containing implants. On the other 
hand, prenatal treatment with T does not appear to cause permanent changes in androgen 
secretion with studies reporting no change in non-induced androgen levels (T, A4 and DHT) 
of adult monkeys when treated with 5-15mg T beginning both early (day 40-60) or late (day 
100-115) in gestation (416-419), with the same being true for the use of TP beginning on day 
40-44 (424), although this treatment did result in a small but significant increase in DHEA but 
not DHEA-S (suggestive of adrenal hyperandrogenism). Interestingly, hyperandrogenism has 
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been observed in these monkeys during infancy (427), however it remains to be seen whether 
this persists into adulthood. Finally, Eisner et al have reported that treatment with 10mg TP 
for 15-35 days beginning on day 40 of gestation resulted in a significant increase in the hCG-
induced secretion of T as well as 17a-hydroxyprogesterone in adult females (420). 
The use of DHT has only been reported in postnatal models of PCOS in monkeys. Vendola et 
al described the decrease in E2 but no change in T following treatment of 145µg/kg DHT daily 
for 5 days in sexually mature females (422). More recently, others have also reported a 
decrease in E2 with no change in A4 when using a 25mg DHT implant in adult monkeys to 
induce the PCOS-like state (423). 
Prenatal exposure to excess androgens has been shown to result in an increase in LH with 
unchanged FSH, P4, and E2, as well as increased DHEA and hCG-induced T secretion. On the 
other hand, postnatal treatments have been reported to result in enhanced LH dynamics, 
decreased E2, and hyperandrogenism. 
1.3.1.4 Metabolic Traits 
Early studies of PCOS in Rhesus monkeys did not focus on metabolic parameters associated 
with the syndrome. Dumesic et al were the first to begin to tease out the apparent metabolic 
component of PCOS when they described the decrease in insulin action following 
recombinant human FSH in monkeys treated early in gestation (beginning on day 40-44) with 
10-15mg TP (417-419). Despite this result though the monkeys failed to show any increase in 
serum glucose or insulin levels. Since then, Bruns et al have shown that 10mg TP treatment 
beginning late in gestation (day 100-118) results in increased fat mass and decreased 
proportional lean body mass (LBM) (415). Others have shown that 15mg TP administered 
early (from day 40 to day 80) increased body weight at 8 weeks of age despite no change 
being observed in birthweight (413,414). They also reported that prenatally androgenised 
monkeys displayed decreases in the insulin sensitivity and disposition indices, the former 
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being a marker of insulin resistance while the later indicates a defect in pancreatic beta cell 
insulin secretion (414). Postnatal treatment with T beginning at 1 year of age has been shown 
to be insufficient to cause changes in percentage fat or LBM, or in glucose tolerance of adult 
monkeys (50).  
Prenatal androgenisation in Rhesus monkeys has resulted in aberrant insulin action as well as 
increased BW and adiposity coupled with a decrease in LBM, while metabolic features have 
not yet been reported following postnatal PCOS induction. 
1.3.1.5 Pros and Cons + Summary 
The most obvious advantage for using non-human primates, such as the Rhesus monkey, in 
the study of conditions such as PCOS is their biological similarity to humans, sharing 
approximately 93% of their genome with us (428). Unlike sheep and rodents, non-human 
primates share a close relationship to us in terms of physiology, anatomy and fetal 
development, making them particularly useful in studies of PCOS. Their close phylogenetic 
relationship to us also makes them invaluable in the study of transgenerational transmission 
studies, which is quickly becoming a popular area of PCOS research (275,429). It is this 
similarity to us that allows research conducted using non-human primates to be more easily 
carried over into humans than is possible when using sheep or rodents. In terms of 
reproduction, non-human primates experience menstrual cycles similar to humans. The 
endocrine profile of these cycles mirrors that of humans with menstrual cycle length being 
28-32 days in the Rhesus monkey (430) just like in humans. While the gestation period length 
in the Rhesus monkey is approximately 60% of that in humans, these primate experience 
comparable placentation and maternal-fetal interactions making them ideal candidates for 
studies of pregnancy. Non-human primates, in particular the Rhesus monkey, are one of very 
few mammals in which naturally occurring hyperandrogenism has been described, with these 
monkeys displaying significantly higher levels of A4, 17a-hydroxyprogesterone, LH, E2 and 
AMH as well as demonstrating impaired fertility (431). Studies into the traits displayed by 
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prenatally androgenised monkeys during infancy and early childhood could provide key 
insights into the pre-pubescent presentation of PCOS and lead the development of screening 
tools in humans and the identification of susceptible individuals who can be treated early and 
possibly prevent the progression to PCOS in later life (432). 
The use of non-human primates in medical research has clear benefits which outweigh the 
expense of setting up and maintaining these models. However, the current inability to 
genetically manipulate these animals does lead to a lack of studies using monkeys for 
fundamental studies of the underlying mechanisms of human disease on the tissue or even 
cell level (433). Also, many believe that ethical restraints placed on human research should 
often apply to studies being carried out in non-human primates. Behavioural studies in these 
animals have revealed sentient behaviours not unlike humans and they display personalities 
and high levels of intelligence (434). Despite this, non-human primate models of PCOS have 
provided key insights into the possible fetal origins of PCOS but, possibly more importantly, 
the detection of key traits present in infants and young children which could identify them as 
being predisposed to PCOS (411). 
1.3.2 Sheep 
1.3.2.1 Establishment of The Model and Methods 
Ovine models of PCOS used today are based on original work carried out by Clarke et al in the 
late 1970s (435-437). Clarke and his colleagues investigated the effects of T on the 
masculinisation of female offspring when exposure occurs during fetal life. After first 
determining that the crucial time during prenatal development in which T would masculinise 
the external genital phenotype of ewes was between days 40 and 50 of gestation, they 
established the effect of T treatment on the ovaries of these animals across a variety of time 
periods both in- and outside of this critical window (435-437). They showed that T treatment 
during gestation lead to irregular estrous cycles (436) and ovaries containing markedly 
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reduced numbers of CLs in adulthood (approximately 2.5 years old). Pregnant female ewes 
treated with T (1g T implant, placed sc.) earlier in gestation, days 30-80 & days 50-100, 
compared to days 70-120 & days 90-140, displayed irregular estrous cycling as well as an 
increase in small follicles, both of which are features seen in the human PCOS condition 
(435,437). 
Since then, a number of studies have expanded on this work in order to determine the effects 
of androgens in PCOS. TP has been utilised to raise androgen levels in vivo due to its slower 
release and metabolism (152,242-244,438-451). TP has been shown to induce a number of 
physiological PCOS-like features, including  altered follicle populations, increased weight gain 
and multicystic ovaries,  when administered during days 30-90 of gestation 
(152,242,243,438,439,442-449,452,453), and to a lesser extent days 60-90 (243,439) and 
days 60-102 (450,451). Furthermore, models have also been established using DHT and 
dihydrotestosterone propionate (DHTP). As DHT and DHTP cannot be aromatised into 
estrogens their use affords the researcher the chance to investigate the effects of androgens 
alone without interference from any estrogenic effects (152,243,438,445-448,454).  
The method of administering androgen treatments has evolved since these early studies. 
Initial methods involved the use of sc. implants (437,441) while more recent studies have 
utilised an intramuscular (im) injection to raise androgen levels in vivo in pregnant ewes. Most 
commonly, a dose of 100mg is given twice weekly of the chosen androgen: TP (152,242-
244,438,440,442-452,454), DHT (445) or DHTP (152,243,447,448,454). This dose has been 
shown to raise androgen levels in female fetuses similar to those seen in male fetuses (445). 
1.3.2.2 Reproductive Traits 
Classical polycystic ovarian morphology has been observed with the use of 100mg TP given 
twice weekly from day 30 to day 90 of gestation, keeping in mind that the average gestation 
period in sheep is around 152 days (438,444,445,452). This was not the case with an 
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equivalent dose of DHT (438,445) which implies that this effect may be estrogenic and 
mediated via the ER as a consequence of aromatisation. Estrous cycling has been shown to 
be affected by androgen treatment but only if treatment commences before day 60 of 
gestation. Cycling was regular in female offspring of mothers treated from day 60-90 of 
gestation (440). If implant treatment occurred from day 30-80, 50-100 or day 40-60 cycles 
were irregular or absent in some but not all sheep (436,437,441). Irregular, absent or longer 
cycles were observed with injectable treatment of TP, DHT and DHTP when administered 
from day 30-90 of gestation (443-445,452). A reduction in the number of cycles has also been 
observed with this treatment regime (453). An increase in ovarian weight and size has been 
observed in some studies (438,444) while not in others (152,242,451). Those that did observe 
an increase in ovarian weight also reported an increase in follicle numbers (preantral, antral 
or both) (242,438,443,444). Others found no change or a decrease in follicle populations at 
various stages of follicle development (152,242,443,444,451) while a small increase in follicle 
death was also observed by Hogg et al (451). 
Steckler et al (445) have shown that 100mg DHT sc. from day 30-90 gestation is able to 
increase follicle numbers and decrease the number of CLs present in the ovaries. Although, 
unlike T treatment in the same study, polycystic ovaries were not present in these animals. 
Estrous cycling is also altered in DHT-induced sheep models of PCOS, with early onset, absent 
and longer cycles all being reported (445). With a dose of 400mg DHT administered from days 
30-90, West et al (438) were not able to report polycystic ovaries or an increase in ovarian 
weight or follicle numbers. 
Classical polycystic ovarian morphology, absent or irregular cycling as well as a decrease in 
cycle number, increased ovarian weight and increased follicle number have all been observed 
in sheep models utilising prenatal androgen treatments, with the induction of these traits 
appearing to be timing-specific.  
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1.3.2.3 Endocrine Traits 
When treating with 100mg TP from days 60-90 Savabieasfahani et al (440) were able to show 
an increase in LH secretion and LH pulse frequency. This has also been shown when treatment 
is administered from days 30-90 (442,452). However, others studies utilising treatment from 
day 30-90 have not found such an increase (438,451), reporting no change in LH parameters. 
A 100mg dose administered on days 30-90 resulted in the number of animals having an LH 
surge during the first breeding season, although LH pulse frequency was higher in these 
treated animals compared to controls, results that were seen again in the second breeding 
season (446). West et al reported no changes in FSH parameters with TP treatment during 
the same treatment window (438). 
An increase in E2 levels has been described when treatment of 100mg TP was administered 
from days 30-90 (442). When over-fed, animals from an identical treatment regime displayed 
a significant decrease in luteal P4 levels (452). Normal-fed ewes experienced a significant 
decrease in the number of animals having a luteal P4 rise (446) with an overall decrease in P4 
levels (453). During a later treatment from day 62-102, no change in systemic E2 was reported 
(451). 
While T or TP are used to increase androgen levels in vivo, levels of androgenic hormones are 
rarely reported in these models. Hogg et al used a later treatment from days 62-102 and 
reported no change in circulating T (450) or systemic T and A4 (451) in 11-month-old lambs. 
More recently, a study has shown that prenatal T treatment was associated with increased 
AR protein levels at the tissue level (455). 
As with T or TP treatment, DHT- or DHTP-induced models describe conflicting results with 
regards to LH and FSH parameters. While some report no change with 400mg DHT 
(administered on days 30-90) (438), others show an increase in mean LH levels with 100mg 
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DHTP over the same time period (454). Max P4 levels have been shown to be increased in 20-
week-old lambs treated with 100mg DHTP (days 30-90) (454). 
Sheep models of PCOS have reported that prenatal androgenisation results in an increase in 
LH secretion as well as LH pulse frequency and increased E2 levels, although results from 
different studies utilising different treatment regimens tend to yield conflicting results. 
1.3.2.4 Metabolic Traits 
An early study utilising a 2g implant of TP over days 40-60 (and removed 3 weeks prior to 
lambing) resulted in a decrease in birth weight coupled with an increase in average daily 
weight gain over a 100-day period (441). They also reported some decrease in fat deposition 
in these animals as well as an increase in liver weight. More recent studies have also found a 
decrease in birth weight with the more common 100mg injections over days 30-90 (243), 
while others report a decrease in (452) or no change in body weight (453) in the first 14 weeks 
or 15 months of life. A later treatment spanning days 62-102 resulted in no change in body 
weight or central obesity in treated animals (450). Genital and reproductive tract 
abnormalities have been reported in two studies utilising the 100mg/day 30-90 treatment 
paradigm. Forsdike et al report the appearance of male genitalia in treated female lambs as 
well as in increase in the incidence of dilated uteri (444) while Padmanabhan et al described 
an increase in the angiogenital:anonavel ratio among their treated ewes (243). 
An increase in basal insulin in 5 week old lambs has been reported with a dose of 60mg given 
over days 30-90 (439), while 100mg over the same time period resulted in an increase in basal 
insulin levels and the insulin:glucose ratio (in 22 month-old hoggets) (243) but no change in 
basal glucose levels at 11 weeks of age. An increase in basal insulin:glucose ratio and insulin 
area under the curve (AUC) was also seen in 13 month ewes treated with 100mg TP over the 
same treatment period (453). These abnormalities have also been reported in later treatment 
models (days 62-102) with an increase in glucose-stimulated insulin secretion in treated ewes 
Chapter One 
 91 
(450). This model also resulted in fatty liver, although no change in free fatty acid, cholesterol 
or triglyceride levels were reported. Most recently, results from an innovative study utilising 
a novel method of applying TP directly to the fetus at either day 62 or 82 of gestation have 
revealed that prenatal androgenism is associated with increased pancreatic beta cell numbers 
and subsequent hyperinsulinemia (456).  
Prenatal androgenisation with T or DHT has led to a variety of features which mimic human 
PCOS such as increased weight, hyperinsulinemia and fatty liver. 
1.3.2.5 Pros and Cons + Summary 
Sheep models of PCOS have provided key insights into the mechanisms behind PCOS and its 
pathogenesis in mammals. With several important milestones of reproductive development 
and function in humans being paralleled in sheep, their importance in animal studies of PCOS 
cannot be overstated. Like humans, sheep are primarily mono-ovulatory allowing closer 
comparisons to be made in terms of reproduction and fertility studies. Sheep also complete 
the formation of all ovarian follicles before birth which gives researchers the chance to mimic 
prenatal exposure to excess androgens – one of the key theories behind the development of 
PCOS in the offspring of those diagnosed with this condition. In addition, sheep respond to 
environmental stimuli, such as overfeeding, in the same way that humans do. The sheep 
model is not without its downsides. Compared to rodent models, sheep are relatively 
expensive per animal and can be difficult to house. Their life span and gestational period 
means that studies of reproductive function or generational studies take many years to 
complete.  
Overall the use of T and TP is much more common in sheep models, with researchers 
reporting many more differences in these animals than in those treated with DHT or DHTP. 
However, as T and TP are able to be aromatised to estrogens, results from their use can be 
misinterpreted and introduce uncertainty as to whether the effects generated by treatment 
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are estrogenic or androgenic in nature. DHT and DHT are stable, potent androgens with 
minimal conversion to estrogenic compounds so researchers can be confident that the 
resultant effects are indeed androgenic and mediated via the AR. Despite this, the use of both 
androgens in sheep models has shed light on windows of prenatal development that are key 
in the development of a PCOS-like phenotype in offspring. Later treatments such as from day 
62-102 (450,451) seem to be more effective at reproducing the metabolic aspects of the PCOS 
phenotype, such as insulin and glucose activity, but not have such a profound effect on follicle 
populations and dynamics within the ovary. The strongest evidence the sheep model has 
provided is that prenatal exposure to excess androgens at a specific time point during 
development (particularly T administered from day 30-90) is able to have a profound effect 
on the reproductive, endocrine and metabolic functioning of these offspring and may shed 
light on the potential time-specific fetal origins of PCOS. 
1.3.3 Rodents 
Initial studies of a PCOS-like phenotype in rodents were first published in the 1960s with the 
characterisation of a rat models displaying polycystic ovaries and persistent estrus, signalling 
chronic anovulation (457). Since then a number of models, in both rats and mice, have been 
established utilising a variety of methods to purposefully induce the PCOS-like phenotype. 
1.3.3.1 Androgen-Induced Models 
1.3.3.1.1 Testosterone and Testosterone Propionate 
As the primary indication of PCOS, hyperandrogenism is the most common method of PCOS 
induction in rodents, particularly mice. Initial studies into the effects of prenatal 
androgenisation in rats failed to produce any apparent effects in the offspring (458) such as 
that by Fels et al who utilised 10mg TP injection of the pregnant mother 1-4 days before 
delivery of her pups. However, this did not result in any disruption of ovulation or have a 
negative effect on ovarian morphology in the adult offspring (459). Taking transplacental 
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transfer into account, the researchers then administered 1mg TP via intra-amniotic injection 
which resulted in multicystic ovaries and anovulation in many of the adult offspring (459).  
Following on from these studies, direct administration of 1.25mg TP to 5-day-old rats was 
reported to result in significant short-term effects with rats displaying increased LH at 40 
days-post-injection (460) before gradually falling to meet those of the control group by 130 
days-post-injection. Conversely, this treatment caused a significant long-term effect on 
prolactin secretion in these rats with levels in the treated groups being more than 10-fold 
those of the control groups at 40 days-post-injection and remaining higher for the duration 
of the experiment (200 days-post-injection). While in humans the role of prolactin is mainly 
confined to pregnancy and lactation, in rodents prolactin plays a crucial role in both the 
maintenance of the CL as well as luteolysis of the same structure at the end of the cycle (461). 
Serum levels of E2 were elevated in TP-treated rats while T concentrations were initially 
significantly higher than controls for the first 20 days-post-injection before dropping sharply 
and remaining only slightly elevated above the control group (460). A lack of CLs, multiple 
cysts and theca cell hyperplasia were observed in treated rats 40 days-post-injection, 
however no observations were made past this time point (460), therefore the long-term 
effects of this model on the ovarian phenotype cannot be established. More recently, 
Beloosesky et al used a daily injection of 1mg/100g BW of T, beginning on day 21 of life, for 
up to 35 days (462). They reported that just 7 days of injections lead to the formation of cystic 
follicles while at 56 days-old (2 weeks after puberty should begin), following 35 days of 
injections, the ovaries of treated rats showed no CLs and P4 levels that were only 20% that of 
controls – indicating anovulation. The ovaries of T-treated rats also displayed an accumulation 
of apoptotic follicles and degenerative oocytes (462). The T-treated rats in this model 
exhibited a decrease in the fasting glucose:insulin ratio, indicating the possible onset of insulin 
resistance in these animals.  
The importance of the timing of prenatal treatments is evident in a study by Wu et al who 
utilised daily injections of 3mg T to pregnant dams from day 16 to 19 of gestation (463). This 
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short treatment resulted in elevated T, P4 E2 and LH in the treated offspring as well as 
irregular cycling, reduced CL numbers and an accumulation of preantral and antral follicles, 
not unlike that seen in human PCOS. A higher dose treatment of 5mg T given over the same 
developmental window resulted in significantly increased BW and fat mass as well as 
hyperlipidemia and fatty liver, the latter of which was exacerbated by consuming a high fat 
diet (464). While TP is the most common form of testosterone treatment in rats, studies in 
mice tend to use free T instead, with its shorter release time compared to TP being preferred 
for the smaller of the rodents (465). Early studies of prenatal T use in C57BL/6 mice, using a 
0.75mg implant of the pregnant mother from day 13 to 18 of gestation, did not find any 
difference in the ovarian phenotype of treated offspring compared to controls (465). On the 
other hand, neonatal exposure to 100µg (sc. injection) on days 1-3 of life leads to disrupted 
ovulation, polycystic-like ovaries and a total lack of CLs (466).  
1.3.3.1.2 Dihydrotestosterone 
As the findings from studies using T and TP often produce varied results, the use of DHT was 
employed to provide a potent source of exogenous androgens that cannot be converted in 
vivo to estrogens, leading to only androgen receptor-mediated effects in treated animals. 
Mannerås et al implanted 21-day-old rats with 90-day slow release pellets containing 7.5mg 
DHT to produce a daily dose of 83µg (245). Following 11-13 weeks of treatment, androgenised 
rats displayed significantly decreased P4 concentrations coupled with a lack of CLs within the 
ovary, indicating anovulation. These animals also showed an increase in large cystic follicles 
with thinned GC walls and theca cell hyperplasia, such as that seen in human PCOS. 
Additionally, plasma DHT levels were almost double those of control animals although T and 
E2 were within the normal range. Metabolically, DHT-treated rats exhibited increased BW and 
body fat, decreased insulin sensitivity and elevated leptin (245). More recently, Wu et al have 
reported that daily injection of 3mg DHT to pregnant dams from day 16-19 of gestation 
resulted in significantly higher T, E2, P and LH levels as well as an increase in the frequency 
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and amplitude of LH pulses in the offspring (463). DHT-treated offspring also experienced 
irregular estrous cycling in addition to reduced CL numbers and accumulation of preantral 
and antral follicles. When treatment with 250µg DHT from day 16-18 of gestation is used to 
prenatally androgenise rats, metabolic features such as increased fasting glucose and 
impaired glucose tolerance, independent of BW, are reported (467). This same treatment, in 
mice, has resulted in disrupted estrous cycles, delayed puberty and reduced fertility, as well 
as reduced CL numbers (468). More recently, a postnatal treatment, beginning on day 19 of 
life, with a 2.5mg DHT pellet implant (90-day continuous release) has been shown to increase 
BW and adipocyte size while reducing adiponectin concentrations and glucose tolerance 
(469). To date, the treatment regime capable of reproducing features closest to human PCOS 
is that of the 90-day continuous implants, with treatment beginning at approximately 3 weeks 
of age (470). 
1.3.3.1.3 Dihydroepiandrosterone 
As DHEA levels are frequently elevated in women with PCOS, models in both rats and mice 
utilising this pro-androgen were developed in an attempt to understand this feature of PCOS. 
Initial studies employed a postnatal treatment of 30mg/kg DHEA injected daily for 35 days 
beginning on day 22 of life in rats. This produced the stereotypical PCOS-like ovarian 
phenotype but failed to induce any change in BW (471). Since then, others have used 
6mg/100g BW for 20 consecutive days in 27-day-old rats and shown that this results in severe 
disruptions to cyclicity and ovulation, as well as multicystic ovaries and a lack of CLs (472-
474). Additionally, rats displayed altered endocrine profiles with hyperandrogenism 
(increased T, DHT and A4), and increased E2, P4 and LH (473). In the mouse, this same dose 
beginning on day 25 of life, resulted in acyclicity and anovulation coupled with a lack of CLs 
(475-477). Mice also displayed an increase in atretic follicles (475,477), however unlike 
human PCOS they exhibited follicles with thinned theca cell layers (477). The endocrine profile 
of DHEA-treated mice shows increased E2 and P4 as well as hyperandrogenism (475-477). 
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Unfortunately, the metabolic characteristics of the DHEA-induced PCOS mouse model have 
not yet been well characterised. 
1.3.3.2 Estrogen-Induced Models 
A PCOS-like phenotype has been induced in rats using E2 valerate, E2 benzoate or E2. E2 
valerate is a long-lasting, potent estrogen which causes rapid changes in rodents. It’s 
administration causes dysregulation of GnRH secretion and subsequent LH hypersecretion 
(478). Treatment with E2 valerate only requires a single dose of 2mg to be given to young 
adult rats in order to produce symptoms similar to human PCOS such as large cystic follicles, 
reduced or absent CLs and theca cell hypertrophy (479). However, this treatment regime fails 
to cause the LH hypersecretion seen in PCOS (480). A single dose of 4mg in 8-week-old rats 
has also been shown to result in hypertension without any change to insulin sensitivity or fat 
accumulation (481). Although P4 levels were higher in these rats they actually displayed 
lowered T levels (480). Unable to reproduce the metabolic and endocrine traits of human 
PCOS, the E2 valerate model is considered to be of a model of the ovarian phenotype of PCOS 
rather than the whole syndrome (429). Similar to E2 valerate, E2 benzoate is a synthetic 
compound which acts as a pro-estrogen. When administered on the first day of life in rats, 
100µg of E2 benzoate resulted in acyclicity and anovulation when the rats reached adulthood 
(482). Despite this, rats did not display the PCOS features of LH hypersecretion or increased 
ovarian weight, with these being decreased in this model. Unlike the sudden changes induced 
by E2 valerate, treatment with E2 requires long-term exposure such as that by McCarthy et 
al who utilised sc. implants of E2, which maintained plasma levels within the physiological 
range, for 8 weeks (483). These rats exhibited acyclicity and anovulation by way of a total lack 
of CLs within the ovary. Ovaries also contained an increase in large atretic follicles and 
displayed theca cell hypertrophy. The endocrine profiles, outside of normal E2 levels, remain 
to be explored, as do any metabolic side effects of chronic E2 exposure. 
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1.3.3.3 Aromatase Inhibitor- and Antiprogestin-Induced Models 
As an alternative to exogenous androgen exposure, the use of aromatase inhibitors allows 
the study of the effect of high levels of endogenous androgens by blocking their aromatisation 
into estrogens with the drug letrozole. Kafali et al utilised 6-week-old rats and three different 
doses of letrozole administered orally (0.1, 0.5 or 1.0mg/kg), for a period of 21 consecutive 
days. They found that the latter doses induced ovarian cysts with minimal GCs, decreased CL 
numbers as well as evidence of theca cell hypertrophy (484). In addition, serum E2 and P4 
were reduced while T, FSH and LH were significantly elevated (485,486). Based on this work, 
Mannerås et al implanted 21-day-old rats with sc. implants containing 36mg letrozole (daily 
dose of 400µg) for three weeks. They reported that not only did this produce acyclicity and 
increased ovarian weight, a feature of human PCOS, as well as an increased number of cysts 
but letrozole-treated mice had significantly increased BW (245). This study also reported that 
plasma T concentrations were increased while P4 levels were decreased, consistent with 
anovulation.  
The antiprogestin RU486 (or mifepristone) is a synthetic P4 antagonist capable of increasing 
GnRH pulse frequency by decreasing the negative feedback of P4 (429). This results in an 
increase in LH secretion and subsequent elevated T levels. Adult rats were administered 4mg 
RU486 via sc. injection on at least 8 consecutive days following the first day of estrus. This 
regime results in enlarged ovaries with an increase in atretic follicular cysts (487,488). In 
addition, the rats were acyclic as serum T, E2 and LH were increased while FSH was decreased.  
1.3.3.4 Light-Induced Models 
Unlike many larger mammals, in rodents the LH surges required to trigger ovulation are 
regulated by the normal cyclic light-dark photoperiods of the environment (489). 
Manipulation of these photoperiods, by varying the intensity and duration of light exposure, 
is able to influence the occurrence and severity of chronic anovulation in these rodents (457). 
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When exposed to continuous light for 25 days, rats initially exhibited no changes in ovulation. 
However, when the duration of light exposure began to increase beyond that point, the rats 
quickly developed irregular cycles and polycystic ovaries, a phenomenon which could be 
reversed when the normal light-dark cycles were resumed (490), in as little as 46 hours (491). 
More recently, researchers have demonstrated that just 24 hours of continuous light 
exposure is sufficient to cause disrupted cycling in rats (492) and that 3 days of exposure leads 
to significant upsets in the LH surge patterns in these rats (493).  
Constant exposure to light has also been shown to impact hormone levels with a reduction in 
serum FSH and P4 and increased E2 and E1 in adult female rats (494). However, these rats 
displayed normal LH levels as opposed to the LH hypersecretion seen in human PCOS. It is not 
yet fully understood how constant exposure to light leads to the development of a PCOS-like 
phenotype in rodents. Some believe that the constant stress placed on the animals by the 
lack of darkness causes hyperstimulation of the sympathetic nerve system, resulting in 
adrenal gland hypertrophy (490,495). Despite this, hyperandrogenism has not been reported 
in these models, nor have any metabolic features of PCOS.  
1.3.3.5 Genetic Models 
1.3.3.5.1 Leptin Deficient Strains 
Leptin is a hormone secreted by adipose cells whose main role is to regulate energy 
homeostasis by inhibiting hunger (470). Despite this, leptin has been found in higher than 
normal levels in many women with PCOS irrespective of BMI, when leptin levels are normally 
positively correlated with BMI (496). This, combined with the fact that leptin has directs 
effects on GnRH signalling, has led to the theory that altered leptin action may play a role in 
the pathogenesis of PCOS (470,497).  
The obese mouse (ob/ob) is leptin deficient, causing it to eat veraciously and become obese. 
These mice are infertile and exhibit the acyclicity, anovulation and altered folliculogenesis 
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seen in human PCOS (498). The same is also true for the diabetes mouse (db/db) who carries 
a spontaneous mutation of the leptin receptor and develops obesity-induced T2DM 
(499,500). Studies of the ob/ob muse have revealed significantly increased T, E2 and P4 levels 
(501) while the db/db mouse displayed decreased serum E2 and P4 (500). Unlike human 
PCOS, neither mouse model displays cystic ovaries, however they do provide the opportunity 
to study the metabolic traits of PCOS with both models exhibiting severe obesity, 
hyperglycemia and glucose intolerance similar to that of human diabetes mellitus, as well as 
hyperinsulinemia (500,502). Like the db/db mouse, the JCR:LA-corpulent (cp/cp) rat also 
carries a defect in the leptin receptor (503). This mouse displays similar obesity, dyslipidemia 
and hyperinsulinemia to the db/db while also being at an increased risk for cardiovascular 
disease (504), much like women with PCOS. The ovaries of these mice display cystic and 
atretic follicles while the mice themselves have disrupted estrous cycles (505). These mice 
also displayed significantly elevated T levels with normal E2 levels (429).(429) 
The New Zealand Obese mouse (NZO), while still displaying normal leptin secretion and leptin 
receptor action, exhibits an impaired transport of leptin across the blood-brain barrier, 
leaving them in a leptin resistant-like state (506). In addition to obesity these mice exhibited 
hyperinsulinemia and insulin resistance as well as dyslipidemia, hypercholesterolemia and 
hypertension, all common traits of human PCOS (506,507). The NZO mouse is subfertile, with 
reduced CL numbers, and their ovaries display an increase in atretic follicles (506). The 
endocrine profile of this mouse includes decreased LH, increased E2 and unchanged T levels, 
meaning that like the ob/ob and db/db mice, although this model provides insights into the 
metabolic traits of PCOS, key features of hyperandrogenism and polycystic ovaries are not 
present (429,470). 
1.3.3.5.2 Other Genetic Strains 
A mouse strain overexpressing LH has been established to determine whether LH 
hypersecretion, a key feature of PCOS, can replicate the multiple features of the syndrome. 
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These mice overexpress a chimeric LHb-subunit/hCGb-subunit gene which produces high 
levels of circulating LH (508). Morphologically, the ovaries of these mice are polycystic in 
appearance and the mice experience anovulation and infertility (509,510). Importantly, these 
mice displayed elevated T and E2 levels as well as some metabolic features such as obesity 
and increased insulin levels (495,508-510). 
Transgenic overexpression of SERPINE1, the gene encoding PAI-1, has led to an ovarian 
phenotype in mice similar to that of human PCOS, with reduced CL numbers and follicular 
cysts with thinned GC walls (511). Overall ovarian volume was also increased, which is 
common in human PCOS as well as significantly raised T levels in these mice. Likewise, 
overexpression of IGF-1 in transgenic mice also resulted in the appearance of polycystic 
ovaries and hyperandrogenism, although these mice displayed a decrease in LH levels 
contrary to human PCOS (126). Metabolic characteristics of these transgenic strains remain, 
as yet, uncharacterised. 
1.3.3.6 Pros and Cons + Summary 
Rodent models of PCOS have provided valuable insights into the pathogenesis of PCOS. Their 
ease of use and stable genetic background allow for more mechanistic studies of the 
underlying causes of disease. The ability to genetically manipulate rodents, in particular mice, 
has made them a valuable and versatile tool in such studies. The short reproductive life span 
of rodents makes studies of the prenatal origins of PCOS much easier (470). Despite the 
evolutionary conserved similarities in the control of reproduction by the HPG axis, which 
allows us to draws parallels between humans and rodents, several key physiological 
differences must be taken into account when using rodent models of human conditions such 
as PCOS. Unlike humans rodents are polyovulatory, suggesting a key difference in the way 
FSH-stimulated follicle growth and selection occurs between the two (433). Also, rodents 
differ from humans in the critical windows of development of the reproductive system, in 
that humans complete the formation of all follicles before birth, while in mice this occurs in 
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the initial neonatal period (512). This is most evident in the differing results from prenatal 
and postnatal treatment applied to both rats and mice (513). 
Despite these differences, rodent models still play a vital role in our understanding of certain 
aspects of PCOS. While prenatal models still present some challenges, in terms of a lack of 
consistent results and barriers to full model characterisation such as the vaginal fusion seen 
in many studies (261,470), postnatal androgenisation initiated in the first 3 weeks of life has 
proven to be an effective method of reproducing traits closest to those seen in human PCOS. 
The use of different androgens has provided models with which to study either the 
reproductive, metabolic or endocrine features of PCOS but, as yet, a comprehensive model in 
which to study all features of PCOS has not been established. Outside of models utilising 
exogenous hormone administration, PCOS models induced by continuous light exposure have 
allowed researchers to study aspects of the PCOS phenotype whilst avoiding any unwanted 
side effects of hormones, as do naturally occurring genetic strains (such as those deficient in 
leptin) while also providing insight into possible biomarkers for early screening for PCOS (470). 
Other non-hormonal models such as the high fat- and high sugar-induced PCOS model in rats 
(514) are emerging as theories of the etiology of PCOS shift to focus on the relationship 
between metabolic disturbances and the onset of the reproductive traits of PCOS. 
Overall, hyperandrogenic rodent models have, thus far, providing the most convincing studies 
of the pathogenesis of PCOS. Even though the effects of androgen administration are often 
transient, with regular estrous cycling being reinstated after termination of androgen 
treatment (429), these models are a practical and effective way to study multiple aspects of 
the human PCOS phenotype. They provide the potential to study the interactions between 
various aspects of the syndrome as well as critical periods of development in which 
susceptibility to developing PCOS may be heightened.  
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1.4 Androgens and The Androgen Receptor 
1.4.1 Normal Function and Role of Androgens 
1.4.1.1 Biosynthesis of Androgens in Females 
Compared to males, females produce androgens at much lower levels in the ovaries, the 
adrenals, and in the pregnant state by the placenta (62,515). In descending order of serum 
concentrations, the major circulating androgens in females are: DHEAS, DHEA, A4, T and DHT, 
however only the latter two are capable of binding to and activating the AR (516). The bulk of 
androgens in females are derived from the peripheral conversion of the former 3 pro-
androgens into these more biologically active and potent androgens. Such conversion occurs 
in adipose tissue as well as the liver and skin (516).  
Under the control of LH, gonadal androgen production in females occurs within the theca cells 
of the ovarian follicle, with some contribution from the CL and the ovarian stromal cells (517). 
Theca cells have a structure characteristic of steroid-secreting cells including ample 
mitochondria, the source of the first enzyme required in the steroidogenic pathway, and lipid 
vesicles for steroid transport (45,518). Throughout the cycle, as LH is released in a pulsatile 
manner, the amplitude and frequency of LH pulses determines the level of androgens, 
particularly T but also A4, produced within the theca cells (45). LH has also been shown to 
increase levels of StAR, the protein responsible for cholesterol transportation within 
mitochondria, as well as key steroidogenic enzymes (45,519). Androgen levels fluctuate 
during the menstrual cycle with T being found at its lowest concentrations during the early 
follicular phase. T peaks at the mid-point of the cycle before remaining slightly elevated 
throughout the luteal phase (517). T produced by the theca cells is transported to 
neighbouring granulosa cells for conversion to estrogens. 
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1.4.1.2 Androgen Receptor (AR) 
The AR is coded by a single-copy gene (AR) located on the X-chromosome, more than 90 
kilobases in size. It’s coding region is comprised of 2757 nucleotides making up 8 exons (89), 
the first of which houses the series of CAG repeats which have been previously implicated as 
a possible cause of the induction of PCOS (391). This exon also encodes the N-terminal domain 
of the translated AR protein responsible for transcriptional regulation (Figure 1.8). The DNA-
binding domain (DBD) is encoded by exons 2 and 3 and is highly conserved among steroid 
hormone receptors (89). The DBD monomer, made up of two zinc fingers, functions as a 
homodimer when it binds to hormone response elements (HREs), the specific sequence of 
which it recognises using just 3 amino acids. The remaining 5 exons code for the AR protein’s 
hinge and ligand binding domain (LBD). The 3-dimentional structure of the LBD is typical of 
nuclear receptor LBDs with one noticeable difference – the lack of an H2 helix which many 
believe allows the AR protein to take on the unique conformation required to bind to 
androgen response elements (AREs) (89).  
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Figure 1.8 Androgen Receptor Gene and Protein 
 
 
Schematic depicting the location and structure of the AR gene on the X chromosome as well as the 
structure of the translated AR protein. Recreated from Tan et al (89). 
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The AR is a member of the steroid nuclear receptor superfamily (82). In addition to the AR, 
this superfamily also contains the receptor for other steroid hormones such as E2, as wells as 
those for mineralocorticoids such as aldosterone and glucocorticoids like cortisol (520). What 
makes these different receptors a family is the common central DBD which allows each 
receptor to target its HRE, a specific DNA sequence designed to bind the receptors in order 
to regulate transcription (86,520). Expression of the AR in rodent ovaries has been well 
characterised. As the androgen-receiving cells of the ovary expression of AR mRNA, as well as 
the AR protein, in GCs is of no surprise. However, these have also been found in the within 
the oocyte and the theca cells (521-523). In rodents, the highest expression is within the GCs 
of preantral follicles and wanes as the follicle matures (522), with the same being true for 
primates (524). In humans, the AR expression has been demonstrated in the theca cells of 
most follicle development stages from the primary stage onwards (516) and the GCs of antral 
follicles, with the most abundant expression being in both cell types of the ovary’s dominant 
follicle (525-527). Outside of the HPG axis, AR expression can found in the uterus (528) and 
breast tissue (529), as well as the brain, adrenal gland, muscle, lungs, liver, GI tract, adipose 
tissue, skin and bone (The Human Protein Atlas (530))(531,532). A study of first trimester 
human fetal tissues has revealed that AR expression corresponds to the onset of fetal 
androgen production at around 6-8 weeks gestation (533). Regulation of AR expression is 
complex and tissue-type dependent. The presence of androgens themselves act to increase 
AR receptor expression at the protein level while concurrently decreasing AR mRNA in a 
manner that is yet to be fully understood (391).  
1.4.2 Androgens in Female Reproduction 
1.4.2.1 The Direct Roles of Androgens 
Studies in animals have revealed that androgens, via the AR, may act to regulate the action 
of key ovarian growth factors by modulating their mRNA expression. In vivo treatment with T 
and DHT have been shown to upregulate FSHR expression in primates (534) and pigs (535), as 
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well as rodents (536,537). This interaction between androgens and FSH is also supported by 
clinical observations in the context of IVF treatments. Some women deemed to be “poor 
responders” to cycle stimulation can show enhanced ovarian response to FSH when 
administered DHEA. This treatment has led to an increase in antral follicle numbers, number 
of oocytes retrieved and ultimately an increase in live birth rates (538). Additionally, 
androgens have also demonstrated the ability to increase the mRNA expression of both IGF-
1 and its receptor in primates (539), while in vitro treatment of porcine GCs revealed the 
ability of DHT to enhances the mitotic effect of GDF-9 in the presence of IGF-1 (540,541). 
Most recently, T has been shown to increase the expression of aromatase and P450scc by 
way of an increase in liver receptor homolog-1 (542), a nuclear receptor protein that has 
recently been shown to be essential for ovulation in mice (543).  
It has been suggested that androgens are responsible for the enhanced follicular recruitment 
and increased pool of growing follicles seen in human PCOS. Prenatal treatment with T or DHT 
in both Rhesus monkeys and sheep has been shown to stimulate primordial follicle initiation 
and hence increase the number of follicles in the growing pool (422,444,544). While the use 
of T does invite questions as to whether the observed effects are truly androgenic, or the 
consequence of aromatisation to estrogens, the use of antiandrogen antibodies or an 
androgen antagonist blocks these stimulatory effects, appearing to confirm the androgenic 
nature of the results on follicle dynamics (537,538). In pigs, androgen administration during 
the follicular phase was shown to increase preovulatory follicle numbers as well as the 
number of CLs, indicating a beneficial role of androgens in ovulation (535,545).  
In addition to ovarian function, there is increasing evidence that androgens play a role in 
normal uterine function. The AR protein has been detected throughout the mouse uterus 
with expression being sensitive to changes in the hormonal milieu of the immediate 
environment. Studies in mice indicate that progestins inhibit AR while estrogens increase 
expression in the uterine stroma (546). This is consistent with AR expression in the human 
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uterus with AR at its most abundant in the endometrial stromal cells during the proliferative 
phase (high estrogens) and decreased during the secretory phase (high P4) (538). Androgens 
have also been demonstrated to regulate important cellular process within uterine tissue 
such as cell proliferation (547), with the supplement of androgens to ovariectomized rodents 
inducing uterine proliferation and growth (548). They are capable of modifying processes 
involved in decidualisation, the process of differentiation undertaken by the uterus during 
the establishment of pregnancy, with the addition of androgens shown to increase several 
markers of decidualisation in human endometrial cells (549). 
1.4.2.2 The Necessity of Androgens in Normal Reproductive Function 
Beyond just that as estrogen precursors, androgens have been shown to play direct roles in 
female reproductive physiology. It is believed that androgens must be maintained within an 
ideal range between too little (hypoandrogenemia) and hyperandrogenemia, with the latter 
being strongly linked to PCOS and the former also having adverse effects of normal ovarian 
function (550). In addition to PCOS, hyperandrogenic conditions such as CAH (551) and the 
exogenous androgen exposure experienced in female-to-male transsexuals (552) can also 
have a negative effect on normal reproductive function and often mimic the features of PCOS 
in these women, in particular the presence of multi-follicular ovaries, which supports both a 
stimulatory role for androgens and a role in follicular arrest (516). Interestingly, PCOS traits 
have also been shown to be present in female-to-male transsexuals before undergoing any 
androgenic treatment, indicating that not all cases of post-treatment PCOS-like traits are a 
result of exogenous androgen therapy (553). Additionally, excess T concentrations have been 
reported in endometriosis tissue lesions (554) and in serum of women who have experienced 
recurrent miscarriages (555).  
Androgen deficiency in women has shown that androgens play a key role in sexual function 
(556), as well as muscle mass, bone density, and adipose tissue distribution (557-559). Such 
androgen deficiency could be due to hypopituitarism (560), ovarian failure, oophorectomy 
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(561) or use of the oral contraceptive pill to name a few (557,562). Androgens, such as T, have 
been shown to display a gradual age-related decline in both sexes with females continuing to 
experience a decrease in T levels post-menopause (562,563). It is not believed that the 
menopausal transition accelerates or slows this process, in fact SHBG tend to fall around the 
time of menopause, potentially causing levels of free T to rise (562). It may be this waning of 
androgens that contributes to the ovary’s diminishing capacity to respond to FSH and, hence 
the decline in fertility experienced with age (516). Conversely, it has been shown that adrenal 
androgen production, of androstenediol in particular, can increase post-menopause when 
estrogen-driven repression is diminished (564). However the weak androgenic properties of 
androstenediol, combined with potent estrogenic activity, is not likely to alleviate the 
decreasing androgen levels following menopause (564). 
1.4.2.2.1 Lessons From Global and Cell-Specific Androgen Receptor Knock Outs 
A wealth of information has come from the study of mice completely insensitive to androgens 
due to a global inactivation of the AR – the AR-/- mouse, known as ARKO. Creation of the ARKO 
mouse, using the Cre/LoxP system, has provided key advances in knowledge of the 
fundamental role that androgens play in female reproductive physiology. Several ARKO 
mouse lines have been developed, differing in the exon targeted during genetic modification. 
ARKO models targeting exon 1 (ARtm1Ska/ARtm1Ska, referred to as ARKOEX1) (565) and exon 2 
(ARtm1.1Chc/ARtm1.1Chc, referred to as ARKOEX2) (566,567) both result in a loss of the AR protein 
due to the insertion of premature stop codons in each of the transcripts. Conversely, targeted 
excision of exon 3 (ARtm1.1Jdz/ARtm1.1Jdz, referred to as ARKOEX3) (568) results in an in-frame 
deletion of the exon and the formation of a truncated AR protein. The loss of exon 3 causes 
the final translated protein to be without the second zinc finger of the DBD, rendering the 
receptor non-functional (523). Males hemizygous for the AREX3-/- mutation confirm the 
complete loss of androgen action and display a phenotype similar to that of the human 
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condition complete androgen insensitivity syndrome (CAIS) with testicular feminisation and 
sterility (569,570). 
ARKO mice are subfertile displaying ovulatory dysfunction, often involving decreased or 
mistimed LH surges (571) with fewer pups born per litter (565-568,572), with mice 
heterozygous for the exon 3 deletion (AREX3+/-) in particular showing an age-related decline in 
litter size (568). This indicates a significant gene dose effect of AR and may suggest important 
implications for the reproductive health of female obligatory carriers of CAIS, who themselves 
must be heterozygous for the mutation (523). Irregular estrous cycling in female ARKO mice 
indicates that the normal function of the HPG axis is disrupted in the absence of regular 
androgen signalling (516). This is further supported by the delay in the birth of the first litter 
experienced by ARKO mice, again indicative of disrupted HPG axis function (568). The ovaries 
of ARKO mice show defects in follicular health, including unhealthy antral follicles and a 
decrease in preovulatory follicle numbers (571). Specific to ARKOEX1 is an accelerated 
depletion of follicles in older mice (565). ARKOEX2 mice appear to have impaired follicle growth 
and oocyte health, features that are not evident in ARKOEX3 mice, indicating that classical AR-
mediated action may not be necessary for these aspects of reproductive function and that 
non-genomic actions of the AR may be at play (523). Non-genomic actions of the AR have 
been reported to include activation of cell signal transduction pathways either by way of 
interaction with Src kinase to induce autophosphorylation, activation of the Ras-Raf-
MAPK/ERK cascade, or triggering of the PI3K/Akt pathway (573). However, ARKOEX3 mice, like 
all ARKO models, do display an increase in follicle atresia (568,571). Studies of 
haploinsufficient ARKO mice (AREX3+/-) have revealed that only one functional copy of AR is 
required to maintain normal fertility up to the age of 6 months, when the aforementioned 
age-related decline in fecundity becomes apparent (568). 
Briefly, uterine growth and development are also perturbed in ARKO mice. Increased uterine 
horn length and decreased uterine diameter have been seen in these mice (572). In addition, 
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the uterine hypertrophy normally seen in response to superovulation is reduced in ARKO mice 
(567). Furthermore, a recent study involving a uterine gland-specific ARKO model has 
revealed a critical role for AR in stimulating uterine growth in response to androgenic 
signalling (574). 
As the main ovarian target for androgens, the GCs provided as obvious target for cell-specific 
ARKO models to be developed. Two such models have been described in the literature to date 
with Sen and Hammes utilising the AMH receptor type 2 gene promoter to create GC-specific 
ARKOEX2 mice (GCARKOEX2), while Walters et al employed the use of the gene promoter of 
AMH itself to produce the in-frame deletion of AREX3 and the resultant GCARKOEX3 model. The 
former results in loss of AR mRNA in the GCs, however non-specific expression of this 
promoter-driven Cre has also been detected in the oocyte and theca cells of the follicle as 
well as the uterus, raising concern as to whether the resultant phenotype is purely due to the 
loss of AR signalling in the GCs or if there is some contribution from the anomalies seen 
elsewhere in the reproductive tract (516). On the other hand, extensive analysis of the 
GCARKOEX3 model has not revealed any unwanted deletion of AR signalling outside of the 
granulosa cells (575). However, analysis also revealed that AR signalling depletion may be 
confined to the GCs of large preantral and antral follicles only and not those of a lesser 
developmental stage. This implies that the finding from these models may underestimate the 
true importance of GC-specific AR actions (575). 
Both GCARKOEX2 and GCARKOEX3 females are subfertile and display reduced fecundity with a 
reduction in litter size or in total litters produced, respectively (575,576). After initially 
displaying normal estrous cycling, by 6 months of age GCARKO mice show aberrant cycling 
patterns, indicating that GC-specific AR actions are necessary in the long-term maintenance 
of correct HPG axis feedback. GCARKOEX3 females exhibit a reduction in large preantral and 
small antral follicles, supporting the role of androgens in stimulating normal follicle growth 
through the later stages of development (575). Both models display significantly decreased 
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follicular health, implying that AR signalling is important for GC survival and protection from 
follicle atresia (575,576).  
Other cell-specific ARKO models include the pituitary-specific (PitARKO) (577) and oocyte-
specific (OoARKO) (576). Deletion of AR in the gonadotrophs of the pituitary in PitARKO mice 
results in subfertility and reduced CL numbers despite normal estrous cycling (577). Follicle 
populations remained normal while follicle health was significantly reduced. OoARKO mice, 
created with the use of the GDF-9 promoter, have been reported to display normal estrous 
cycling and fertility, follicle population and CL numbers (576). However, these mice 
experience impaired oocyte maturation. Additionally, a recently developed theca cell-specific 
ARKO (ThARKO) has been reported to display normal fertility as well as normal T and E2 levels 
(578). However, following DHT treatment ThARKO mice experienced a partial rescue of 
estrous cycling and fertility compared to WT mice also treated with DHT. 
Overall, androgen actions mediated via the AR have be shown to be crucial to normal 
reproductive function in females. Although also serving as estrogen precursors, androgens 
have direct roles in female physiology, including follicle development, ovulation, uterine 
growth and fertility. 
1.4.3 Human PCOS and The Role of Androgens 
It is clear that the PCOS is a complex, multifactorial condition that, despite its name, involves 
more than just the ovaries and reproductive function. Three current diagnostic criteria are 
used in the clinical management of PCOS: 1) the 1990 United States NIH criteria (144), 2) the 
2003 Rotterdam criteria (146), and 3) the 2006 AE-PCOS Society criteria (148). The broader 
and more widely accepted Rotterdam criteria results in an estimated PCOS prevalence of 5.5-
19.9% worldwide (579,580). The inclusion of more patients using this criteria, and the 
variability in characteristic features of PCOS, has led to several different phenotypes being 
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described, with phenotypes C and D being more common in unselected (unbiased) 
populations (Figure 1.9).  
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Figure 1.9 Proposed Phenotypes of PCOS 
The four proposed phenotypes of PCOS and the diagnostic criteria under which they are included. 
Recreated from Azziz et al (579). 
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Without definitive knowledge of the underlying, mechanistic cause(s) of PCOS current 
treatments are focussed on individual symptoms rather than the syndrome as a whole. 
Lifestyle modification has proven effective in ameliorating the metabolic dysfunction seen in 
PCOS with weight loss having a positive effect on inducing ovulation in obese patients (581). 
Hyperandrogenism is a key target of medical intervention. Anti-androgens and other 
suppressors of ovarian androgen secretion, including the OCP and flutamide, can result in an 
improvement in androgen-induced symptoms such as hirsutism and severe acne, as well as 
menstrual dysfunction (579). However, flutamide is not used universally in the fertility clinic 
due to its high cost and risk of hepatocellular toxicity while the OCP carries the risk of insulin 
resistance and adverse blood coagulation (582). Effective reproductive therapies to overcome 
infertility and achieve pregnancy include ovarian surgery and ARTs, with PCOS women having 
similar outcomes from IVF procedures to non-PCOS patients (583). 
As the unifying feature of PCOS diagnoses, hyperandrogenism is currently, and will remain, at 
the core of PCOS research. A critical advancement will be the unravelling of whether 
hyperandrogenism is a cause or consequence of PCOS. Steroid hormone profiles of women 
with PCOS indicate that a failure of the normal HPG axis functioning is evident, however as 
the axis is not linear, but rather a complex feedback loop system, it is not yet clear if 
hyperandrogenism is the initial aberration involved in the onset of PCOS or rather a 
downstream effect of something else and simply acts to propagate and worsen many of the 
traits displayed in PCOS. What is known is that androgen levels are constantly elevated in 
women with PCOS, as is the enzyme 3β-HSD which is critical for the conversion of pro-
androgens to their more bioactive androgen counterparts (516). High levels of androgens, be 
it endogenous (CAH) or exogenous (female-to-male transsexuals) are well documented in 
causing a PCOS-like phenotype which strongly implicate androgens in the etiology of this 
condition (551,552). Additionally, human theca cells from PCOS ovaries, when cultured in 
vitro have been shown to produce androgens at levels 20 times those taken from normal 
ovaries (584). The successful use of AR antagonists, such as flutamide, to ameliorate 
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reproductive dysfunction in some PCOS women only strengthens the hypothesis that 
androgens play a causative role in the pathogenesis of PCOS (585,586).  
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1.5 Objectives and Aims 
While significant advances have been made in several aspects of PCOS research, there is still 
much more that remains elusive. Conflicting findings on the etiologies of specific features of 
PCOS require large world-wide studies to tease out the common underlying cause(s) across 
multiple ethnicities. In addition to hyperandrogenism, the emerging importance of metabolic 
dysfunction in PCOS is also at the forefront of studies into the pathogenesis of this disorder, 
as little is currently known about the interactive relationship between metabolic traits, such 
as obesity and hyperinsulinemia, and the reproductive and endocrine characteristics of PCOS. 
More research is required into the relationship between the metabolic dysfunction and 
reproductive anomalies seen in PCOS. While weight loss and changes in body composition 
have long been used as a frontline treatment for ovulation induction in PCOS (587,588) it is 
not yet known precisely how these interact in a dose-dependent manner to the point where 
attenuation of these processes can be utilised to provide effective treatment for PCOS women 
suffering from infertility. 
It is not yet known whether managing pre- and peripubertal obesity in adolescents 
susceptible to PCOS may prevent the propagation of symptoms and the development of 
diagnosed PCOS. It is also important to note that very little research has been conducted into 
the long-term health of post-menopausal PCOS women (589), which will be crucial in shaping 
the management of patients with different phenotypes of PCOS. In order to properly 
understand the manifestation of PCOS both before and after the female reproductive 
lifespan, it is crucial that we know more about the underlying, mechanistic cause(s) of PCOS. 
The important questions of ‘where are the key sites of AR-mediated androgen action’ and 
‘how does hyperandrogenism contribute to the etiology of PCOS’ (590) form the basis of this 
current study. While the improvement of current treatments must continue, the 
development of new, and more effective, treatments for PCOS needs to stem from research 
into the development and propagation of the syndrome. A successful treatment, or even a 
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cure, for PCOS will only be possible once a full understanding of this complex syndrome’s 
etiology has been established. 
Despite the abundance of animal models of PCOS, a lack of consistency in and breadth of 
reported results has meant there was need to develop a model in which multiple theories of 
PCOS etiology and androgen action in PCOS could be tested. The overarching aim of the 
current study was to develop and characterise such a model. 
Chapter Three of this thesis focuses on the comprehensive characterisation of four distinct 
hyperandrogenised mouse models in which reproductive, endocrine and metabolic features 
associated with PCOS are assessed within a single strain. The aim of this study was to develop 
an optimal PCOS mouse model which reflects the most accurate representation of human 
PCOS. 
Chapter Four concentrates on the theory that PCOS may have its origins in fetal life. The 
hypothesis of this study is that prenatal exposure to excess androgens in female mice causes 
a PCOS-like phenotype in affected offspring and that these effects are mediated via the 
androgen receptor. The aim was to combine a prenatally androgenised mouse model of PCOS 
with a model of androgen receptor inactivation to investigate the potential contributions of 
androgen receptor-mediated androgen actions in the pathogenesis of PCOS. 
Finally, Chapter Five of this thesis centres on the question of the site of androgen action in 
PCOS. This in-depth study hypothesised that androgens are core in the etiology of PCOS and 
that their actions are tissue-specific in nature. This study aimed to combine the optimal 
postnatally androgenised mouse model of PCOS from Chapter Three with three different 
models of androgen receptor knockout: a global model (from Chapter Four), and neuronal- 
and granulosa cell-specific inactivation models to elucidate the site(s) of androgen action in 
PCOS.
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2.1 Water, Chemicals and Ethanol 
All water used in this work was filtered by reverse osmosis (RO water, Millipore) unless 
otherwise stated. RO water was sterilised by autoclave prior to use. When required, Milli-Q 
water (Millipore) was used. All chemicals used were certified analytical grade unless 
otherwise stated. All concentrations of ethanol (EtOH) were made by dilution of 100% 
absolute ethanol (Sigma-Aldrich, Missouri, USA, 24102) with the appropriate volume of Milli-
Q water that had been passed through a filter (Millex 0.22µm Express® Filter Unit, Millipore, 
Carrigtwohill, Co. Cork, Ireland, SLGP033RS).  
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2.2 Animals 
This study, and all experiments contained within, were approved by the Sydney South West 
Area Health Service’s Animal Welfare Committee and conducted under the National Health 
and Medical Research Council’s (NHMRC) guidelines for animal experimentation and the New 
South Wales Research Act of 1985. 
All mice were housed in the ANZAC Research Institute’s animal facility, maintained under 
standard housing conditions with ad libitum access to water and standard chow (energy from 
60.2% carbohydrate, 25.5% protein, 14.3% fat, Specialty Feeds SF14-008, WA, Australia). 
Housing rooms were temperature- and humidity-controlled (temperature 22 ± 1°C, humidity 
50-60%) and operating on a 12-hour light/dark cycle. 
2.2.1 Generation of Mouse Lines 
The site-specific recombination of the Cre-Lox system was used to produce the genetically-
modified mouse lines used in this study. This method allows for the targeted deletion of a 
gene (or part thereof) by placing loxP sites at either end of the gene sequence that is to be 
excised, known as ‘flanking’ (591). Removal of floxed sequences occurs when both loxP sites 
are orientated in the same direction (592). This excision occurs under the control of the 
enzyme Cre recombinase (known simply as ‘Cre’). Cre-driven recombination can be targeted 
to specific tissues by the use of a tissue-specific promoter (593), such as those used in this 
study. 
We employed the strategy of targeting exon 3 of the androgen receptor (AR) which encodes 
the second zinc finger, a crucial DNA binding domain. Excision of exon 3 results in a truncated, 
non-functional protein being produced that, while still capable of binding androgens, is 
unable to bind to DNA within the nucleus and is therefore unable to carry out any nuclear 
receptor signalling actions, including transcription (569,594). To target the AR and render it 
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inactive, exon 3 is floxed and the resulting mouse line referred to as ARflox. These mice can 
then be crossed to any Cre-expressing mouse line to produce global and cell-specific excision 
of exon 3 and therefore a knockout of AR activity (571,574,595). 
2.2.1.1 Global Androgen Receptor Knockout (ARKO) 
All females were homozygous for the ARKO genotype and were generated by crossing ARflox 
mice (569) with Sox2-Cre expressing mice (596). Sox2-Cre mice have active Cre expression in 
all cells throughout the body with Cre expression in these mice being driven by the Sox-2 
promotor. Sox-2 is a universally expressed member of the Sox gene family, a group of 
transcription factors with a wide variety of roles, particularly in embryonic development and 
the central nervous system (597,598). The result of crossing these two lines of mice is a model 
of complete, global inactivation of the AR in all cells. These mice are referred to as ARKO 
(Figure 2.1). 
2.2.1.2 Granulosa Cell-specific Androgen Receptor Knockout (GCARKO) 
To generate mice with a granulosa cell-specific inactivation of the AR, ARflox mice (from the 
same colony as above) were crossed with a mouse line in which the Cre recombinase gene 
was driven by the AMH promotor (AMH-Cre). In females, expression of the AMH promoter is 
confined to the ovarian granulosa cells (599,600) and as such the inactivation of the AR only 
occurs in these cells, while all other cell types remain sensitive to androgens (575). The 
resulting mouse line is referred to as GCARKO (Figure 2.1). 
2.2.1.3 Neuron-specific Androgen Receptor Knockout (NeurARKO) 
In order to target AR inactivation to the brain, NeurARKO mice were generated by crossing 
the ARflox line to a line of CamKIIa-Cre-expressing mice. As with the AMH-Cre mouse, Cre 
recombinase activity is tissue specific by way of a promoter that is unique to the target tissue. 
In this case, CamKIIa-Cre is expressed at its highest in the brain’s cortex and hippocampus 
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with lower expression also seen in the hypothalamus (601). This results in the subsequent 
inactivation of AR activity in neurons only (Figure 2.1). 
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Figure 2.1 Generation of Mouse Lines Used in This Study 
 
 
Schematic showing the generation of the three genetically-modified mouse lines used in this study. 
All lines began with the same colony of ARflox mice crossed to one of three different Cre recombinase-
expressing mouse lines. Each resulting AR knockout model utilised its own WT littermates as controls.  
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2.2.2 Genotyping of Mice  
2.2.2.1 Tissue Lysis 
Prior to experimental use, all animals were genotyped using genomic DNA extracted from 
toe-clip biopsies taken from pups prior to weaning. If needed, the genotype of a mouse could 
be re-analysed using a tail-clip biopsy following collection at the end of the experiment. Tissue 
samples were placed in 250µl of lysis mixture for 2 hours at 55°C followed by 15 minutes at 
98°C to lyse the tissue and release DNA. The lysis mixture contained: 25µl Taq DNA 
Polymerase Reaction Buffer (Fisher Biotec, WA, Australia, TQRB-50), 25µl 20mM MgCl2 
(Bioline, NSW, Australia, BIO-37026) and 1.7µl proteinase K (Roche Diagnostics, Mannheim, 
Germany, 03 115 887 001). Lysed samples we stored at 4°C until use. 
2.2.2.2 Genotyping PCR 
PCR primers (Table 2.1) were purchased from Sigma-Aldrich (manufactured in NSW, 
Australia) as previously described (568). RNase- and DNase-free water was used as a negative 
control in all PCR reactions. Detailed genotyping PCR protocols can be found in Appendix One. 
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Table 2.1 Genotyping PCR Primers 
Primer Sequence 
CRE-F (forward) 5’-CTGACCGTACACCAAAATTTGCCTG-3’ 
CRE-R (reverse) 5’-GATAATCGCGAACATCTTCAGGTTC-3’ 
ARNeo-F (forward) 5’-TAGATCTCTCGTGGGATCATTG-3’ 
ARCut-F (forward) 5’-CAGAAATCCACGTGCCTCTACC-3’ 
AREX3-F (forward) 5’-CTTCTCTCAGGGAAACAGAAGT-3’ 
ARIN3-R (reverse) 5’-GGGAGACACAGGATAGGAAATT-3’ 
SRY-F (forward) 5’-AGAGATCAGCAAGCAGCTGG-3’ 
SRY-R (reverse) 5’-TCTTGCCTGTATGTGATGGC-3’ 
 
Cre PCR: Primers CRE-F and CRE-R (Table 2.1) were used to identify the presence of the Cre 
gene in mice to be used for mating with the ARflox line. Cre was confirmed as present with a 
PCR product of 213 base pairs (bps). 
ARflox PCR: In order to identify mice with a floxed exon 3 within the androgen receptor gene 
(AR), the primers used were AREX3-F, ARNeo-F and ARIN3-R (Table 2.1). Exon 3 of the AR was 
confirmed to be floxed with a PCR product of 289bps, unfloxed (or wild-type) AR had a 
product of 613bps.  
ARCut PCR: Using the primer pair ARCut-F and ARIN3-R deletion of exon 3 of the AR gene was 
confirmed with a PCR product of 510bps. Intact AR exon 3 was detected at 1650bps. 
SRY PCR: Due to the fact that males with the global ARKO genotype appear phenotypically 
similar to females, males were excluded by PCR using the SRY-F and SRY-R primers to detect 
the sex-determining region of the Y chromosome.  
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2.3 Knockout Model Validation 
2.3.1 RNA Extraction 
For model validation and confirmation of correct tissue-specific truncation, tissue samples 
were collected from representative mice of each genotype for RNA extraction and 
subsequent PCR. A detailed protocol can be found in Appendix One.  
Briefly, tissue samples were homogenised using TRI Reagent (Sigma-Aldrich, Missouri, USA, 
93289) and a handheld homogeniser (IKA Ultra-Turrax Disperser). After homogenisation was 
complete and the sample was incubated at room temperature (RT) or 5 minutes, chloroform 
(Sigma-Aldrich, Missouri, USA, C2432) was added to initiate phase separation. The 
homogenate was then transferred to Eppendorf tubes and centrifuged to complete phase 
separation. Following centrifugation, the top aqueous phase, containing RNA, was then 
transferred to fresh 1.5ml Eppendorf tubes and isopropanol (Sigma-Aldrich, Missouri, USA, 
I9516) added to precipitate the RNA. Samples were centrifuged before the supernatant was 
discarded. The pellet was then washed twice with 80% EtOH before final supernatant was 
removed and the tubes allowed to air dry to evaporate the remaining EtOH, without drying 
out the pellets themselves. Pellets were then resuspended in RNAse-free water and the 
concentration and purity measured using a NanoDrop (Thermo Fisher Scientific). All RNA 
samples had a 260nm:280nm ratio between 1.9 and 2.1. RNA samples were stored at -80°C 
until conversion to cDNA. Pituitary RNA samples were too dilute and were concentrated prior 
to cDNA conversion using the method found in Appendix One. 
2.3.2 cDNA Conversion 
RNA samples were first treated with DNase I, Amplification Grade (Invitrogen, California, USA, 
18068015) to eliminate any DNA contamination. Samples were then converted to cDNA by 
reverse transcription using the SuperScript III First-Strand Synthesis System (Invitrogen, 
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California, USA, 18080051). A detailed protocol of cDNA conversion can be found in Appendix 
One. 
2.3.3 Model Validation PCR 
Table 2.2 Model Validation PCR Primers 
Primer Sequence 
AR_Exon3_F (forward) 5’-GGACAGTACCAGGGACCAT-3’ 
AR_Exon3_R (reverse) 5’-CCAAGTTTCTTCAGCTTACGA-3’ 
 
The above cDNA primers were designed to flank exon 3 of the AR in order to validate each 
knockout model and confirm tissue-specific inactivation of the AR by way of exon 3 deletion. 
Intact exon 3 was confirmed by a PCR product size of 288bp while the exised exon 3 had a 
product size of 171bp. b-actin was used as an internal control for all samples. PCR protocol 
for model validation and b-actin control can be found in Appendix One. 
2.3.4 Agarose Gel 
All genotyping and model validation samples from this work were analysed on an agarose gel 
in Tris/Borate/EDTA (TBE) buffer. Gels were made fresh on the day of use and contained 1.5% 
agarose (Amresco, Ohio, USA, 0710-500G) in 1x TBE buffer (diluted with RO water from 10x 
stock solution, Amresco, Ohio, USA, 0658-4L). Gels also contained 7.5µl SYBR® Safe (10,000x 
in DMSO, Invitrogen, California, USA, S33102) per 150ml of gel. Samples were flanked at 
either end of the gel by HyperladderTM 50bp (Bioline, Sydney, NSW, Australia, BIO-33039), a 
control ladder used to compare the size of PCR product bands. 
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2.4 Surgery 
2.4.1 Anaesthetic 
All surgical procedures we carried out using an anaesthetic mixture customised for these mice 
and optimised to keep the mice under general sedation for the duration of the surgery 
(approx. 10-15 minutes) and allow for a quick recovery thereafter. The mixture was prepared 
by combining 0.9ml of Ketamine (100mg/ml, Parnell Laboratories, Alexandria, NSW, 
Australia) with 0.2ml of Xylazine (100mg/ml) and 8.9ml Milli-Q water. Mice were 
administered 10µl anaesthetic per gram of body weight using a 1ml insulin syringe, pre-fitted 
with a ½ inch 27-gauge needle (Terumo Medical Corporation, Maryland, USA). 
Dual-energy x-ray absorptiometry (DEXA) scanning was a non-invasive procedure performed 
under isoflurane inhalable anaesthesia as an alternative to ketamine/xylazine to allow for an 
immediate recovery following cessation of exposure. 
2.4.2 Implant Insertion 
DHT and blank implants were placed under general anaesthetic. Mice were deemed to be 
fully under anaesthetic when they no longer displayed a reflex to toe pinch. Once this was 
achieved, a small incision (0.5cm) was made through the skin on the back of the neck 
approximately 1cm from the base of the skull. Implants fashioned from SILASTIC® tubing 
(inner diameter = 1.47mm and outer diameter = 1.95mm, Dow Corning, Sydney, NSW, 
Australia, 508-006, made of medical-grade silicon and sealed at each end with liquid silicon) 
were then placed subdermally. Implants were made to be 1cm long, contained ~10mg DHT 
(Merck, Darmstardt, Germany) and were closed at either end. Blank implants were comprised 
of empty SILASTIC® tubing cut to 1cm and open at each end. After placing the implant the skin 
was stitched closed using 4-0 PERMA-HAND® silk suture (Ethicon, Johnson&Johnson Medical, 
Sydney, NSW, W501H). 
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Many thanks to Mr Mark Jimenez, of the ANZAC Research Institute, for preparing the implants 
for use in this study. 
2.4.3 Recovery 
After surgery, mice were allowed to recover underneath paper towelling near a heat lamp. 
Once mice were observed to be able to move about their environment and capable of 
reaching the food within their cage, they were returned to a clean cage with their cage mates. 
Mice with DHT implants were never housed with those containing blank implants, and only 
with other mice that had also had surgery the same day. Wounds were examined each day 
for the following two days to check for proper healing and, if required, re-sutured under 
isoflurane anaesthesia. 
  
Chapter Two 
 130 
2.5 Sample Collection 
2.5.1 Estrous Cycle Stage Identification 
In order to collect all mice at the same stage of the estrous cycle, mice were collected during 
diestrus. As endogenous hormones are low at this stage, this allowed the true effects of the 
exogenous DHT treatment to be displayed as well as allowing for acyclic mice to be collected 
at the same cycle stage as those mice who had functioning estrous cycles. Mice had vaginal 
smears taken daily following the cessation of in vivo sampling. Sterile saline (15µl, Livingstone, 
Sydney, NSW, Australia, DWSC0010) was used to collect vaginal epithelial cells which were 
then transferred to a glass slide to air dry. Slides were then stained with 0.5% toluidine blue 
(Appendix Two) and examined under a light microscope (Figure 2.2). 
Proestrus was characterised by the presence of predominantly nucleated epithelial cells with 
some cornified epithelial cells. At the estrus stage, all epithelial cells present were cornified 
and enucleated. Metestrus was characterised by the presence of both cornified epithelial cells 
and leukocytes. At diestrus, primarily leukocytes were visible with very few or no other cells 
present. 
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Figure 2.2 Estrous Cycle Stage Identification 
 
 
Representative vaginal epithelium smears stained with toluidine blue, representing the four distinct 
stages of the estrous cycle. 
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2.5.2 Anaesthetic for Final Sample Collection 
For final sample collection mice were administered the same anaesthetic recipe as for live 
surgery, this time at a dose of 20µl per gram of body weight. Each mouse was tested for a 
tow pinch reflex to ensure proper sedation before blood collection was carried out. Final body 
weight was measured at this time. 
2.5.3 Blood and Serum Collection 
Blood was collected from fully anaesthetised mice by cardiac puncture using a 1cc/ml 
tuberculin syringe and a 5/8 inch 25-gauge needle (both Terumo, Medical Corporation, 
Maryland, USA). Blood was left at room temperature to clot for at least 30 minutes before 
being centrifuged at 5000 x g for 5 minutes. Serum could then be removed and stored in clean 
Eppendorf tubes at -20°C until use. 
2.5.4 Tissue Collection 
The volume of blood collected was sufficient to cause cardiac arrest by exsanguination. Due 
to this, quickly after blood collection, mice were euthanized by way of cervical dislocation. A 
small tissue sample was taken from the tail tip for genotype confirmation and stored at -20°C. 
Confirmation of the presence of the implant was obtained by first palpating the skin behind 
the head to determine the location and then making a small incision in the skin and carefully 
removing the implant, intact. 
First, a sagittal incision was made through both the skin and bone of the skull to expose the 
brain, the body of the mouse was then inverted to allow gravity to gently remove the brain 
from the skull cavity. Cuts were made through the optic nerves and the brainstem to allow 
the brain to be released. The brain was then weighed on a fine analytical balance (Mettler 
AE163) before being snap frozen on dry ice and stored at -80°C. The pituitary gland was 
removed from the sella turcica of the sphenoid bone using extra-fine forceps (Dumont #55 
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forceps, World Precision Instruments Inc., Florida, USA), taking care not to close the forceps 
on the delicate tissue. Pituitaries were weighed immediately to avoid drying out.  
A midline incision was made along the full length of the abdomen, first cutting through just 
the skin of the abdomen and upper hind legs. Once the skin was reflected outwards the pair 
of inguinal fat pads were removed and weighed. A midline incision was then made through 
the peritoneal wall to expose the abdominal organs. The pair of parametrial fat pads along 
with the uterus (cut above the cervix) and ovaries were removed in one piece, dissected ex 
vivo under a dissecting stereo microscope (Olympus SZ40), and weighed separately. The 
oviduct was removed from between each ovary and the uterus and not included in the weight 
of either. The pair of retroperitoneal fat pads were carefully dissected away from the kidneys 
and adrenal glands and weighed. Care was taken where the fat was connected to the liver in 
order to avoid tearing the liver tissue.  
To collect mesenteric fat, the entire fat pad was removed along with the pancreas, stomach, 
and small and large intestines. Under the microscope, the mesenteric fat was stripped from 
the length of the gastrointestinal tract and separated from the pancreas before being 
weighed. The liver was carefully dissected from the surrounding organs using curved, blunt-
ended Iris forceps with serrated ends (no teeth, World Precision Instruments Inc.) to protect 
the delicate tissue. The liver was weighed as whole before being further dissected. The right 
lateral lobe was fixed in 10% neutral-buffered formalin (Fronine, Thermo Fisher Scientific, 
Scoresby, VIC, Australia, JJ018) for a minimum of 18 hours at RT before being soaked in a 30% 
sucrose solution (Appendix Two) for 48 hours. 
Cuts were then made through each side of the ribcage, parallel to the sternum, until the 
sternum could be reflected towards the head. The heart was then dissected from the lungs in 
vivo before having the major vessels trimmed as close to the heart as possible under the 
microscope. The heart was then weighed. 
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All fat pads, ovaries and remaining liver were fixed in 4% paraformaldehyde (PFA) (Appendix 
Two) at 4°C for a minimum of 18 hours before processing.  
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2.6 Histology 
2.6.1 Processing of Paraformaldehyde-fixed Tissues (Excluding Ovaries) 
The following day, after fixation, tissues were transferred to 70% EtOH and stored at RT. 
Tissues were then processed into paraffin wax using the Shandon™ Excelsior™ ES Tissue 
Processor (Thermo Fisher Scientific). A detailed processing protocol can be found in Appendix 
Three.  
2.6.2 Sectioning of Paraffin-embedded Tissues 
Paraffin blocks were stored at RT until 48 hours prior to sectioning when they were place in 
the freezer at -20°C. This allows the paraffin block to cool entirely and provides much 
smoother cutting. A rotary microtome (MicroTEC Cut4060) was used to cut 5µm (liver) or 
8µm (adipose tissue) thick sections that were floated on a 38°C water bath before being 
mounted on glass slides (Menzel-Glaser Superfrost™ Plus, Thermo Fisher Scientific, Sydney, 
NSW, Australia, 4951PLUS). Slides were then dried overnight in a 37°C oven. 
2.6.3 Processing of Formalin-fixed Liver Tissue 
Following 48 hours in sucrose, 1cm x 1cm sections were excised from the base of the liver 
lobe and placed cut-side down into a mould and encased in Tissue-Tek ® Optimal Cutting 
Temperature (OCT) compound (ProSciTech, Kirwan, QLD, Australia, IA018). Moulds were then 
placed on top of a plastic rack floating in liquid nitrogen. Moulds were not placed directly into 
the liquid nitrogen to avoid cracking due to rapid freezing. The remainder of the lobe was 
wrapped in tinfoil and snap frozen in the liquid nitrogen. Frozen OCT blocks and remaining 
liver pieces were stored at -80°C. 
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2.6.4 Sectioning of OCT-embedded Livers 
Frozen OCT blocks were cryosectioned at 10µm thickness on a cryostat set to -25°C (Leica 
CM3050 S Research Cryostat). Sections were mounted on room temperature glass slides 
(Menzel-Glaser Superfrost™ Plus, Thermo Fisher Scientific, Sydney, NSW, Australia, 
4951PLUS) using a small, dry paintbrush. Slides were air-dried and stored at 4°C until staining. 
2.6.5 Processing of Ovaries into Methacrylate Resin 
As ovaries were to be serially sectioned entirely and without loss of any section, methacrylate 
resin was used as an alternative to paraffin wax. Resin allows for much thicker sections to be 
cut, to reduce the number of serial sections produced. One ovary per mouse was processed 
into methacrylate resin using the Tecknovit 7100 kit (Heraeus Kulzer, Wehrheim, Germany, 
64709003) according to the manufacturer’s instructions. A detailed protocol can be found in 
Appendix Three. 
2.6.6 Sectioning of Methacrylate Resin-embedded Ovaries 
Cured resin blocks were sectioned using the Polycut-S sliding microtome (Leica Reichert-Jung, 
Wetzlar, Germany) at 20µm. Sections were floated on RO water kept at RT and mounted 5 
per slide onto glass slides (Menzel-Glaser Superfrost™ Plus, Thermo Fisher Scientific, Sydney, 
NSW, Australia, 4951PLUS). Slides were dried on a warming plate at 37°C and stored at RT 
until stained.  
2.6.7 Haematoxylin and Eosin Staining 
Paraffin-embedded adipose tissue and liver were stained with haemotoxylin and eosin (H&E). 
Briefly, deparaffinisation was achieved using 100% xylene (Sigma-Aldrich, Missouri, USA, 
534056). Sections were then rehydrated through graded alcohols before being stained with 
Harris haematoxylin (Fronine, Thermo Fisher Scientific, Scoresby, VIC, Australia, FNNII001). 
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Excess stain was removed and cell nuclei definied using acid alcohol (Appendix Two) before 
sections were blued using Scott’s Blue Solution (Fronine, Thermo Fisher Scientific, Scoresby, 
VIC, Australia, FNNII021). Sections were then counter-stained with 0.5% Alcoholic Eosin Y 
(Appendix Two). Finally, sections were dehydrated through graded alcohols and left to dry 
overnight at RT. The following day slides were coverslipped using DPX Mountant for histology 
(Sigma-Aldrich, Missouri, USA, 06522) and 24mm x 50mm glass coverslips (Coverglass No.1, 
ProSciTech, Kirwan, OLD, Australia, G417). Detailed staining protocol can be found in 
Appendix Three. 
2.6.8 Oil Red O Staining 
Before staining, slides previously kept in 4°C were brought up to room temperature before 
being rinsed in tap water for 3 minutes. Sections were then stained in freshly prepared Oil 
Red O solution (Appendix Two) for 15 minutes. Sections were rinsed in tap water for 5 
minutes and counter-stained with Harris haematoxylin at a 1:20 dilution with RO water for 30 
seconds. Finally, slides were rinsed in RO water until the water ran clear. Excess water was 
removed from the slide using a paper towel, without touching the tissue sections. Once 
partially dry, the sections were mounted using an aqueous mountant (Clearmount, Life 
Technologies, Mulgrave, VIC, 008110), to preserve the lipid content of the tissue, and dried 
in a 60°C oven for 5 hours.  
2.6.9 Periodic Acid-Schiff Staining 
Slides of methacrylate resin sections were first placed in periodic acid (POCD Scientific, 
Artarmon, NSW, Australia, PER50%/250) for 30 minutes before rinsing in tap water for 10 
minutes. Slides were then stained in Schiff’s reagent (Fronine, Thermo Fisher Scientific, 
Scoresby, VIC, Australia, FNNII029), which had been allowed to come up to RT, for 45 minutes. 
After rinsing in tap water for 10 minutes slides were counter-stained with Mayer’s 
haematoxylin (Sigma-Aldrich, Missouri, USA, MHS1) for 2 hours at 37°C. Mayer’s 
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haematoxylin was always filtered immediately prior to use through filter paper. Following 
this, slides were rinsed in running tap water for 10 minutes before being blued in Scott’s Blue 
Solution. After a final tap water rinse of 3 minutes the slides were allowed to air dry overnight 
at RT. Slides were mounted using DPX Mountant. 
2.6.10 Liquid Chromatography Tandem-Mass Spectrometry (LC-MS/MS) 
LC-MS/MS analysis of serum hormones was kindly performed by Reena Desai of the 
Andrology Laboratory at the ANZAC Research Institute, as previously developed and 
described by Harwood and Handelsman (602) adapted for mouse serum (603), and further 
modified (Appendix Four). Serum levels of T, DHEA, DHT, its two principal metabolites 5α-
androstane-3α,17β-diol (3α-diol) and 5α-androstane-3β,17β-diol (3β-diol), and P4 were 
measured in 100μL extracts of mouse serum. The limits of quantitation (the lowest level that 
can be detected with a coefficient of variation of <20%) were 25pg/mL for T, 100pg/mL for 
DHEA, DHT, 3α-diol, and 3β-diol, and 50pg/mL for P4. 
2.6.11 Ovarian Follicle and Corpora Lutea Classification and Enumeration 
Serial sections of resin-embedded ovaries were analysed using an Olympus microscope with 
Stereo Investigator software (MicroBright Field) as previously described (568). For all analysis, 
repetitive counting of follicles was avoided by only counting follicles containing an oocyte 
with a visible nucleolus. To avoid bias, all ovaries were analysed without knowledge of 
genotype/treatment group. 
The follicle classification used in this study was based on that described by Myers et al (51). 
Follicle stages quantified in this study are described in Table 2.3.  
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Table 2.3 Follicle Classification 
 
 
Classification and description of the follicle developmental stage analysed in this study accompanied 
by a representative image. Also included are atretic cyst-like follicles and corpus lutea. Based on the 
descriptions provided by Myers et al (51).   
Classification Description Image
Small	
Preantral
Oocyte	surrounded	by	1.5-2	
layers	of	cuboidal	granulosa	
cells
Large	
Preantral
Oocyte surrounded	by	2-5	
layers	of	cuboidal	granulosa	
cells
Small Antral
Oocyte	surrounded	by	more	
than	5	layers of	granulosa	cells	
and/or	1-2	small	areas	of	
follicular	fluid
Large	Antral Follicles contained	an	oocyte	and	a	single,	large	antral	cavity
Preovulatory
An	expanded	large	antral	
follicle	with	the	oocyte	
surrounded	by	cumulus	cells	at	
the	end	of	a	stalk	of	mural	
granulosa	cells
Atretic	Cyst-
like	Follicle
A	large,	fluid-filled	cyst	with	an	
attenuated	granulosa	cell	layer,	
dispersed	theca	cell	layer, and	
an	oocyte	lacking	connection	
the	the	granulosa	cells
Corpus	
Luteum
Luteinized	follicle	indicative	of	
ovulation
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For all analyses, large antral follicles and preovulatory follicles were grouped together and 
called “large antral follicles.” Follicles were classified as unhealthy if they contained a 
degenerate oocyte and/or more than 10% of the granulosa cells were pyknotic in appearance, 
as previously described (21, 22). The proportion of unhealthy follicles per ovary was cal- 
culated as the percentage of all follicles at that developmental stage. For all large antral 
follicles, granulosa cell-layer thickness and theca cell-layer area were measured using ImageJ 
version 1.48 software (open-source, developed by the National Institutes of Health), as 
previously reported (21). 
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3.1 Abstract 
Polycystic ovary syndrome (PCOS) affects 5-10% of women of reproductive age, causing a 
range of reproductive, metabolic and endocrine defects including: anovulation, infertility, 
hyperandrogenism, obesity, hyperinsulinism and an increased risk of type 2 diabetes and 
cardiovascular disease. Hyperandrogenism is the most consistent feature of PCOS, but its 
etiology remains unknown, and ethical and logistic constraints limit definitive 
experimentation in humans to determine mechanisms involved. In this study, we provide the 
first comprehensive characterization of reproductive, endocrine and metabolic PCOS traits in 
four distinct murine models of hyperandrogenism, comprising prenatal dihydrotestosterone 
(DHT, potent non-aromatizable androgen) treatment during days 16-18 of gestation, or long-
term treatment (90 days from 21 days of age) with DHT, dehydroepiandrosterone (DHEA), or 
letrozole (aromatase inhibitor). Prenatal DHT treated mature mice exhibited irregular estrous 
cycles, oligo-ovulation, reduced preantral follicle health, hepatic steatosis and adipocyte 
hypertrophy, but lacked overall changes in body fat composition. Long-term DHT treatment 
induced polycystic ovaries displaying unhealthy antral follicles (degenerate oocyte and/or > 
10% pyknotic granulosa cells), as well as anovulation and acyclicity in mature (16 week old) 
females. Long-term DHT also increased body and fat pad weights, and induced adipocyte 
hypertrophy and hypercholesterolemia. Long-term letrozole treated mice exhibited absent or 
irregular cycles, oligo-ovulation, polycystic ovaries containing hemorrhagic cysts atypical of 
PCOS, and displayed no metabolic features of PCOS. Long-term DHEA treatment produced no 
PCOS features in mature mice. Our findings reveal that long-term DHT treatment replicated 
a breadth of ovarian, endocrine and metabolic features of human PCOS, and provides the 
best mouse model for experimental studies of PCOS pathogenesis. 
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3.2 Introduction 
Polycystic ovary syndrome (PCOS) affects 5–10% of women of reproductive age (143). It is a 
complex, heterogeneous disorder with reproductive, endocrine, metabolic and psychological 
features. Various clinical definitions are used to define PCOS, and in general women must 
have at least 2 of the following: ovulatory disturbance (or dysfunction), hyperandrogenism 
and polycystic ovaries (143,148). Apart from these hallmark features, PCOS is also 
characterised by reproductive hormone dysregulation involving luteinising hormone (LH) 
hypersecretion and hyperandrogenism leading to acne and hirsutism, reduced fertility, due 
to dysfunctional follicular maturation, ovulatory disturbance and miscarriage (149,156). Non-
reproductive metabolic abnormalities are also often present in women with PCOS, including 
obesity, metabolic syndrome, hyperinsulinemia, insulin resistance, dyslipidemia and an 
increased risk of cardiovascular disease and type 2 diabetes (143,149). Yet, despite its 
prevalence and health impact the etiology and pathogenesis of PCOS remains poorly 
understood.  
Unravelling the etiology and developing novel biomarkers as well as optimal or curative 
treatments for PCOS remains difficult due to the heterogeneity of the syndrome and lack of 
understanding of its origins and pathogenic mechanisms. Due to the ethical and logistic 
limitations on human experimentation, suitable animal models that mimic all or most PCOS 
traits are indispensable. Since the 1960’s a range of animal models, including rodents, sheep 
and non-human primates have been generated to study the pathogenesis of PCOS 
(156,470,604,605). Prenatal exposure of sheep and non-human primates to androgens have 
provided models that show striking similarities to women with PCOS (156,604). In utero 
exposure to testosterone (T) in female sheep (152,243,443,604) and rhesus monkeys 
(156,411,416) induces the key PCOS-like phenotypes of oligo-ovulation or anovulation, 
polycystic ovaries, enhanced follicle recruitment, LH hypersecretion and insulin resistance. 
However the primate, in particular, has a long developmental period to reproductive 
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competence and both models are expensive, difficult to house and are not amenable to 
genetic manipulations. Mouse models, on the other hand, are affordable, easy to handle and 
maintain, have short reproductive lifespan and generation times and genetic manipulations 
are feasible. Hence, mouse models provide a valuable and versatile tool to allow the specific 
evaluation of genetic and other mechanistic pathways that may be involved in the 
pathogenesis of PCOS.  
Numerous rodent PCOS models have been described, including treatment with androgens, 
estrogens, aromatase inhibitors, antiprogestins, changes in light exposure and genetic 
manipulations all being used to induce PCOS-like characteristics (reviewed in: (470)). 
Hyperandrogenism is the most consistent PCOS trait (156), and hence the majority of recent 
studies have focused on utilizing androgens to induced PCOS in rodent models 
(245,463,467,469,513). Rodents have been treated prenatally and postnatally with the 
androgens T, testosterone propionate (TP) and DHT, and postnatally with DHEA and letrozole, 
an aromatase inhibitor which blocks aromatization, the conversion of androgens to 
estrogens, and therefore increases circulating and ovarian androgen levels. While postnatal 
treatment with T and TP induced typical PCOS features such as of acyclicity, anovulation, 
polycystic ovaries, hyperandrogenism and insulin resistance (462,466), the fact that T can be 
aromatized to estradiol (E2) makes it difficult to define androgen mediated mechanisms, as 
steroid effects may be induced via the androgen receptor (AR) and/or the estrogen receptor 
(ER). Previous studies have shown that rodents prenatally exposed to DHT exhibit irregular 
reproductive cycles, LH hypersecretion (261,463), and impaired glucose tolerance but normal 
insulin sensitivity and body mass (467). However, polycystic ovaries are not present (463), 
and a comprehensive analysis of metabolic features is lacking. On the other hand, long-term 
treatment of rats and mice with DHT from 3 weeks of age induces acyclicity, polycystic ovaries 
and key metabolic features of obesity and insulin resistance (245,469). Results from two 
studies describing the PCOS features using a long-term DHT mouse model point towards this 
being an attractive model to assess the etiology of PCOS, however detailed analysis of steroid 
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profiles, cycle matched gonadotropin levels, cholesterol and triglyceride levels and other 
metabolic features are lacking. DHEA treatment of mice (475,476) and rats (473,606) from 3 
weeks of age for 20 days parallels PCOS reproductive features of acyclicity and anovulation, 
but limited data is available on whether DHEA treatment induces the metabolic disturbances 
associated with PCOS. Lastly, no letrozole induced mouse PCOS model has been described 
although rat models where letrozole has been given for at least 21 consecutive days have 
been reported (245,484,607). Hence, there is no gold standard rodent PCOS model and a 
comprehensive comparative evaluation of all reproductive, endocrine and metabolic 
characteristics taking into account potential strain differences (608) is needed. Therefore, in 
this study we set out to comprehensively assess reproductive, endocrine and metabolic 
features associated with PCOS in four distinct hyperandrogenised murine models within a 
single mouse strain. 
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3.3 Material and Methods 
3.3.1 Mice 
Mice were maintained under standard housing conditions (ad libitum access to food and 
water in a temperature and humidity controlled, 12-h light cycle environment) at the ANZAC 
Research Institute. All mice had a wildtype androgen receptor (AR) genotype, and were taken 
from a colony used to generated AR knockout mice (568,595). This colony has been 
backcrossed onto a C57Bl/6J background for at least 10 generations prior to use in 
experiments. In all experiments littermate controls were used. All procedures were 
performed under ketamine/xylazine anaesthesia. All procedures were approved by the 
Sydney Local Health District Animal Welfare Committee within NHMRC guidelines for animal 
experimentation. 
3.3.2 Generation of PCOS Mouse Models 
3.3.2.1 Prenatal Treatment 
Females were paired with fertile males (a total of 6 breeding pairs) and checked daily for 
copulatory plugs. The date of plug was treated as day 1 of gestation. On days 16-18 of 
gestation, pregnant females were injected daily sc. with either 100µl sesame oil (controls) or 
100µl sesame oil containing 250µg DHT (Merck, Darmstadt, Germany), as previously 
described (261). Female offspring (control: n = 8 and DHT: n =12) were studied as adults at 16 
weeks of age.  
3.3.2.2 Postnatal Treatment 
At 21 days of age female mice were implanted sc. with either a 1cm silastic brand implant (id, 
1.47 mm; od, 1.95mm, Dow Corning Corp., Midland, MI, catalog no. 508-006) containing 
about 10mg DHT, or one 90-d continuous-release pellet containing 7.5mg DHEA (Innovative 
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Research of America, Sarasota, FL), or two 90-d continuous-release pellets containing 4mg of 
letrozole (total 8mg letrozole) (Letrozole provided by Novartis Pharma AG, Basel, Switzerland 
and made into 90-d continuous-release pellet by Innovative Research of America, Sarasota, 
FL). The experimental strategies chosen for DHT, DHEA and letrozole were based on previous 
studies. DHT has previously been used to induce PCOS in rats (7.5mg DHT 90-d continuous-
release pellet (245)) and mice (2.5mg DHT 90-d continuous-release pellet (469)). In the latter 
study DHT treatment of mice was reported to result in more than a 6-fold increase in serum 
DHT levels compared with controls (469). Using DHT filled implants, as previously carried out 
in our lab (609), we have achieved a similar 8-fold increase in serum DHT levels, in DHT treated 
mice compared to controls (Table 3.1). DHEA levels are consistently elevated in women with 
PCOS (610), and short term postnatal treatment of mice with 6mg/100g BW DHEA for 20 
consecutive days induces features associated with PCOS (475,476). To establish if a constant 
long term elevation in DHEA, as present in women with PCOS, would also induce PCOS 
characteristics we implanted mice with 90-d continuous-release pellets containing 7.5mg 
DHEA. Compared to controls, this resulted in more than a 3-fold increase in serum DHEA levels 
in DHEA treated mice (Table 3.1). Previously, a rat model of PCOS used a daily letrozole dose 
of 400µg (36mg pellet) (245). Using the body weight proportionality, we aimed to use a daily 
dose of ~40µg per mouse. This was administered in a 4mg implant for 90 days. Initial 
treatment of female mice with one letrozole pellet did not lead to the development of any 
features associated with PCOS, therefore, two pellets of letrozole were used in the present 
study. Controls received blank 1cm silastic implants. Mice were collected after 13 weeks of 
drug administration (control: n = 8; DHT: n = 9; DHEA: n = 7 and letrozole: n = 5), when the 
mice were 16 weeks of age. 
3.3.3 Assessment of Estrous Cycle 
Estrous cycle stage was determined daily by light microscope analysis of vaginal epithelial cell 
smears (575). The stage of the estrous cycle was determined based on the presence or 
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absence of leukocytes, cornified epithelial and nucleated epithelial cells. Proestrus was 
characterised by the presence of mostly nucleated and some cornified epithelial cells, at the 
estrus stage mostly cornified epithelial cells were present, at metestrus both cornified 
epithelial cells and leukocytes were present, and at diestrus primarily leukocytes were visible. 
3.3.4 Specimen Collection 
Dissected ovaries, fat pads, heart and liver were weighed and fixed in 4% paraformaldehyde 
at 4°C overnight, and stored in 70% ethanol before histological processing. 
3.3.5 Ovary Collection and Follicle Classification, Enumeration and 
Health 
Ovaries were fixed and then processed through graded alcohols into glycol methacrylate resin 
(Technovit 7100; Heraeus Kulzer, Chatswood, Australia). Ovaries were serially sectioned at 
20µm, stained with periodic acid-Schiff, and counterstained with haematoxylin. Total 
numbers of small preantral follicles (oocyte with 1.5-2 layers of cuboidal granulosa cells), large 
preantral follicles (oocyte surrounded by more than 2 and up to 5 layers of granulosa cells), 
small antral (oocyte surrounded with more than 5 layers of granulosa cells, and/or one or two 
small areas of follicular fluid), large antral follicles (contained a single large antral cavity), 
preovulatory follicles (possessed a single large antrum and an oocyte surrounded by cumulus 
cells at the end of a stalk of mural granulosa cells) and atretic cyst-like follicles (large fluid-
filled cyst with an attenuated granulosa cell layer, dispersed theca cell layer and an oocyte 
lacking connection with the granulosa cells (Figure 3.3 D (iii) and 3.3 H (v)), corpora lutea and 
zona pellucida remnants were counted on all serial sections throughout each ovary using an 
Olympus microscope with Stereo Investigator software (MicroBrightField, Williston, VT, USA), 
as previously described (51,568,575). For all analyses, large antral follicles and preovulatory 
follicles were grouped together and called large antral follicles. For all histological analysis, 
repetitive counting of follicles was avoided by only counting/measuring follicles containing an 
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oocyte with a visible nucleolus. To avoid bias, all ovaries were analysed without knowledge 
of treatment group. Follicles were classified as unhealthy if they contained a degenerate 
oocyte and/or > 10% of the granulosa cells were pyknotic in appearance, as previously 
described (568). The proportion of unhealthy follicles/ovary was estimated as the percentage 
of all follicles at that developmental stage. For all large antral follicles, granulosa cell layer 
thickness and theca layer area were measured using ImageJ v1.44 software (open source, 
developed by NIH, USA). 
3.3.6 Hormone Assays 
Blood was collected from females at the diestrus stage (unless females were acyclic) by 
cardiac exsanguination under ketamine/xylazine anesthesia, and collected serum was stored 
at -20°C. Mouse serum LH and FSH were determined using a species-specific 
immunofluorometric assay, as previously described (575,611,612). The mLH detection limit 
was 0.04ng/ml, the intra-assay coefficient of variation (CV) = 5.2%, and the inter-assay CV = 
8.6%. The mFSH detection limit was 0.1ng/mL, the intra-assay CV = 3.1%, and the inter-assay 
CV = 7.2%. All immunoassays were performed in a single batch. 
Serum levels of testosterone (T), androstenedione (A4), dehydroepiandrosterone (DHEA), 
dihydrotestosterone (DHT) and its two principal metabolites 5α-androstane-3α,17β-diol 
(3αdiol) and 5α-androstane-3β,17β-diol (3βdiol), estradiol (E2) and progesterone (P4) were 
measured in extracts of 100µl mouse serum by liquid chromatography tandem mass 
spectrometry (LC-MS/MS) (602) as adapted for mouse serum (603) and further modified 
(Appendix Four). The limits of quantitation (defined as lowest level that can be detected with 
a CV of <20%) were T (25pg/mL), A4 (25pg/mL), DHEA (100pg/mL), DHT (100pg/mL), 3αdiol 
(100pg/mL), 3βdiol (100pg/mL), E2 (2.5pg/mL) and P4 (50pg/mL). To characterize DHT 
metabolism, the sum of DHT’s two major primary metabolites 3αdiol and 3βdiol was 
calculated.  
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3.3.7 Body Mass Analysis – PIXImus 
Body composition measurements were performed on a Lunar PIXImus Densitometer for mice 
(GE Medical Systems), as previously described (613). 
3.3.8 Adipose Tissue Histology 
Parametrial and retroperitoneal fat pads were fixed in 4% paraformaldehyde, embedded in 
paraffin, sectioned at 8µm, stained with H&E and evaluated by histomorphometry at 40x 
magnification, using an Olympus microscope with Stereo Investigator software 
(MicroBrightField, Williston, VT, USA). 
3.3.9 Hepatic Steatosis Analysis 
Liver sections were embedded in paraffin, sectioned at 5µm and stained with H&E before 
histomorphometric analysis. The presence of steatosis was microscopically quantified blindly 
by two independent investigators by classification into 4 different categories (0 = non-fatty 
liver, 1 = possible early steatosis, 2 = moderate steatosis, 3= severe steatosis, as outlined in a 
previous study (614)). There were no disagreements in the classifications between the two 
investigators. 
3.3.10 Triglyceride and Cholesterol Assays 
Serum levels of total cholesterol and triglycerides were assayed enzymatically with 
commercial kits obtained from Wako, Osaka, Japan (Cholesterol E kit: Cat. No. 439-17501 and 
Triglyceride E kit: Cat. No. 342-40201). 
3.3.11 Insulin Tolerance Tests 
Insulin tolerance tests (ITTs) were carried out, as previously described (613). Mice were fasted 
for 6 hours prior to baseline blood glucose reading, followed by an intraperitoneal injection 
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of insulin at 0.75IU/kg body weight (Eli Lilly). Blood glucose was then measured at 15, 30, 60, 
90 and 120 minutes after insulin injection. Blood was obtained from a tail prick, and blood 
glucose was measured on glucose strips and an Accu-Chek glucometer (Roche). 
Measurements were taken at the start and end of each experiment. Blood glucose data is 
presented as percentage of baseline blood glucose.  
3.3.12 Statistical Analysis 
Statistical analysis was performed using NCSS 2007 software (NCSS Statistical Software, 
Kaysville, UT). Data that was not normally distributed was transformed prior to analysis using 
a log transformation. Statistical differences were tested by T-Test or ANOVA with post hoc 
test using Fisher’s LSD Multiple-Comparison Test. Proportions were analysed by Fisher’s exact 
test or Kruskal-Wallis exact test. All parametric tests were confirmed by the analogous 
nonparametric tests. P values smaller than 0.05 were considered statistically significant. 
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3.4 Results 
3.4.1 Cyclicity 
3.4.1.1 Prenatal Treatments 
All females treated prenatally with oil (control) cycled (8 of 8), whereas 50% of females 
treated prenatally with DHT (6 of 12) failed to cycle (P < 0.05) (Figure 3.1 A & C) and 
completed significantly fewer estrous cycles in 2 weeks (0.5 ± 0.2 vs 2.5 ± 0.2, P < 0.01) (Figure 
3.1 B).  
3.4.1.2 Postnatal Treatments 
All DHT treated (9/9, 100%) and the majority of letrozole treated (3/5, 60%) females failed to 
cycle (P < 0.05), whereas all DHEA treated (7/7, 100%) and control (8/8, 100%) mice cycled 
regularly (Figure 3.1 D & F). Similarly, the number of estrous cycles completed in 2 weeks was 
zero for DHT and reduced for letrozole females (0.8 ± 0.6) compared to DHEA (2.4 ± 0.3) and 
control (2.1 ± 0.3) females (Figure 3.1 E, P < 0.01). The letrozole treated females that did cycle 
exhibited irregular cycles (Figure 3.1 F). Observation of vaginal smears identified leukocytes 
as the predominant cell type observed in the vaginal smears from DHT and letrozole treated 
females, indicating they were static in pseudo-diestrus. 
3.4.2 Ovary Weight and Ovarian Follicle Populations 
3.4.2.1 Prenatal Treatments 
Ovary weight (4.6 ± 0.1 vs 5.8 ± 0.4, P < 0.01) and corpora lutea numbers (5.0 ± 0.4 vs 9.75 ± 
1.79, P < 0.05) were both significantly reduced in prenatal DHT treated females compared 
with controls (Figure 3.2 A & B). Prenatal DHT ovaries featured an increased number of 
follicles with an atretic cyst-like appearance (5.5 ± 1.2 vs 0.0 ± 0.0, P < 0.01), but otherwise 
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did not exhibit the classic polycystic appearance (Figure 3.2 C & D). Growing follicle 
populations did not differ between prenatal DHT and oil (control) groups (Figure 3.2 D).  
3.4.2.2 Postnatal Treatments 
Ovary weight did not differ between DHT (4.1 ± 0.2), DHEA (4.5 ± 0.4) or letrozole (6.6 ± 1.0) 
treated and control females (5.0 ± 0.6) (Figure 3.2 E). Corpora lutea numbers were reduced 
in DHT (0 ± 0) and letrozole (2.6 ± 1.6) treated females compared with DHEA (9.0 ± 1.8) and 
control females (10.8 ± 2.1) (P < 0.01) (Figure 3.2 F). DHT treated females exhibited multi-
cystic ovaries, whereas letrozole treatment ovaries displayed hemorrhagic cysts, atypical of 
PCOS (Figure 3.2 G). Compared to controls, the number of follicles with an atretic cyst-like 
appearance was significantly increased in ovaries from DHT mice (12.4 ± 3.1 vs 4.8 ± 2.2, P < 
0.05). There was no significant difference in growing follicle populations in DHT, DHEA and 
letrozole treated mice compared to control ovaries (Figure 3.2 H). 
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Figure 3.1 Estrous Cycling 
 
A and D, Percentage of females to complete one cycle in 2-week period, A (P < 0.05) and D (P < 0.01). B and E, Average number of cycles in 2-week period, A 
(P < 0.01) and D (P < 0.01). Data are the mean ± SEM (n = 5-12/treatment group). C and F, Estrous cycle pattern in representative females. P, proestrus; E, 
estrus; M, metestrus; D, diestrus.
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3.4.3 Ovarian Follicle Health and Morphology 
3.4.3.1 Prenatal Treatments 
Ovaries from prenatally DHT treated females exhibited a significant increase in the 
percentage of morphologically unhealthy small and large preantral follicles present, 
compared with control ovaries (small preantral, 20.3 ± 3.9% vs 1.6 ± 1.0%; and large preantral: 
20.2 ± 3.2% vs 6.0 ± 1.3%) (P < 0.01) (Figure 3.3 A). The number of zona pellucida remnants 
within ovaries did not differ between treatment groups (data not shown). In large antral 
follicles, there was no significant difference in granulosa cell layer thickness or theca cell layer 
area between prenatal DHT and control females (Figure 3.3 B, 3 C and 3 D (i) and (ii)).  
3.4.3.2 Postnatal Treatments 
DHT (60.4 ± 11.6%) and letrozole (45.9 ± 5.5%) treated mice exhibited a significant increase 
in the percentage of morphologically unhealthy large antral follicles present within their 
ovaries, compared with DHEA (23.2 ± 6.7%) or control (20.6 ± 6.2%) females (P < 0.01) (Figure 
3.3 E). The number of zona pellucida remnants within ovaries did not differ between any 
treatment group (data not shown). Atretic follicles in control mice exhibited a compact theca 
cell layer, however the theca layer of atretic follicles in DHT and letrozole mice appeared to 
be dispersing and there was not a discrete separation between the theca cell layer and the 
surrounding stroma. Large antral follicles within both DHT (59.4 ± 3.1µm) and letrozole (45.9 
± 5.5µm) treated ovaries exhibited a significant decrease in the thickness of the granulosa cell 
layer compared to DHEA (77.8 ± 2.1µm) or controls (72.8 ± 2.2µm) (P < 0.01) (Figure 3.3 F and 
3 H (i-iv)). The theca cell layer area of large antral follicles was significantly increased in DHT 
treated ovaries (23.2 ± 0.5% theca area/follicle) but decreased in letrozole treated ovaries 
(17.4 ± 0.5% theca area/follicle), compared to DHEA (19.9 ± 0.7% theca area/follicle) or 
control ovaries (19.1 ± 0.3% theca area/follicle) (P < 0.01) (Figure 3.3 G and 3 F (i-iv)). 
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Figure 3.2 Ovary weight, Ovarian Phenotype and Ovarian Follicle and Corpora Lutea Numbers 
 
A and E, Ovary weights, A (P < 0.01). Data are the mean ± SEM. n = 5-12/treatment group. B and F, Average number of corpora lutea/ovary. B (P < 0.05) and 
F (P < 0.01). Data are the mean ± SEM. n ≥ 4/treatment group. C and G, Histological sections of representative ovaries from each treatment group. White 
asterisk = corpora lutea, black arrow = arrested large antral follicle, white triangle = hemorrhagic cyst. D and H, Average number of growing follicles/ovary, D 
(P < 0.01) and H (P < 0.05). Data are the mean ± SEM. n ≥ 4/treatment group 
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Figure 3.3 Ovary Follicle Health and Morphology 
 
A and E, Percentage of unhealthy follicles. A (P < 0.01) and E (P < 0.01). Data are the mean ± SEM (n ≥ 4/treatment group). B and F, Average thickness of 
granulosa cell layer. F (P < 0.01). Data are the mean ± SEM (n ≥ 15-36 follicles/treatment group). C and G, Average percentage theca cell area per follicle. G (P 
< 0.01). Data are the mean ± SEM (n ≥ 15-36 follicles/treatment group). D (i and ii) and H (i-iv), Histological sections of representative follicles from each 
treatment group. Double-arrowed white line = granulosa cell layer thickness, white line = theca cell layer thickness. D (iii) and H (v), Histological sections of 
representative cysts from each treatment group showing attenuated granulosa cell layer, dispersed theca cell layer (white arrow) and an oocyte lacking 
connection with the granulosa cells.  
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3.4.4 Serum FSH and LH Concentrations 
3.4.4.1 Prenatal Treatments 
Serum levels of FSH and LH were not significantly different between control and DHT 
prenatally treated groups at diestrus (Table 3.1).  
3.4.4.2 Postnatal Treatments 
Serum levels of FSH and LH were not significantly different between any of the treatment 
groups at diestrus (Table 3.1). 
3.4.5 Serum Steroid Levels  
3.4.5.1 Prenatal Treatments 
At diestrus, serum P4 levels were decreased by 85% in DHT females compared with controls 
(P ≤ 0.05) (Table 3.1). Serum levels of T, A4, DHT, DHEA, 3αdiol, 3βdiol and E2 did not differ 
between females treated prenatally with DHT or controls (Table 3.1).  
3.4.5.2 Postnatal Treatments 
At diestrus, only letrozole treated mice exhibited a significant increase in T levels compared 
with control females (0.29 ± 0.14ng/ml vs 0.02 ± 0.01ng/ml) (P < 0.01) (Table 3.1). Serum A4 
levels were decreased by 33% in DHT females, increased by 100% in DHEA females, but not 
altered in letrozole females compared with control females (P < 0.01) (Table 3.1). As 
expected, there was more than 8-fold increased serum DHT levels in DHT females compared 
with control females (P < 0.01), but DHT levels were not altered in any other long-term 
treatment group (Table 3.1). There was more than 3-fold increase in serum DHEA levels in 
DHEA females, but no change in DHT and letrozole mice, compared with control females (P < 
0.01) (Table 3.1). Serum levels of 3αdiol and 3βdiol (two primary DHT metabolites) were only 
significantly increased in DHT females compared with control females (7.03 ± 0.25ng/ml vs 
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0.3 ± 0.03ng/ml) (P < 0.01) (Table 3.1). There was no significant difference in E2 levels 
between any of the treatment groups. DHT females were the only long-term group to exhibit 
a significant decrease in serum P4 compared with control females (0.36 ± 0.07ng/ml vs 4.55 
± 2.18ng/ml) (P < 0.01) (Table 3.1). 
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Table 3.1 Serum Hormone and Steroid Levels in Androgenized Mouse Models 
 
Serum levels of FSH, LH, T (long-term Letrozole treatment, P < 0.01), A4 (long-term DHT and DHEA 
treatment, P < 0.01), DHT (long-term DHT treatment, P < 0.01), 3α- and 3β-diol (long-term DHT 
treatment P < 0.01), E2 and P4 (prenatal DHT treatment, P ≤ 0.01, and long-term DHT treatment, P < 
0.01). Data are the mean ± SEM (n = 5-9/treatment group). * Denotes a statistically significant 
difference. 
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Figure 3.4 Body Weight and Composition 
 
A and B, Body weight and composition calculated by dual-energy x-ray absorptiometry (DEXA), and representative DEXA images from each treatment group 
(n = 5-12/treatment group). Body mass (BM), Lean body mass (LBM), bone mineral density (BMD).
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3.4.6 Body Weight and Body Composition 
3.4.6.1 Prenatal Treatments 
DEXA analysis of body weight, fat, lean body mass (LBM) and bone mineral density (BMD) did 
not differ between prenatal DHT or control females (Figure 3.4 A). 
3.4.6.2 Postnatal Treatments 
Compared with control females, DHT females exhibited a 9% increase in body weight, (P < 
0.01), a 16% increase in body fat (P < 0.01), a 7% increase in LBM (P < 0.01), but a 6% decrease 
in BMD (P < 0.01) (Figure 3.4 B). DHEA females exhibited a 9% decrease in body weight (P < 
0.01), a 7% decrease in LBM (P < 0.01), but a 4% increase in BMD (P < 0.01) (Figure 3.4 B). 
There was no difference in body weight, body fat, LBM or BMD between letrozole and control 
groups (Figure 3.4 B). 
3.4.7 Adipose Tissue Weight and Histology 
3.4.7.1 Prenatal Treatments 
Fat depot weights did not differ between control and prenatal DHT females (Figure 3.5 A). 
However, there was a 57% increase in adipocyte size in parametrial (P < 0.05) but not 
retroperitoneal fat depots (Figure 3.5 B).  
3.4.7.2 Postnatal Treatments 
DHT treatment resulted in a 49% increase in inguinal and a 134% increase in retroperitoneal 
fat depot weights compared with controls (P < 0.01) (Figure 3.5 C). Adipocyte cell size was 
increased by 70% in retroperitoneal (P < 0.01), but not parametrial fat depots from DHT 
females (Figure 3.5 D). There was no significant difference in fat depot weights or adipocyte 
cell size between DHEA or letrozole and control females (Figure 3.5 C and D). 
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3.4.8 Serum Cholesterol and Triglyceride Concentrations 
3.4.8.1 Prenatal Treatments 
There was no significant difference in serum total cholesterol and triglyceride levels between 
prenatal control and DHT females (Figure 3.6 A and B). 
3.4.8.2 Postnatal Treatments 
Serum total cholesterol was increased by 47% in DHT treated females compared with controls 
(P < 0.05) (Figure 3.6 F). There was no significant difference in serum total cholesterol 
between control, DHEA and letrozole groups, or serum triglyceride levels between any of the 
treatment groups (Figure 3.6 F and G). 
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Figure 3.5 Fat Depot Weight and Adipocyte Size 
 
A and C, Fat depot weights. C (P < 0.01). Data are the mean ± SEM. B and D, Adipocyte size. B (P < 0.05) and D (P < 0.01). Data are the mean ± SEM (n = 4-
5/treatment group). Histological sections of representative fat pads from each treatment group. 
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3.4.9 Insulin Tolerance  
3.4.9.1 Prenatal Treatments 
At 16 weeks of age, fasting glucose levels (Control: 8.2 ± 0.5mmol/l; DHT: 7.8 ± 0.3mmol/l) or 
insulin sensitivity (as indicated by serial blood glucose in the insulin tolerance test) were not 
different between control and prenatal DHT mice (Figure 3.6 C and D). 
3.4.9.2 Postnatal Treatments 
At 16 weeks of age, fasting glucose levels were not different between any of the treatment 
groups (Control: 7.3 ± 0.2mmol/l; DHT: 8.1 ± 0.3mmol/l; DHEA: 7.8 ± 0.4mmol/l; letrozole: 6.8 
± 0.5mmol/l). There was no difference in insulin sensitivity prior to (3 weeks of age) and after 
(16 weeks of age) treatment with DHT, DHEA or letrozole compared to controls (Figure 3.6 H 
and I). 
3.4.10 Heart Tissue Weight  
3.4.10.1 Prenatal Treatments 
Prenatal DHT treatment resulted in a significant decrease in heart weight compared to control 
females prenatally treated with oil (Control: 5.9 ± 0.2mg/BW; DHT: 5.4 ± 0.1mg, P < 0.05).  
3.4.10.2 Postnatal Treatments 
There was no significant difference in heart weights between any of the treatment groups 
(Control: 5.9 ± 0.3mg/BW; DHT: 6.2 ± 0.2mg/BW; DHEA: 6.0 ± 0.2mg/BW; letrozole: 6.8 ± 
0.1mg). 
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3.4.11 Liver Tissue Weight and Histology 
3.4.11.1 Prenatal Treatments 
Prenatal DHT treatment did not alter liver weight compared to control females (Control: 51.5 
± 1.5mg/BW; DHT: 48.1 ± 1.4mg/BW). However, prenatal treatment with DHT resulted in a 
significant increase in the presence of fatty livers (hepatic steatosis) (P ≤ 0.01) (Figure 3.6 E).  
3.4.11.2 Postnatal Treatments 
There was no significant difference in liver weights between control females and females 
postnatally treated with DHT, DHEA or letrozole (Control: 44.5 ± 2.8mg/BW; DHT: 50.6 ± 
2.1mg/BW; DHEA: 47.6 ± 2.2mg/BW; Letrozole: 42.8 ± 3.0mg/BW). The extent of hepatic 
steatosis was different between treatment groups, with DHT and DHEA treatment producing 
more severe steatosis than control and letrozole mice (P < 0.01) (Figure 3.6 J).
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Figure 3.6 Serum Cholesterol and Triglyceride Levels, Insulin Tolerance Tests and Steatosis Analysis 
 
A and F, Serum cholesterol levels. F (P < 0.01). Data are the mean ± SEM (n = 5-6/treatment group). B and G, Serum triglyceride levels. Data are the mean ± 
SEM (n = 5-6/treatment group). C and H, Insulin tolerance test (ITT) at 3 weeks of age. D and I, ITT at 16 weeks of age. Data are the mean ± SEM. E and J, 
Degree of steatosis. E (P ≤ 0.01) and J (P < 0.01) (n = 5-9/treatment group). Histological sections of representative livers from each treatment group.
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3.5 Discussion 
This study provides the first comprehensive characterization and evaluation of reproductive, 
endocrine and metabolic PCOS traits in four distinct hyperandrogenized female murine 
models of PCOS. We have established the first letrozole and long-term DHEA mouse models, 
and compared them with prenatal DHT and long-term DHT androgenized murine models. Our 
findings show that only the in vivo elevation of the potent bioactive androgen DHT, but not 
the pro-androgen DHEA, induces features that in mice replicate PCOS traits, including 
irregular estrous cycling with oligo-anovulation, polycystic ovaries, obesity, dyslipidemia and 
hepatic steatosis. Genetic and environmental factors contribute to the development of PCOS 
(240). Importantly, in this study differences in strain-specific responses, such as those 
previously observed for metabolic response to excess androgen exposure during puberty 
(615), were controlled for by all experimental mice arising from a single mouse strain. Our 
findings have identified the superiority of long-term DHT treatment in mice, as overall the 
best approach to simulate the breadth of reproductive, endocrine and metabolic features of 
human PCOS (Table 3.2 summaries features of the androgenized mouse models relative to 
PCOS).  
In our study prenatal DHT, and long-term DHT, or letrozole treatment induced irregular cycles 
or acyclicity, but long-term DHEA treatment had no effect on estrous cyclicity. In 
concordance, vaginal smears revealed that long-term DHT treatment left females fixed in 
pseudodiestrus, whereas prenatal DHT or letrozole treatment produced females that spent 
little time in proestrus, the prelude to ovulation. Our findings support previous observations 
of disrupted estrous cycles in rodents treated prenatally (261,463) or postnatally (245,469) 
with DHT, and rats treated with letrozole (245,484) but differ from findings in mice treated 
with DHEA (473,476). Acyclicity in long-term DHT females, indicative of anovulation, was 
confirmed by lack of corpora lutea and reduced serum P4 levels. Acyclicity without elevated 
gonadotropin levels in all long-term DHT females, implies aberrant neuroendocrine regulation 
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of ovarian function, although this cannot exclude additional and contributory defects at the 
ovary level. Reduced corpora lutea numbers in some female mice treated prenatally with 
DHT, and with letrozole, is consistent with ovulatory dysfunction and the wide heterogeneity 
of ovarian cycling patterns in PCOS (148). By contrast, long-term DHEA treated females 
maintained regular estrus cycling, did not differ from controls in circulating T or P4 
concentrations, and displayed continued regular ovulation, evident by fresh corpora lutea. 
These findings differ from previous studies of rodents treated with DHEA for 20 days where 
elevated circulating T concentrations and irregular estrous cycles or acyclicity were observed 
(473,475,476). In concert, these findings suggest that while short term DHEA treatment may 
disrupt central neuroendocrine regulatory mechanisms, this disruption is transient and not 
sustained over 3 months in this longer term study. 
We found that prenatal DHT treatment induced some ovarian morphological features of 
PCOS, including fewer corpora lutea and an increased prevalence of atretic cyst-like follicles, 
although not the classic polycystic appearance. Reduced ovarian weights of prenatal DHT 
treated mice may reflect fewer corpora lutea and/or absence of PCOS-like morphological 
features such as numerous large fluid filled cysts or theca cell hyperplasia that enlarge the 
ovary. We used the pure androgen DHT in our prenatal androgenised group, but this does not 
exclude that estrogen receptor mechanisms may also be involved. In utero excess of 
androgens or estrogens results in anovulation and hyperandrogenism (616), however, our 
animal models and others(rodent, sheep and primate) confirm that prenatal androgen excess 
more closely mimics the ovarian phenotype of human PCOS (470,616). Long-term DHT 
treatment induced a wide spectrum of ovarian PCOS traits, including a classic multi-cystic 
ovary exhibiting large arrested and atretic cyst-like follicles, more unhealthy large antral 
follicles displaying thick theca cell layers and thin degenerate granulosa cell layers, in 
agreement with previous findings in related DHT-induced rodent models of PCOS (245,469). 
Surprisingly, androgenized mouse models in the present study did not exhibit the PCOS 
characteristic of increased ovarian preantral and antral follicles numbers (617). This was 
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unexpected as androgens stimulate follicle development (422,536,537) and previous 
prenatally androgen-induced rodent (463), sheep (438,444) and primate (618) models have 
reported increased preantral and antral follicle populations. These findings may imply that 
elevated androgen exposure may be required during specific time windows for aberrant 
follicle development to occur, consistent with previous findings in a rat model (513). In our 
work, letrozole treatment resulted in the expected increase in circulating T concentrations, 
reflecting the block in aromatase activity and accumulation of endogenous ovarian androgen 
secretion. Furthermore, ovaries from letrozole treated females exhibited some reproductive 
features of PCOS, including a greater frequency of atretic cystic-like follicles, more unhealthy 
large antral follicles, and the majority, but not all ovaries, resembled human polycystic ovaries 
with the appearance of large cysts with an attenuated granulosa cell layer. However, these 
were hemorrhagic cystic follicles, which is atypical of PCOS ovaries and more in keeping with 
several genetic mouse lines with defective ovarian function such as the aromatase knockout 
(619), ER-a knockout (620) and the transgenic FSH overexpressing (621) mice. These latter 
models have in common elevated gonadotropins, especially LH, with corresponding high 
circulating T concentrations. By contrast, in this present study, serum LH at diestrus remained 
normal in the letrozole treated mice, although we cannot exclude increased pulsatile LH 
secretion at other stages of the estrus cycle stimulating the cystic growth of follicles. In 
concert, these findings suggest that elevated LH per se, may not be a key factor causing 
classical PCOS development. Unexpectedly, sustained DHEA delivery had no long-term effects 
on ovarian morphology or follicle function in our 3-month study, contrasting with the 
reported induction of polycystic ovaries and anovulation due to short term (20 day) DHEA 
administration (473,475,477). Hence, we proposed that the reported effects of short term 
DHEA treatment may be transient rather than permanent features, and may reflect that the 
elevated DHEA levels present in PCOS patients (622) are unlikely to cause/maintain the 
ovarian features of human PCOS.  
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Table 3.2 Summary of Dysfunctional Reproductive, Endocrine and Metabolic 
Traits in PCOS Women and the Androgenized Mouse Models Examined in the 
Current Study 
 
ü, present; û, not present. 
*, hemorrhagic cysts which are not a true PCOS phenotype.  
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Long-term exposure to DHT induced several features that are consistent with metabolic 
features of PCOS. Postnatally DHT-treated females exhibited increased body weight and 
adiposity, and adipocyte hypertrophy was present in retroperitoneal fat pads, which is known 
to alter levels of adipokines (623) and has been implicated in the pathophysiology of PCOS 
(624,625). In addition, DHT treated females exhibited hypercholesterolemia, which is present 
in women with PCOS, and is a risk factor for cardiovascular disease (626). Prenatal DHT 
treatment did not alter body weight, body fat and lean body mass, which is in agreement with 
earlier findings showing that prenatally androgenized rodents do not exhibit altered body 
composition (467,513). Adipocyte hypertrophy was present in parametrial fat pads, but total 
fat depot weights were not changed. This observation supports previous work showing that 
androgen exposure in a mouse model alters adipocyte differentiation and/or function (467). 
Whether or not changes in adipocyte function play a role in the etiology of PCOS remains to 
be determined. Despite the presence of hypertrophic adipocytes, which are inherently insulin 
resistant (627), in prenatal and long-term DHT females, insulin resistance was not detected in 
any of the four androgenised mouse models. This may reflect the fact that muscle and/or liver 
but not adipose tissue are the main determinants of overall body insulin sensitivity. However, 
the possibility that the mice in our experiments were still too young to fully display age-
related insulin resistance, cannot be ruled out. While most previous publications using PCOS-
induced rodent models did not address insulin sensitivity, in three studies postnatal DHT 
(245), DHEA (476) and letrozole (607) treatment was shown to produce insulin resistance. In 
another recent study, prenatally androgenized females exhibited impaired glucose tolerance 
without any increase in body weight or fat, or change in insulin sensitivity. In these mice, 
glucose intolerance was associated with defective pancreatic islet function, leading to 
impaired glucose sensing and regulation of insulin secretion (467). Hence, future studies are 
required to elucidate if and how androgen action regulates pancreatic islet and insulin 
function. Body composition, insulin resistance, and plasma triglyceride and cholesterol levels 
were not influenced by long-term letrozole treatment, contrasting with reported rat PCOS 
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models where letrozole treatment increased body weight, body fat, lean body mass, fat depot 
weights and triglyceride and cholesterol levels (245,607,628). Additionally, long-term DHEA 
treatment in the current study had no effect on body fat, insulin resistance, nor serum 
cholesterol or triglyceride levels, although it did reduce body and lean mass weight. This 
contrasts with short term (20 day) DHEA treatment in other rodent PCOS models which did 
not alter body weight (471,476), but induced insulin resistance (476). These discrepancies 
identify limitations about the suitability of DHEA and letrozole treatment models to 
investigate metabolic mechanisms in the pathogenesis of PCOS.   
For the first time in a mouse PCOS model, we reveal that the presence of hepatic steatosis is 
significantly increased by prenatal DHT administration in mice, and by the long-term presence 
of DHT and DHEA. Women with PCOS are more likely to exhibit hepatic steatosis (non-
alcoholic fatty liver disease), which is associated with insulin resistance and metabolic 
syndrome (629). In a recent sheep PCOS model, prenatal T exposure induced fat accumulation 
in the liver, an early sign of liver damage (450). Our findings extend the data from the prenatal 
androgenised sheep model to this more versatile and complementary mouse model, which, 
in concert, suggest that circulating androgen levels may play a role in hepatic dysfunction in 
women with PCOS. 
The Rotterdam consensus criteria and the Androgen Excess-PCOS Societies recommend that 
the presence of two of the following three diagnostic criteria fulfils a diagnosis of PCOS: oligo-
ovulation or anovulation, hyperandrogenism and polycystic ovaries (146,148,630). Using 
these criteria, in the current study we have identified that long-term DHT treatment of female 
mice is the most congruent with clinical features of human PCOS (Table 3.2 summaries 
features of the androgenized mouse models relative to PCOS). Along with these criteria, long-
term DHT females also displayed antral follicle arrest, thickening of the theca layer in antral 
follicles, and several metabolic PCOS features including obesity, increased body fat, adipocyte 
hypertrophy and dyslipidemia. The presence of hemorrhagic cysts in letrozole mice, atypical 
Chapter Three 
 174 
for PCOS, and lack of PCOS features in the prenatal DHT and long-term DHEA mice raise doubt 
about the suitability of these models to investigate the etiology of PCOS. In summary, we have 
revealed that the more androgen selective long-term DHT treatment in female mice 
replicates a breadth of PCOS features and thus provides the most informative whole animal 
approach in mice. 
Acknowledgements 
The authors thank Jenny Spaliviero and Lucy Yang for technical support, Bone Biology 
Laboratory, in particular Dr Tara Brennan-Speranza, at the ANZAC for assistance with the 
Lunar PIXImus Densitometer and insulin tolerance tests, Dr Maaike Kockx for assistance with 
triglyceride and cholesterol analysis, and Alessandra Warren for assistance with liver 
histological analysis.
  
Chapter Four  
 
Haplosufficient Genomic 
Androgen Receptor Signaling is 
Adequate to Protect Female Mice 
from Induction of Polycystic 
Ovary Syndrome Features by 
Prenatal Hyperandrogenization  
 
 
 
 
The content of this chapter has been published as: 
A.S.L. Caldwell, S. Eid, C.R. Kay, M. Jimenez, A.C. McMahon, R. Desai, C.M. Allan, J.T. Smith, 
D.J. Handelsman, K.A. Walters. Haplosufficient genomic androgen receptor signaling is 
adequate to protect female mice from induction of polycystic ovary syndrome features by 
prenatal hyperandrogenization. Endocrinology 2015; 156(4):1441-1452 
  
Chapter Four 
 176 
4.1 Abstract 
Polycystic ovary syndrome (PCOS) is associated with reproductive, endocrine and metabolic 
abnormalities. As hyperandrogenism is the most consistent PCOS feature, we used wildtype 
(WT) and androgen receptor (AR) knockout mice (ARKO), together with a mouse model of 
PCOS, to investigate the contribution of genomic AR-mediated actions in the development of 
PCOS traits. PCOS features were induced by prenatal exposure to dihydrotestosterone 
(250µg) or oil vehicle (control) on days 16-18 of gestation in WT, heterozygote and 
homozygote ARKO mice. DHT treatment of WT mice induced ovarian cysts (100% vs 0%), 
disrupted estrous cycles (42% vs. 100% cycling) and led to fewer corpora lutea (5.0 ± 0.4 vs. 
9.8 ± 1.8). However, diestrus serum LH and FSH, and estradiol-induced negative feedback as 
well as hypothalamic expression of kisspeptin (Kiss1), neurokinin B (NKB) and dynorphin (Dyn) 
were unaffected by DHT treatment in WT mice. DHT-treated WT mice exhibited a more than 
48% increase in adipocyte area but without changes in body fat. In contrast, heterozygous 
and homozygous ARKO mice exposed to DHT maintained comparable ovarian 
(histo)morphology, estrous cycling and corpora lutea numbers, without any increase in 
adipocyte size. These findings provide strong evidence that genomic AR signaling is an 
important mediator in the development of these PCOS traits with a dose dependency that 
allows even AR haploinsufficiency to prevent induction by prenatal androgenization of PCOS 
features in adult life.  
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4.2 Introduction 
Polycystic ovary syndrome (PCOS) affects 5-10% of women of reproductive age, and is a 
heterogeneous disorder with complex reproductive, endocrine, metabolic and psychological 
features (143). PCOS is characterised by reduced fertility, due to dysfunctional follicular 
maturation, ovulatory disturbance and miscarriage (149,156), as well as reproductive 
hormone dysregulation involving luteinising hormone (LH) hypersecretion and 
hyperandrogenism. Women with PCOS are also predisposed to metabolic dysfunction often 
displaying obesity, metabolic syndrome, hyperinsulinemia, insulin resistance, hepatic 
steatosis, dyslipidemia, with an increased risk of cardiovascular disease and type 2 diabetes 
(143,149). Common to all classifications (144,146,148,630), a clinical diagnosis of PCOS must 
have at least 2 of oligo/anovulation, hyperandrogenism and polycystic ovaries (143,148), thus 
hyperandrogenism is usually the most consistent biochemical feature. Despite its high 
prevalence and health impact, the etiology of PCOS remains unclear although a fetal origin 
related to hyperandrogenic exposure is a prominent hypothesis. 
Androgens mediate their steroidal actions via the androgen receptor (AR). Over the last 
decade a direct role for AR-mediated actions in female reproductive function has been proven 
by studies using AR knockout mouse models (ARKO) (565,568,571,572,575-577,631). These 
findings have demonstrated that AR-mediated androgen actions are crucial in maintaining 
female fertility by optimizing follicle growth, health and ovulation (reviewed in: 
(516,523,594)). Androgens have been implicated in the development of PCOS with 
hyperandrogenism being the most consistent feature of PCOS (156,610), and adrenal 
hyperandrogenism (551,632) or exogenous testosterone (T) treatment in female-to-male 
transsexuals (552,633) producing clinical features of polycystic ovaries. Intrinsic defects in 
steroidogenesis culminating in increased androgen production have also been identified, with 
PCOS patients displaying enhanced steroidogenic enzyme activity (P450scc and P450c17) 
(302), theca interna cells collected from PCOS ovaries producing 20 times more 
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androstenedione (A4) than those from normal ovaries (584), and by increased expression of 
P450scc and P450c17 implying enhanced steroidogenic activity in PCOS thecal cells (634). 
Additional evidence also suggests a direct role for the AR in PCOS with aberrant distribution 
of the CAG repeat polymorphism (384,635), a polymorphism which determines tissue 
androgen sensitivity (636), implying that AR-mediated androgen actions influence the 
progression of PCOS. Moreover, the importance of AR-mediated actions are also implicated 
by evidence that the anti-androgen flutamide improves fertility in some women with PCOS 
(585,637) and reverses acyclicity in prenatally androgenized mice (261).  
As hyperandrogenism is the most consistent PCOS trait (156), the majority of recent 
experimental animal studies have focused on utilizing androgens to induce PCOS features 
(156,470,516,604). Prenatal androgenisation in primate, sheep and rodent models of PCOS 
induces reproductive, endocrine and metabolic features of PCOS (156,470,604). This 
corresponds with the finding that women with PCOS exhibit elevated circulating androgen 
levels during late gestation, potentially exposing their offspring to androgen excess (246). 
Taken together these findings imply that prenatal androgenisation may play a role in the 
development of PCOS. On this basis, we developed a prenatally androgenised mouse model 
(Chapter Three), based on previous studies (261,467), which develops PCOS features in 
mature offspring. Previously, we and others have reported reproductive and metabolic 
features of PCOS present in this model, including irregular estrous cycles, oligo-ovulation, 
reduced follicle health, LH hypersecretion, impaired E2-negative feedback, normal insulin 
sensitivity and body mass but impaired glucose tolerance, adipocyte hypertrophy and hepatic 
steatosis (Chapter Three)(261,467,468). Mouse models provide a valuable tool to allow the 
specific evaluation of genetic and molecular mechanistic pathways that may be involved in 
the pathogenesis of PCOS. In the present study, we have combined our prenatally 
androgenised PCOS mouse model with our AR knockout mouse model to determine the 
potential contribution of AR-mediated actions in the development of features associated with 
PCOS in adult life. 
Chapter Four 
 179 
4.3 Materials and Methods 
4.3.1 Mice 
Mice were maintained under standard housing conditions (ad libitum access to food and 
water in a temperature and humidity controlled, 12-h light cycle environment) at the ANZAC 
Research Institute. All procedures were performed under ketamine/xylazine anaesthesia. All 
procedures were approved by the Sydney Local Health District Animal Welfare Committee 
within NHMRC guidelines for animal experimentation. 
4.3.2 Generation and Genotyping of ARKO Mice 
Female homozygous ARKO mice were generated by crossing ARflox mice (569) with Sox2-Cre 
mice (596) as previously described (571,595). Genomic DNA isolated from toe clip or tail 
biopsy (609), was used as a template for PCR genotyping to detect rearrangements in the 
mouse Ar gene as described (568). Forward PCR primers upstream of the first LoxP site (within 
mouse AR exon 3 (AREx3-F, CTTCTCTCAGGGAAACAGAAGT) and within NEO cassette (ARNeo-
F, TAGATCTCTCGTGGGATCATTG) were used with a common reverse primer located within 
intron 3 (AR-R, GGGAGACACAGGATAGGAAATT). Two product sizes were obtained, 613 bp for 
intact Ar and 289 bp for AR floxed Ar. Mice containing the Sox2-Cre gene were detected using 
primers and PCR conditions as described (638). Global ARKO males and females were 
distinguished using primers and PCR conditions for the mouse Y chromosome sry gene as 
previously described (568,569). 
4.3.3 Generation of PCOS Mouse Model  
PCOS was induced by prenatal androgenisation as described (Chapter Three). Briefly, females 
were paired with fertile males and checked daily for copulatory plugs with the date of a visible 
plug defined as day 1 of gestation. On days 16-18 of gestation, pregnant females were 
injected daily sc with either 250µg DHT in 100µl sesame oil or 100µl sesame oil vehicle. 
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Female offspring were studied as adults at 13-16 weeks of age. Some (estrous cycling, 
hormone and steroid levels, corpora lutea counts and body composition) but not all findings 
from the AR+/+ prenatally treated oil and DHT groups have been reported previously 
(Chapter Three). 
4.3.4 Assessment of Estrous Cycle 
Estrous cycling was assessed for a 2-week period at 13 weeks of age. Estrous cycle stage was 
determined daily by light microscope analysis of vaginal epithelial cell smears (575). The stage 
of the estrous cycle was determined based on the presence or absence of leukocytes, 
cornified epithelial and nucleated epithelial cells. Proestrus was characterised by the 
presence of mostly nucleated and some cornified epithelial cells, at the estrus stage mostly 
cornified epithelial cells were present, at metestrus both cornified epithelial cells and 
leukocytes were present, and at diestrus primarily leukocytes were visible. 
4.3.5 Specimen Collection 
Dissected ovaries, pituitary, fat pads, and liver were weighed on a balance and fixed in 4% 
paraformaldehyde at 4°C overnight, and stored in 70% ethanol before histological processing. 
4.3.6 Ovary Collection and Follicle Classification, Enumeration and 
Health 
Ovaries were fixed and then processed through graded alcohols into glycol methacrylate resin 
(Technovit 7100; Heraeus Kulzer, Chatswood, Australia). Ovaries were serially sectioned at 
20µm, stained with periodic acid-Schiff, and counterstained with haematoxylin. Total 
numbers of corpora lutea (identified by morphological properties consistent with luteinized 
follicles and visible throughout several serial sections) were counted on all serial sections 
throughout each ovary using an Olympus microscope with Stereo Investigator software 
(MicroBrightField, Williston, VT, USA), as previously described (51,568,575). It was also 
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recorded if ovaries contained any atretic cyst-like follicles (large fluid-filled cyst with an 
attenuated granulosa cell layer, dispersed theca cell layer and an oocyte lacking connection 
with the granulosa cells (Figure 4.2 D)), as previously described (Chapter Three). To avoid 
bias, all ovaries were analysed without knowledge of treatment group. 
4.3.7 Neuroendocrine Response to E2 Treatment 
A prenatally androgen-induced mouse model of PCOS has been reported to display impaired 
post-castration LH hypersecretion, interpreted as impaired E2 negative hypothalamic 
feedback (468). The hypothalamic neuropeptides kisspeptin, neurokinin B (NKB) and 
dynorphin (Dyn) are key mediators of this feedback (639). Therefore, these neuroendocrine 
characteristics in response to a pharmacological dose of E2, sufficient to inhibit LH secretion, 
were evaluated in non-castrate AR+/+ females treated prenatally with oil or DHT as previously 
described (571,572). Mice were implanted subdermally with a capsule comprising SILASTIC 
tubing (Dow Corning Corp., Midland, MI) closed at both ends with SILASTIC adhesive and 
containing about 10mg 17β-estradiol. Mice had SILASTIC E2 implants for 7 days before 
collection. 
4.3.8 RNA Extraction and Real-Time Quantitative Reverse Transcriptase 
PCR (qRT-PCR) 
For gene analysis, mice were decapitated, and brains immediately removed and frozen on 
crushed dry ice. Hypothalami were dissected laterally at the peri-hypothalamic sulci, from the 
optic chiasm to the posterior border of the mammillary bodies, and the anterior commissure 
dorsally. Hypothalami were then bisected in the coronal plane immediately anterior to the 
pituitary stalk as described previously (640). The anterior dissection contained all of the 
anteroventral periventricular nucleus (AVPV) kisspeptin population, and the posterior 
dissection contained the entire arcuate nucleus (ARC). 
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Total RNA was isolated from tissue samples using the Qiagen extraction protocol (Qiagen, 
Melbourne, Australia) as per the manufacturer’s instructions. RNA was quantified using the 
NanoDrop (ND-1000) spectrophotometer and RNA (1μg) was reverse transcribed using 
Mouse Moloney Leukemia virus reverse transcriptase and random hexamers (Promega, 
Sydney, Australia). The resultant cDNAs were purified using an ultraclean PCR spin kit (MoBio 
Laboratories, Inc., Carlsbad, CA) as per manufacturer’s instructions. 
Analyses of mRNA expression levels for kisspeptin (Kiss1), NKB (Tac2), and Dyn (Pdyn), their 
respective receptors Kiss1r, Tacr3, Oprk1 and the reference genes peptidylprolyl isomerase A 
(Ppia), succinate dehydrogenase complex, subunit A (Sdha) and TATA box binding protein 
(Tbp) were performed by real-time PCR on the Rotorgene 6000 system (Corbett Research, 
Sydney, Australia). Primer pairs for all genes (Table S4.1) were purchased as QuantiTech 
primers with the exception of Ppia, Sdha and Tbp, which were designed using Primer-BLAST 
(http://www.ncbi.nlm.nih.gov). Primer pairs were designed to span introns to prevent 
amplification of product from genomic DNA. Melting-curve analysis showed a single PCR 
product for each gene and this was confirmed by gel electrophoresis and DNA sequencing 
(data not shown). Standard curves were generated with 10-fold serial dilutions of gel 
extracted (QIAEX II; Qiagen, Doncaster, Victoria, Australia). PCR products and relative gene 
expression was analyzed using the Rotorgene 6000 software. All samples were run in 
duplicate and normalized against Ppia, Sdha and Tbp using the GeNorm algorithm. 
4.3.9 Hormone Assays 
Blood was collected from females by cardiac exsanguination under ketamine/xylazine 
anesthesia, and collected serum was stored at -20°C. Mouse serum LH and FSH were 
determined using a species-specific immunofluorometric assay, as previously described 
(575,611,612). For the mouse LH assay the capture antibody used was the anti-LH antibody 
(5303 SPRN-1, Medix Biochemica, Turku, Finland) and the detection antibody was the anti-LH 
antibody (MAb 518B7, supplied by Dr J Roser, Dept of Animal Science, UC Davis, (641)) directly 
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labelled with a Europium chelate using the DELFIA Eu-labelling kit (Perkin Elmer) as per 
suppliers methodology. The mLH detection limit was 0.04ng/ml, the intra-assay coefficient of 
variation (CV) = 5.2%, and the inter-assay CV = 8.6%. For the mouse FSH assay the capture 
antibody used was the anti-FSH antibody (MCA-a-hFSH 56A) and the detection antibody was 
the anti-FSH antibody (PCA-a-LH-alfa labelled with biotin) as supplied by Dr Jos Verhagen from 
Akzo Nobel, The Netherlands. The mFSH detection limit was 0.1ng/mL, the intra-assay CV = 
3.1%, and the inter-assay CV = 7.2%. All immunoassays were performed in a single batch. 
Serum levels of testosterone (T), and progesterone (P4) were measured in extracts of 100µl 
mouse serum by liquid chromatography tandem mass spectrometry (LC-MS/MS) (602) as 
adapted for mouse serum (603) and further modified (Chapter Three). Serum was extracted 
with 1ml of methyl tert-butyl ether fortified with testosterone-1,2,3-d3 (d3-T), 
dihydrotestosterone-16,16,17-d3 (d3-DHT), and estradiol-2,4,16,16-d4 (d4-E2) as internal 
standards. The organic layer, separated by freezing the aqueous layer, was dried and 
reconstituted in 75µl of 20% methanol and 50µl injected onto the kinetex XB C18, 1.7µm 
column for analysis. The limits of quantitation (defined as lowest level that can be detected 
with a CV of <20%) were 25pg/mL for T, and 50pg/mL for P4. 
4.3.10 Body Composition 
Body composition measurements (body weight, body fat, lean body mass (LBM) and bone 
mineral density (BMD)) were performed on a Lunar PIXImus Densitometer for mice (GE 
Medical Systems), as previously described (613). Mice were anesthetized and had body 
weight and composition measured using the DEXA (Dual Energy X-ray Absorptiometry) 
analyser at the time of collection (16 weeks of age). 
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4.3.11 Fat Pad Weight and Adipocyte Morphometry  
Parametrial and retroperitoneal fat pads were fixed in 4% paraformaldehyde, embedded in 
paraffin, sectioned at 8µm, stained with H&E and adipocyte size was qualified by 
histomorphometry at 40x magnification, using an Olympus microscope with Stereo 
Investigator software (MicroBrightField, Williston, VT, USA), as described (Chapter Three). 
4.3.12 Adiponectin Assay 
Serum levels of adiponectin were measured using a Quantikine® ELISA kit from R&D Systems 
(catalog no. MRP300) according to the manufacturer’s instructions. 
4.3.13 Hepatic Steatosis  
Liver sections were embedded in paraffin, sectioned at 5µm and stained with H&E before 
histomorphometric analysis. Steatosis grade was assessed semi-quantitatively 
microscopically by two independent investigators classifying into 4 categories (0 = non-fatty 
liver, 1 = possible early steatosis, 2 = moderate steatosis, 3= severe steatosis) as described 
(Chapter Three)(614). There were no disagreements in the classifications between the two 
investigators. 
4.3.14 Insulin Tolerance Tests 
Insulin tolerance tests (ITTs) were carried out, as previously described (Chapter Three)(613). 
Mice were fasted for 6 hours prior to baseline blood glucose reading, followed by an ip. 
injection of insulin 0.75 IU/kg BW (Eli Lilly). Blood glucose was then measured at 15, 30, 60, 
90 and 120 minutes after insulin injection. Blood was obtained from a tail prick, and blood 
glucose was measured with glucose strips and an Accu-Chek glucometer (Roche). 
Measurements were taken at 16 weeks of age. Blood glucose data are presented as 
percentage of baseline blood glucose. 
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4.3.15 Statistical Analysis 
Statistical analysis was performed using NCSS (NCSS Statistical Software, Kaysville, UT) and 
SPSS software. Data that was not normally distributed was transformed prior to analysis using 
a log transformation. Statistical differences were tested by t-test or two-way ANOVA (to 
assess the effect of genotype, prenatal DHT treatment and genotype x prenatal DHT 
treatment interaction) with post hoc test using Fisher’s LSD Multiple-Comparison Test. Main 
effects of genotype and treatment are reported, with interaction results omitted if not 
significant. Proportions were analysed by logistic regression, followed by a post hoc Fisher’s 
Exact Test to assess the effect of prenatal DHT treatment (% of females cycling) or ordinal 
regression (presence of steatosis). Insulin sensitivity was analysed by a repeated measures 
two-way ANOVA. All parametric tests were confirmed by the analogous nonparametric tests. 
P ≤ 0.05 was considered statistically significant. 
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4.4 Results 
4.4.1 Cyclicity 
Prenatal DHT treatment had a significant effect (P < 0.01) with an interaction between 
genotype and treatment (P < 0.01), but there was no main effect of genotype (P = 0.08). The 
effect of prenatal DHT treatment was only evident in AR+/+ females who were either acyclic 
(7 of 12, 58%) or cycled irregularly (5 of 12, 42%) compared with WT (AR+/+) females treated 
prenatally with oil (control) who all cycled regularly (8 of 8, 100%; P < 0.01) (Figure 4.1 A and 
B). By contrast, heterozygous (AR+/-, 10 of 10, 100%) and homozygous (AR-/-, 10 of 10, 100%) 
mice treated with DHT prenatally all cycled regularly comparable with their respective oil 
vehicle treated controls (AR+/-, 10 of 10, 100% and AR-/-, 8 of 9, 89%) (Figure 4.1 A and B). 
4.4.2 Serum LH, FSH and T levels at Diestrus 
Neither genotype (P = 0.5) nor treatment (P = 0.2) influenced serum LH levels at diestrus 
(Figure 4.1 C). Serum FSH was significantly influenced by genotype (P < 0.01) but not 
treatment (P = 0.2) with AR+/- females exhibiting elevated FSH levels compared to AR+/+ and 
AR-/- females (Figure 4.1 D). Serum T levels at diestrus displayed no effect of genotype (P = 
0.8) or treatment (P = 0.06) (Figure 4.1 E). 
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Figure 4.1 Estrous Cycling and LH, FSH and Testosterone Levels 
 
 
A, Percentage of females to complete one cycle in 2-week period, showing a significant interaction 
between genotype and treatment (P < 0.01, logistic regression). * = Significant effect of DHT identified 
by post hoc Fisher’s Exact Test (P < 0.01). n = 8-12/genotype/treatment group. B, Estrous cycle pattern 
in representative females. P, proestrus; E, estrus; M, metestrus; D, diestrus. C, Serum levels of LH 
showing no effect of genotype (P = 0.5) or treatment (P = 0.2, two-way ANOVA). Solid line indicates 
median. D, Serum levels of FSH showing a significant effect of genotype (P < 0.01) but not treatment 
(P = 0.2, two-way ANOVA). Solid line indicates median. E, Serum levels of T showing no effect of 
genotype (P = 0.8) or treatment (P = 0.06, two-way ANOVA). Solid line indicates median. n = 8-
9/genotype/treatment group. G = genotype, T = treatment, * = significant difference, ns = no 
significant difference. 
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4.4.3 Ovary Weight, Corpora Lutea Numbers and Serum Progesterone 
Levels 
Ovary weight was affected by genotype (P < 0.01) and there was an interaction between 
genotype and treatment (P < 0.05), there was no significant effect of treatment (P = 0.1). 
Prenatal DHT treatment of WT (AR+/+) females reduced ovary weight (4.6 ± 0.1mg vs 5.8 ± 
0.4mg, P < 0.05) compared with oil treated WT (AR+/+) controls (Figure 4.2 A). Ovary weights 
of oil treated AR+/- (4.8 ± 0.3mg) and AR-/- (3.9 ± 0.2mg) females were significantly reduced 
compared with AR+/+ control ovary weight (5.8 ± 0.4mg) (P < 0.01). However, within 
genotypes, prenatal DHT treatment had no significant effect on ovary weight in AR+/- (4.7 ± 
0.3mg vs 4.8 ± 0.3mg) or AR-/- (4.2 ± 0.2mg vs 3.9 ± 0.2mg) females (Figure 4.2 A). Corpora 
lutea were significantly influenced by genotype (P < 0.01) and prenatal DHT treatment (P < 
0.05), with oil treated AR-/- (5.0 ± 0.4) ovaries displaying fewer corpora lutea than oil treated 
AR+/+ (9.8 ± 1.8) and AR+/- (7.0 ± 1.6) ovaries. The effect of treatment was apparent in WT 
(AR+/+) females, as prenatal DHT treatment decreased the number of corpora lutea (5.0 ± 0.4 
vs 9.8 ± 1.8) (Figure 4.2 B and D), but prenatally DHT and oil treated AR+/- (7.3 ± 1.3 vs 7.0 ± 
1.6) and AR-/- (2.4 ± 0.8 vs 5.0 ± 0.4) mice displayed comparable corpora lutea numbers 
(Figure 4.2 B and D). Serum P4 levels at diestrus were unaffected by genotype (P = 0.5) but 
were significantly reduced by prenatal DHT treatment (P ≤ 0.05) (Figure 4.1 C) with prominent 
effects in AR+/+ females exhibiting an 86% decrease (1.05 ± 0.8ng/ml vs 7.05 ± 3.16ng/ml) in 
serum P4 levels (Figure 4.2 C), whereas serum P4 levels at diestrus in AR+/- and AR-/- females 
treated prenatally with DHT or oil vehicle control were similar (Figure 4.2 C). Prenatally DHT-
treated AR+/+ ovaries displayed follicles with an atretic cyst-like appearance whereas no such 
changes in ovarian morphology were evident in AR+/- and AR-/- ovaries treated prenatally 
with DHT (Figure 4.2 D).
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Figure 4.2 Ovary Weight, Ovarian Phenotype, Corpora Lutea Numbers and 
Progesterone Levels 
 
A, Ovary weights showing a significant interaction between genotype and treatment (P < 0.05, two-
way ANOVA). Data are the mean ± SEM. n = 8-12/genotype/treatment group. Different superscript 
letters denote statistically significant differences. B, Average number of corpora lutea/ovary showing 
a significant effect of genotype (P < 0.01) and treatment (P < 0.01, two-way ANOVA). Solid line 
indicates median. n = 4-5/genotype/treatment group. C, Serum levels of progesterone showing no 
effect of genotype (P = 0.1) but a significant effect of treatment (P < 0.05, two-way ANOVA). Solid line 
indicates median. n = 8-9/genotype/treatment group. G = genotype, T = treatment, GxT = genotype x 
treatment interaction, * = significant difference and ns = no significant difference. D, Histological 
sections of representative ovaries from each experimental group and representative image of cyst. 
White asterisk = corpora lutea, white arrow = cystic follicle with attenuated granulosa cell layer, 
dispersed theca cell layer and an oocyte lacking connection with the granulosa cells.
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4.4.4 Neuroendocrine Characteristics in Response to E2 Treatment 
Following E2 treatment for 7 days, prenatal DHT treatment in AR+/+ females did not alter 
Kiss1 mRNA expression in the AVPV or the ARC, compared to oil treated controls AR+/+ 
females (Figure 4.3 A). NKB and Dyn mRNA were also unchanged in the ARC of AR+/+ females 
following prenatal DHT treatment (Figure 4.3 B). Similarly, the receptor expression for each 
neuropeptide, Kiss1r, Tacr3, Oprk1 respectively, was unchanged in either the anterior or 
posterior hypothalamus (data not shown). There was no significant difference in pituitary 
weight (Figure 4.3 C), or serum LH (Figure 4.3 D) or FSH (Figure 4.3 E) levels between any 
control and DHT treated AR+/+ females. Due to the fact that no change was observed in any 
neuroendocrine characteristic, these experiments were not repeated in AR+/- or AR-/- 
females. 
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Figure 4.3 Neuroendocrine Characteristics 
 
A, Kiss1 mRNA expression in the anteroventral periventricular nucleus (AVPV) and the arcuate nucleus 
(ARC). B, NKB and Dyn mRNA expression in the ARC. C, Pituitary weight. Serum levels of LH (D) and 
FSH (E). Solid line indicates median. For all n ≥ 7 per genotype/treatment group.   
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4.4.5 Body Weight and Body Composition 
Body weight was reduced by DHT treatment (P ≤ 0.01), but there was no effect of genotype 
(P = 0.8) (Figure 4.4 A). Body fat displayed a significant effect of genotype (P < 0.01), but not 
treatment (P = 0.1), with AR+/- and AR-/- females exhibiting reduced body fat compared with 
AR+/+ females (Figure 4.4 A). DHT treatment significantly reduced LBM (P < 0.01), but 
genotype (P = 0.3) had no effect (Figure 4.4 A). Neither genotype (P = 0.1) nor prenatal DHT 
treatment (P = 0.4) altered BMD (Figure 4.4 A). 
4.4.6 Fat Pad Weight and Histology 
Inguinal, parametrial, retroperitoneal and mesenteric fat depot weights differed by genotype 
with AR+/+ inguinal weight significantly greater than AR+/- females (P < 0.05), and AR+/+ 
parametrial (P < 0.01), retroperitoneal (P < 0.01) and mesenteric (P < 0.01) weights 
significantly greater than AR+/- and AR-/- females. Prenatal DHT treatment had no effect on 
inguinal (P = 0.4), parametrial (P = 0.9), retroperitoneal (P = 0.7) and mesenteric (P = 0.5) fat 
depot weights (Figure 4.4 B). Analysis of parametrial fat depot adipocyte size revealed no 
effect of genotype (P = 0.3), but a significant effect for treatment (P ≤ 0.05), and a significant 
interaction between genotype and treatment (P < 0.05), with prenatally DHT treated AR+/+ 
females exhibiting an increase in parametrial fat depot adipocyte size (DHT 1778.9 ± 88.6μm2 
vs. oil 1130.6 ± 83.6μm2) (P < 0.05) (Figure 4.5 A and C). Similarly, analysis of retroperitoneal 
fat depot adipocyte size revealed a significant interaction between genotype and treatment 
with prenatal DHT treatment in AR+/+ females increasing retroperitoneal fat depot adipocyte 
size (DHT 1233.2 ± 199.1μm2 vs. oil 839.0 ± 88.6μm2) compared with oil vehicle controls (P < 
0.05), but there was no effect of genotype (P = 0.3) nor treatment alone (P = 0.2) (Figure 4.5 
B). In contrast, neither parametrial fat depot or retroperitoneal fat depot adipocyte size 
differed between AR+/- or AR-/- females treated prenatally with DHT or oil (Figure 4.5 A, B 
and C). 
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Figure 4.4 Body Weight, Body Composition and Fat Depot Weight 
 
 
A, Body weight and composition calculated by DEXA. Body weight, showing no effect of genotype (P 
= 0.8) but a significant effect of treatment (P < 0.01, two-way ANOVA). Body fat, showing a significant 
effect of genotype (P < 0.01) but not treatment (P = 0.1, two-way ANOVA). LBM, showing no effect of 
genotype (P = 0.3) but a significant effect of treatment (P < 0.01, two-way ANOVA). BMD, showing no 
effect of genotype (P = 0.1) or treatment (P = 0.4, two-way ANOVA). Data are the mean ± SEM. n = 8-
12/genotype/treatment group. B, Fat depot weights showing a significant effect of genotype for 
inguinal (P < 0.05, two-way ANOVA), parametrial (P < 0.01, two-way ANOVA), retroperitoneal (P < 
0.01, two-way ANOVA) and mesenteric (P < 0.01, two-way ANOVA) fat depots. Data are the mean ± 
SEM. n = 8-12/genotype/treatment group. G = genotype, T = treatment, * = significant difference and 
ns = no significant difference. 
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4.4.7 Serum Adiponectin Levels  
There was no significant difference in serum adiponectin levels between oil and DHT 
prenatally treated AR+/+, AR+/- or AR-/- females (P = 0.3 for genotype and P = 0.6 for 
treatment) (Figure 4.5 D). 
4.4.8 Presence of Hepatic Steatosis  
The presence and severity of hepatic steatosis was increased according to genotype (degree 
of loss of AR function) (P < 0.05) and prenatal DHT treatment (P < 0.01) (Figure 4.6 A and B). 
4.4.9 Insulin Tolerance 
At 16 weeks of age, fasting glucose levels (AR+/+ oil 8.2 ± 0.2mmol/L, AR+/+ DHT 7.8 ± 
0.3mmol/L, AR+/- oil 6.9 ± 0.5mmol/L, AR+/- DHT 7.6 ± 0.4mmol/L, AR-/- oil 7.6 ± 0.4mmol/L, 
AR-/- DHT 7.5 ± 0.4mmol/L, P = 0.6 for genotype and P = 0.2 for DHT treatment) or insulin 
sensitivity (as indicated by serial blood glucose in the insulin tolerance test, P = 0.9 for 
genotype and P = 0.8 for DHT treatment) were not different according to any genotype or 
effected by prenatal DHT treatment (Figure 4.6 C). 
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Figure 4.5 Adipocyte Size and Adiponectin Levels 
 
A, Parametrial adipocyte size showing a significant interaction between genotype and treatment (P < 
0.05, two-way ANOVA). B, Retroperitoneal adipocyte size showing a significant interaction between 
genotype and treatment (P < 0.05, two-way ANOVA). Data are the mean ± SEM. n = 4-
5/genotype/treatment group. Different superscript letters denote statistically significant differences. 
C, Histological sections of representative parametrial fat pads from each experimental group. D, 
Serum levels of adiponectin showing no effect of genotype (P = 0.3) or treatment (P = 0.6, two-way 
ANOVA). Data are the mean ± SEM. n = 6/genotype/treatment group. G = genotype, T = treatment, 
GxT = genotype x treatment interaction, * = significant difference and ns = no significant difference. 
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Figure 4.6 Steatosis Analysis and Insulin Tolerance Tests 
 
A, Degree of steatosis showing a significant effect of genotype (P < 0.05) and treatment (P < 0.01, 
ordinal regression). n = 8-13/genotype/treatment group. B, Histological sections of representative 
livers from each experimental group. C, Insulin tolerance test at 16 weeks of age showing no effect of 
genotype (P = 0.8) or treatment (P = 0.2, two-way ANOVA). Data are the mean ± SEM. n = 8-
12/genotype/treatment group. G = genotype, T = treatment, * = significant difference and ns = no 
significant difference.  
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4.5 Discussion 
This study provides strong evidence that genomic AR signaling is an important mediator in 
the etiology of PCOS traits (Figure 4.7), in particular reproductive features, as experimental 
AR-dependent prenatal hyperandrogenism induces PCOS traits in adult life. By combining our 
established prenatal DHT PCOS murine model with our unique ARKO mouse model we have 
shown that the potent bioactive androgen DHT acting via the AR induces the PCOS traits of 
irregular estrous cycles, oligo- or anovulation, the presence of atretic cystic follicles within 
ovaries and adipocyte hypertrophy. Furthermore, we demonstrate that even AR 
haploinsufficiency can fully protect against these prenatal DHT-induced PCOS traits. 
In our study, prenatal DHT treatment induced irregular cycles or acyclicity in AR+/+ females, 
in contrast to all oil treated AR+/+ females, as well as AR+/- and AR-/- prenatally DHT treated 
females which all continued to cycle regularly. Furthermore, prenatally DHT treated AR+/+ 
females spent little time in proestrus, the prelude to ovulation. These findings are in 
agreement with our and others previous observations that prenatal DHT treatment in rodents 
can disrupt estrous cycles (Chapter Three)(261,463). Furthermore, the fact that a global loss 
(AR-/-) or even AR haploinsufficiency (AR+/-) for genomic AR signaling protected estrus 
cyclicity and ovulation further verifies that AR-mediated androgen action is directly involved 
in the development of PCOS ovulatory disturbance. These findings are consistent with clinical 
evidence for a direct role for AR-mediated actions whereby menstrual cycle regularity was 
restored in some PCOS patients treated with the AR antagonist flutamide (586) as well as 
acyclic prenatally androgenized mice (261). 
Ovulatory dysfunction is a key cause of the reduced fertility observed in PCOS patients (642). 
This PCOS trait was reproduced in the present study whereby prenatally DHT treated wildtype 
(AR+/+) females displayed fewer corpora lutea and reduced serum P4 levels consistent with 
our and other previous studies (Chapter Three)(463). In contrast, in AR+/- and AR-/- females, 
Chapter Four 
 198 
although corpora lutea numbers were reduced compared to controls (AR+/+), corpora lutea 
numbers and serum P4 concentrations were unaffected by prenatal DHT treatment. These 
findings, along with the observation that flutamide, an AR blocker, can restore ovulation in 
some PCOS women (585,586), confirm the importance of genomic AR signaling as playing an 
important role in the development of the ovulatory dysfunction that is characteristic of PCOS. 
Enlarged ovaries are a feature of human PCOS (643), however prenatal DHT treatment did 
not increase AR+/+ ovarian weight, which is consistent with previous studies (Chapter 
Three)(468). However, oil treated AR+/- and AR-/- ovarian weight was reduced compared to 
oiled treated AR+/+ ovarian weight, confirming our previous findings that AR+/+ and AR-/- 
females exhibited reduced ovarian weight due to the presence of fewer corpora lutea (568). 
Although the classic appearance of a multi-cystic ovary was not observed, prenatal DHT 
treatment induced the PCOS-like ovarian morphology with an increased prevalence of atretic 
cystic-like follicles in AR+/+ females but not in oil treated AR+/+ or in prenatally DHT treated 
AR+/- or AR-/- females, again confirming the importance of AR-mediated mechanisms. In 
concert, these results further support experimental findings from a range of animal models 
(primate, sheep and rodent) (411,470,604) that excessive exposure to androgen in utero can 
replicate reproductive features of human PCOS in adulthood. However, previous studies were 
unable to dissect out the involvement of AR vs ER mechanisms in the development of these 
traits, as while DHT is a potent pure androgen that can only bind to the AR, it is capable of 
being enzymatically reduced to the 5α-androstanediols, 3α-diol and 3β-diol, the latter of 
which can bind to and activate ERβ to exert indirect estrogen-like effects (62). Findings from 
the present study confirm for the first time that excessive levels of androgens during prenatal 
life, acting directly via the AR, can induce acyclicity, anovulation and reduced ovarian follicular 
health and function in adult life. 
PCOS patients often exhibit LH hypersecretion (149), however this was not observed, at least 
at diestrus, in DHT treated AR+/+ females. Elevated serum LH levels and/or an increase in LH 
pulse frequency have been described in some (261,463), but not all (Chapter Three)(513), 
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previously reported prenatally androgen-induced rodent PCOS models. In the present study 
inhibition of LH secretion after E2 administration was maintained, and pituitary weight and 
mRNA expression of Kiss1, NKB, Dyn and their respective receptors Kiss1r, Tacr3, Oprk1 in the 
arcuate nucleus were also unchanged. These data suggest that normal kisspeptin to GnRH 
stimulation of gonadotropins is maintained in this prenatally hyperandrogenized mouse 
model of PCOS. However, as these analyses were carried at a single time point, this may have 
missed changes in LH pulse frequency and/or amplitude. In contrast to our data, another 
experiment using the same model described reduced post-castration LH hypersecretion as 
well as reduced LH suppression after E2 administration after ovariectomy (468); however, the 
apparent reduction in E2-mediated negative feedback may be due to the minimal post-
castration rise in serum LH. Thus, further studies are required to characterize 
positive/negative feedback in the prenatally hyperandrogenised PCOS mouse model before 
an alteration in underlying kisspeptin signaling can be completely ruled out. 
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Figure 4.7 Summary of PCOS Traits in This Mouse Model 
 
 
Schematic diagram of the PCOS traits displayed in this PCOS mouse model which can be induced by 
prenatal hyperandrogenism acting via direct AR-mediated actions. 
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PCOS is associated with obesity, however prenatal DHT treatment of wildtype (AR+/+) as well 
as AR+/- or AR-/- mice reduced body weight and lean body mass, but had no effect on body 
fat, which is in agreement with previous studies (Chapter Three)(467). However, even though 
overt obesity was not present, prenatal hyperandrogenism did induce the PCOS metabolic 
feature of adipocyte hypertrophy, with AR+/+ DHT treated females exhibiting increased 
adipocyte cell size in parametrial and retroperitoneal fat pads. Adipocyte dysfunction has 
been linked with the mechanisms leading to the development of PCOS (624,625), and 
dysfunction of adipose tissue is known to disrupt adipokine secretion (623). However, 
adiponectin, known as a beneficial adipokine (644) and reported in some studies to be 
decreased in PCOS patients (376,645), was not found to be altered in AR+/+, AR+/- or AR-/- 
DHT vs oil treated females, however this does not account for other adipokines associated 
with PCOS such as leptin, visfatin and chemerin (625). This may not be surprising, as DHT 
prenatally treated AR+/+ mice were not obese and dysregulation of adipokine secretion is 
directly associated with obesity. The observed alteration in adipocyte morphology in AR+/+ 
DHT treated females was not apparent in AR+/- or AR-/- females treated prenatally with DHT, 
implying that AR-dependent prenatal hyperandrogenism can induce adipocyte hypertrophy. 
However, the consequence or impact of this change in adipocyte morphology in relation to 
PCOS requires further investigation. Hypertrophic adipocytes are inherently insulin resistant 
(627), however insulin resistance was not present in prenatally treated DHT AR+/+ females, 
or AR+/- or AR-/- with and without prenatal DHT treatment. These findings imply that muscle 
and/or fat must be affected as well rather than adipose tissue alone to reduce insulin 
sensitivity, and that neither elevated prenatal exposure to DHT or loss of AR signaling play a 
prominent role in the origins of altered insulin sensitivity in maturity. 
Hepatic steatosis (non-alcoholic fatty liver disease) is more frequent in PCOS patients (629), 
and in the current study, prenatal DHT administration significantly increased the severity of 
hepatic steatosis in AR+/+ mice. However, both AR+/- and AR-/- females, regardless of DHT 
treatment, also exhibited a significant increase in severity of hepatic steatosis relative to oil 
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treated controls. These findings confirm that a balance in androgenic actions is essential in 
maintenance of normal liver function, and confirm previous findings that androgens and AR-
mediated actions play important roles in normal liver function (646), functional AR signaling 
plays an important in preventing steatosis (647), and that maternal androgen excess leads to 
an increased presence of non-alcoholic fatty liver in female offspring (Chapter Three)(648). 
In the current study, we have shown that prenatal androgen excess acting directly via the AR 
can induce several clinical traits of human PCOS including irregular estrous cycles, oligo- or 
anovulation, decreased follicular health, adipocyte hypertrophy and an increased presence of 
hepatic steatosis, but not a neuroendocrine deficiency. With the exception of hepatic 
steatosis which may have multiple causal mechanisms, female mice were protected from the 
development of all of these characteristics of PCOS by the complete or partial loss of AR, 
confirming that AR-dependent prenatal hyperandrogenism can induce several reproductive 
and metabolic features in adult life. This protection by AR haploinsufficiency has notable 
implications for the reproductive function of mothers of genetic males with complete 
androgen insensitivity syndrome (CAIS) who are obligate heterozygotes for the same 
mutation. Our present findings suggest that these women may have a reduced susceptibility 
to androgen-associated disorders including less liability to develop PCOS than women with 
two wild-type AR alleles, a hypothesis that warrants clinical investigation. However, while our 
findings provide strong evidence to support genomic AR signalling as an important mediator 
in the development of PCOS, estrogen receptor mediated actions may also play a role, with 
several studies using animal PCOS models reporting differences in the induction of PCOS traits 
by aromatizable and non-aromatizable androgens (reviewed in: (411,470,649)). In summary, 
we have revealed that prenatal androgen exposure in mice, acting directly via the AR, 
replicates key clinical diagnostic features of PCOS which are protected against by AR haplo- 
or complete insufficiency. 
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4.6 Supplemental Information 
Table S4.1 qRT-PCR conditions  
Gene QuantiTech name or Primer sequence 
Size 
(bp) 
Melting 
Temperature Accession Code 
Kiss1 Mm_Kiss1_2 146 88 C NM_178260 
Kiss1r Mm_Kiss1r_1 123 86 C NM_053244 
Tac2 Mm_Tac2_2 74 74 C NM_009312 
Tacr3 Mm_Tacr3_1 109 80 C NM_021382 
Pdyn Mm_Pdyn_1 143 86 C NM_018863 
Oprk1 Mm_Oprk1_1 73 78 C NM_011011 
Sdha F, 5’-TGGGGCGACTCGTGGCTTTC- 3ʹ 134 85 C NM_130428 
 R, 5’-CCCCGCCTGCACCTACAACC- 3ʹ    
Ppia F, 5’-AGCATACAGGTCCTGGCATC- 3ʹ 127 83 C NM_017101 
 R, 5’-TTCACCTTCCCAAAGACCAC- 3ʹ    
Tbp F, 5’-GGGAGAATCATGGACCAGAA- 3ʹ R, 5’-CCGTAAGGCATCATTGGACT- 3ʹ 113 85 C NM_013684.3 
 
QuantiTech name, primer sequences, product size (bp, base pairs), melting temperature, and 
accession code for analysis and reference genes. F, forward; R, reverse. 
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is a Key Extra-Ovarian Mediator 
in The Development of Polycystic 
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Walters. Neuroendocrine androgen action is a key extra-ovarian mediator in the 
development of polycystic ovary syndrome. Proceedings of the National Academy of 
Sciences USA 114(16):E3334–E3343 
 
*The structure of this chapter has been modified from its published version in that the Materials and Methods section has been bought 
forward and now follows the Introduction  
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5.1 Abstract  
Polycystic ovary syndrome (PCOS) is a complex hormonal disorder characterised by 
reproductive, endocrine and metabolic abnormalities. As the origins of PCOS remain 
unknown, mechanism-based treatments are not feasible and current management relies on 
treatment of symptoms. Hyperandrogenism is the most consistent PCOS characteristic, 
however it is unclear if androgen excess, which is treatable, is a cause or a consequence of 
PCOS. As androgens mediate their actions via the androgen receptor (AR), we combined a 
mouse model of DHT-induced PCOS with global and cell-specific AR resistant (ARKO) mice to 
investigate the locus of androgen actions which mediate the development of the PCOS 
phenotype. Global loss of the AR reveals that AR signaling is required for all DHT-induced 
features of PCOS. Neuron-specific AR signaling was required for the development of 
dysfunctional ovulation, classic polycystic ovaries, reduced large antral follicle health and 
several metabolic traits including obesity and dyslipidemia. In addition, ovariectomized ARKO 
hosts with wild-type ovary transplants displayed normal estrous cycles and corpora lutea, 
despite DHT treatment, implying extra-ovarian and not intra-ovarian AR actions are key sites 
of androgen action in generating the PCOS phenotype. These findings provide strong evidence 
that neuroendocrine genomic AR signaling is an important extra-ovarian mediator in the 
development of PCOS traits. Thus targeting AR-driven mechanisms that initiate PCOS is a 
promising strategy for the development of novel treatments for PCOS.  
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5.2 Significance Statement 
The cause of PCOS is unknown but androgen excess is a key feature of PCOS. We combined a 
hyperandrogenised PCOS mouse model with global, tissue and cell-specific androgen 
resistant mouse lines to uncover the sites of androgen action that initiate PCOS. We 
demonstrate that direct androgen actions, particularly in neurons, but less so in granulosa 
cells, are required for the development of key reproductive and metabolic PCOS features. 
These data highlight the previously overlooked importance of extra-ovarian neuroendocrine 
androgen action in the origins of PCOS. Targeting androgen-driven mechanisms may 
represent new options to develop a mechanism-based treatment of PCOS. 
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5.3 Introduction 
Polycystic ovary syndrome (PCOS) is the most frequent endocrine disorder of young women 
with a prevalence of 6-15% (143), and accounts for more than 75% of anovulatory infertility 
(650). It is characterised by reproductive hormone dysregulation involving luteinising 
hormone (LH) hypersecretion and hyperandrogenism (292), the consequences of which can 
be acne and hirsutism, as well as reduced fertility, due to aberrant follicular maturation, 
ovulatory disturbance, and miscarriage (292). Associated non-reproductive abnormalities, 
such as obesity, metabolic syndrome, hyperinsulinemia, insulin resistance, hepatic steatosis, 
and dyslipidemia predispose affected women to heightened risk of cardiovascular disease and 
type 2 diabetes (292,651). Yet, despite the high prevalence and significant health impact, the 
pathogenesis of PCOS remains unclear so that mechanism-based treatments remain 
unattainable.  
Hyperandrogenism the most consistent feature of PCOS (652), is implicated as a key mediator 
in the pathogenesis of PCOS. Supportive evidence includes that androgen excess from 
endogenous (congenital adrenal hyperplasia (653)) or exogenous (female-to-male 
transsexuals (633)) sources can produce polycystic ovaries. Furthermore, androgens induce 
reproductive, metabolic and endocrine features of PCOS in rodent, sheep and primate animal 
models of PCOS (411,470,604). As all androgen action is mediated via the androgen receptor 
(AR), AR-mediated actions are thereby strongly implicated in the development of PCOS. 
Support for AR-mediated androgen actions influencing the progression of PCOS include that 
variation in androgen sensitivity via the CAG triplet repeat length polymorphism of AR (636) 
is associated with PCOS prevalence (387), and alternative splicing of the AR in granulosa cells 
is associated with aberrant follicle development (389,390). Treatment with the AR antagonist 
flutamide is reported to restore ovulation in some women with PCOS (585) and rescue 
acyclicity (261) and anxiety-like behaviour (654) in PCOS mouse models. Moreover, we 
Chapter Five 
 209 
recently identified that loss of AR signaling protects female mice from induction of PCOS 
features by prenatal hyperandrogenism (Chapter Four). 
Animal models have shown that systemic treatment with androgens induces PCOS-like clinical 
features (516), however systemic treatments cannot elucidate the target tissue(s) of 
androgenic actions. While the naming of PCOS implies a primarily ovarian condition, it has yet 
to be established if the disorder originates in the ovary or elsewhere, with ovarian 
manifestations as downstream ramifications. We hypothesize that androgens are central in 
the etiology of PCOS, so in the current study we combined an optimised PCOS mouse model 
(Chapter Three)(469) with global, and neuronal- and granulosa cell-specific androgen 
receptor knockout (ARKO) mouse lines (568,575) to identify the sites of androgen action 
(Figure 5.1). Our findings highlight the importance of extra-ovarian AR-mediated androgen 
actions in the origins of PCOS features, which is strongly supported by findings from recent 
genome-wide association studies (GWAS) of PCOS highlighting the importance of 
gonadotropins in PCOS (334-336). 
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5.4 Materials and Methods 
5.4.1 Mice 
Mice were maintained under standard housing conditions (ad libitum access to food and 
water in a temperature- and humidity-controlled, 12-hour light/dark environment) at the 
ANZAC Research Institute. All surgical procedures were carried out under ketamine/xylazine 
anaesthesia while non-surgical procedures were carried out under isoflurane inhalation 
anaesthetic. All procedures were approved by the Sydney Local Health District Animal 
Welfare Committee within NHMRC guidelines for animal experimentation. 
5.4.2 Experimental Design 
To elucidate the site of AR-mediated androgen actions in the etiology of PCOS, three mouse 
lines with site-specific loss of AR signaling were examined: 1) androgen receptor knock-out 
(ARKO) mice with global loss of AR signaling, 2) neuron-specific ARKO mice (NeurAKO) with 
brain-specific loss of AR signaling, and 3) granulosa cell-specific ARKO mice (GCARKO) lacking 
granulosa cell AR signaling. Each were compared to their relevant wild-type controls. All 6 
groups were treated without (controls) or with long-term exposure to dihydrotestosterone 
(DHT) postnatally (Figure 5.1), which induces PCOS in wild-type mice as previously described 
(Chapter Three) and based on prior reports of DHT induction of experimental PCOS in rats 
(245) and mice (469). Briefly, 3 week old female mice were implanted with either a 1cm 
SILASTIC implant (id, 1.47 mm; od, 1.95 mm, Dow Corning Corp, catalog no. 508–006) 
containing about 10mg DHT or an empty, blank control. All DHT-treated experimental groups 
exhibited a significant increase in serum DHT levels (Table 5.1, P<0.01). Mice were collected 
after approximately 13 weeks of drug administration (WT: control, n = 7, DHT, n = 8; ARKO: 
control, n = 7, DHT, n = 7; NeurWT: control, n = 5, DHT, n = 5; NeurARKO: control, n = 5, DHT, 
n = 5; GCWT: control, n = 8, DHT, n = 8; GCARKO: control, n = 9, DHT, n = 9;), when the mice 
were approximately 16 weeks of age.  
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Figure 5.1 Experimental Design 
 
 
For this study, PCOS was induced in wildtype (WT), global (ARKO), neuron-specific (NeurARKO) and 
granulosa cell-specific (GCARKO) androgen receptor knockout mice by sc. insertion of 
dihydrotestosterone (DHT) implants in the mice for 3 months. Control mice were implanted with blank 
implants. Body weight, estrous cycling, blood pressure, fasting glucose, oral glucose tolerance (oGTT) 
and insulin tolerance (ITT) were assessed before collection of serum and tissues at 16 weeks of age. 
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5.4.3 Generation and Genotyping of ARKO, GCARKO and NeurARKO 
Mice 
Homozygous female ARKO mice were generated by crossing ARflox mice (569), in which exon 
3 is flanked by loxP sites, with Sox2-Cre mice (596) as a universal deletor, as previously 
described (571). Female GCARKO mice were generated by crossing ARflox mice (46) with 
AMH-Cre mice (600), as previously reported (575). To generate female NeurAKO mice ARflox 
mice (46) were mated with transgenic CamKIIα-Cre mice (601). Genomic DNA isolated from 
toe clip or tail biopsy was used as a template for PCR genotyping to detect rearrangements in 
the mouse Ar gene, as described (568). Mice containing the Sox2-Cre gene or the AMH-Cre 
gene were detected using primers and PCR conditions as described (571,575). Mice 
containing the CamKIIα-Cre gene were detected using the following PCR primers (Cre1: 5’-
GGTTCTCCGTTTGCACTC-3’, Cre2: 5’-CTGCATGCACGGGACAGCTCT-3’, and Cre3: 5’-
GCTTGCAGGTACAGGAGGTA-3’). Two products are obtained in cre-positive mice, 375bp for 
transgenic Cre and 290bp for endogenous Cre. All knockout models were confirmed using RT-
PCR for appropriate, tissue-specific inactivation of the AR using RNA extracted from ovary, 
uterus, brain and pituitary (S4), as described (568). Primers specific for mouse β-actin were 
used as an internal control. Baseline phenotypic characteristics of the different ARKO mouse 
models is provided in Table S5.1. 
5.4.4 Ovarian Transplantation 
Reciprocal paired ovarian transplants were performed between wild-type and ARKO females 
as well as between wild-type and wild-type females as surgical controls for the procedure, as 
previously described (572). Females served as both donors and recipients whenever possible. 
4-week-old mice were anesthetized, and each ovary exposed via a flank incision. The 
surrounding bursa was incised, and the ovary gently removed at the hilum. After excision 
from the donor, the ovaries were held in cold sterile saline until placed inside the ovarian 
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bursa of the ovariectomized recipient. A single stitch of 8-0 silk suture was placed through the 
incision in the bursa. The reproductive tract was then returned to its normal anatomical 
position and the abdominal wall and skin closed using 6-0 silk sutures. At the same time as 
mice underwent ovarian transplantation, females were also implanted with a DHT implant or 
blank implant as described above. 
5.4.5 Assessment of Estrous Cycle 
Estrous cycle stage was analysed using vaginal epithelial cell smears taken daily for 14 
consecutive days (Chapter Three). Smears were collected at the same time each day (10am) 
using 15µl of 0.9% sterile saline, transferred to glass slides to air dry. Dry smears were stained 
with 0.5% toluidine blue before being examined under light microscope. Estrous cycle stage 
was determined based on the presence or absence of leukocytes, cornified epithelial cells, 
and nucleated epithelial cells. Proestrus was characterized by the presence of mostly 
nucleated and some cornified epithelial cells; at the estrus stage primarily cornified epithelial 
cells were present; at metestrus both cornified epithelial cells and leukocytes were present; 
and at diestrus predominantly leukocytes were present. 
5.4.6 Ovary Preparation, Morphological Analysis and Follicle Health 
Dissected ovaries were weighed, fixed in 4% paraformaldehyde overnight at 4°C and stored 
in 70% ethanol before histological processing. Ovaries were processed through graded 
alcohols and embedded in glycol methacrylate resin (Technovit 7100; Heraeus Kulzer). Serial 
sections of 20µm were stained with periodic acid- Schiff (PAS) and counterstained with 
haematoxylin. For corpora lutea (CL) quantification, whole-section scans of every second 
section were taken under light microscope using the EVOS® FL Auto System (Life 
Technologies). To quantify antral follicle populations and assess follicular health, sections 
were examined using an Olympus light microscope with Stereo Investigator software 
(MicroBrightField), as previously described (Chapter Three). Total numbers of small antral 
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follicles (oocyte surrounded with greater than 5 layers of granulosa cells, and/or one or two 
small areas of follicular fluid), large antral follicles (contained a single large antrum), 
preovulatory follicles (a large antral follicle with an oocyte surrounded by cumulus cells at the 
end of a stalk of mural granulosa cells), and atretic cyst-like follicles (large fluid-filled cysts 
with an attenuated granulosa cell layer, dispersed theca cell layer, and an oocyte lacking 
connection with the granulosa cells, see Figure 5.3 D), were classified and quantified as 
previously reported (Chapter Three)(568). To avoid repetitive counting, each follicle was only 
counted in the section where the oocyte’s nucleolus was visible. For all analyses, large antral 
follicles and preovulatory follicles were grouped together and called “large antral follicles”. 
Follicles were classified as unhealthy if they contained a degenerate oocyte and/or more than 
10% of the granulosa cells were pyknotic in appearance, as previously described (Chapter 
Three)(568). The proportion of unhealthy follicles per ovary was calculated as the percentage 
of all follicles at that developmental stage. For all large antral follicles, granulosa cell layer 
thickness and theca layer area were measured using ImageJ v1.48 software (open source, 
developed by National Institutes of Health), as previously reported (Chapter Three).  
5.4.7 Steroid Analysis 
Blood was collected from females by cardiac exsanguination under ketamine/xylazine 
anesthesia, and collected serum was stored at -20 °C. Serum levels of testosterone (T), DHEA, 
DHT, and its 2 principal metabolites 5α-androstane-3α,17β-diol (3αdiol) and 5α-androstane-
3β,17β-diol (3βdiol) and progesterone (P4) were measured in extracts of 100µl mouse serum 
by liquid chromatography tandem mass spectrometry (LC-MS/MS), as previously described 
(18). The limits of quantitation (defined as lowest level that can be detected with a CV of 
<20%) were 25 pg/mL for T, 100pg/mL for DHEA, DHT, 3αdiol and 3βdiol, and 50 pg/mL for 
P4. 
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5.4.8 Hormone Assays 
Blood was collected from females by cardiac exsanguination under ketamine/xylazine 
anesthesia, and collected serum was stored at -20 °C. Mouse serum LH and FSH were 
determined using a species-specific immunofluorometric assay, as previously described 
(Chapter Four). The mouse LH detection limit was 0.04 ng/mL, the intraassay coefficient of 
variation (CV) = 5.2%, and the interassay CV = 8.6%. The mouse FSH detection limit was 0.1 
ng/mL, the intraassay CV = 3.1%, and the interassay CV = 7.2%. All immunoassays were 
performed in a single batch.  
Serum levels of testosterone (T), DHEA, DHT, and its 2 principal metabolites 5α-androstane-
3α,17β-diol (3αdiol) and 5α-androstane-3β,17β-diol (3βdiol) and progesterone (P4) were 
measured in extracts of 100µl mouse serum by liquid chromatography tandem mass 
spectrometry (LC-MS/MS), as previously described (Chapter Four). The limits of quantitation 
(defined as lowest level that can be detected with a CV of <20%) were 25 pg/mL for T, 
100pg/mL for DHEA, DHT, 3αdiol and 3βdiol, and 50 pg/mL for P4. 
5.4.9 Adipose Tissue Analysis 
Parametrial fat pads were weighed, fixed in 4% paraformaldehyde, embedded in paraffin and 
sectioned at 8µm. Sections were stained with haematoxylin and eosin before images were 
taken for histomorphometry at x40 magnification under a light microscope using the EVOS® 
FL Auto System (Life Technologies). Five distinct images were taken from each of three 
sections of the fat pad, with at least 200µm separating these sections. 
5.4.10 Hepatic Steatosis Analysis 
Livers were weighed whole before the right lateral lobe was excised from the whole liver and 
fixed in 10% neutral buffered formalin overnight at 4°C before being soaked in 30% sucrose 
v/v for 48 hours. 1cm x 1cm segments were excised from the lobe and embedded in OCT 
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compound (Tissue-Tek) before 10µm sections were cryosectioned and air-dried onto slides. 
Slides were stained with Oil Red O in 60% isopropanol to visualise lipid deposition, as 
previously described (52), before histomorphometric analysis. ImageJ v1.48 software (NIH) 
was used to quantify Oil Red O–positive staining. Three separate images were analysed from 
three distinct sections taken at least 200µm apart. 
5.4.11 Insulin and Oral Glucose Tolerance Tests 
Insulin tolerance test (ITT) and oral glucose tolerance test (oGTT) were carried out as 
previously reported, with modifications (613). Mice were fasted for 6-hours prior to a baseline 
blood glucose reading, followed by an ip injection of 0.75 IU/kg BW insulin (Eli Lilly) or an oral 
bolus of glucose at 2 g/kg BW. Blood glucose was then measured at 15, 30, 60, 90, and 120 
minutes. Blood was obtained from a tail prick, and blood glucose was measured on glucose 
strips and an Accu check glucometer (Roche). ITTs and oGTTs were carried out at 16 weeks of 
age.  
5.4.12 Blood Pressure 
Blood pressure was measured with an automated tail-cuff system (MC4000; Hatteras 
Instruments), as previously described (655). Animals were acclimatized to the system for 3 
days prior to data being collected on the fourth day. Animals were conscious at the time of 
measurement. Measurements were taken at 16 weeks of age. 
5.4.13 Cholesterol and Triglyceride Assays 
Serum levels of triglycerides and total cholesterol was assayed enzymatically with kits 
obtained from Wako (Cholesterol E kit, catalog no. 439-17501; Triglyceride E kit, catalog no. 
432-40201).  
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5.4.14 Adiponectin Assay 
Serum levels of total full-length mouse adiponectin were measured using a Quantikine® ELISA 
kit from R&D Systems (catalog no. MRP300), according to the manufacturer’s instructions. 
The mean minimum detectable dose of mouse Adiponectin ranged was 0.003 ng/mL. This kit 
specifically measures natural and recombinant full-length mouse Adiponectin. < 0.5% cross-
reactivity is observed with available related molecules. 
5.4.15 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism 6 software (GraphPad Software, Inc). 
Data that were not normally distributed were transformed before analysis using log 
transformation. Statistical differences were tested by two-way ANOVA followed by Fisher’s 
LSD Multiple-Comparison Test as a post hoc test. Proportions were analysed by Fisher’s Exact 
Test. P values <0.05 were considered statistically significant.  
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5.5 Results 
Neuron but not granulosa cell AR signaling is required for the development of anovulation 
in the PCOS mouse model. Irregular menstruation is a key diagnostic criterion for PCOS. The 
development of PCOS-like features in our mice was confirmed by the detection of acyclicity 
in 100% of WT females treated with DHT (P<0.01, Figures 5.2 A and S5.1), as well as in 
NeurWT (100% acyclic, P<0.01) and GCWT (75% acyclic, P<0.01; 2 of the 8 mice exhibiting 
only 1 long irregular cycle) females, relative to non-DHT treated controls. In contrast ARKO, 
but not NeurARKO or GCARKO females maintained normal estrous cycle patterns after DHT 
treatment, hence global AR inactivation protected against the development of the PCOS trait 
of aberrant cycles (Figures 5.2 A and S5.1).  
Similarly, oligo/anovulation is a key reproductive characteristic of PCOS. Histologically, the 
number of corpora lutea (CL) present was notably diminished in DHT-treated WT, NeurWT, 
GCWT and GCARKO groups, demonstrating oligo/anovulation (P < 0.01, Figure 5.2 B and C). 
Conversely, global loss of AR signaling protected against the induction of ovulatory 
dysfunction (Figure 5.2 B and C). Loss of AR signaling in granulosa cells allowed the 
development of DHT-induced irregular estrous cycles and ovulatory dysfunction, with 
GCARKO females exhibiting a significant reduction in completed estrous cycles in 2 weeks (P 
< 0.01, Figure 5.2 A) and the number of CL present in their ovaries (P<0.01, Figure 5.2 B and 
C).  
NeurARKO females did not develop ovulatory dysfunction displaying multiple CLs when 
treated with DHT (Figure 5.2 B and C) but displayed apparent acyclicity according to vaginal 
smears (Figure 5.2 A). As androgens can directly impact vaginal epithelium (656), this 
apparent discrepancy of NeurARKO female cyclicity may be due to the persistence of direct 
DHT effects on the NeurARKO vaginal epithelium. Analysis of serum steroid levels by LC-
MS/MS revealed that DHT was significantly increased in all groups of DHT-treated mice 
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compared to strain-matched WT controls (P<0.01, Table 5.1). DHT treatment also had 
significant effects on serum T (P<0.01) and 3α- and 3b-diol (P<0.01), but not DHEA or P4 
concentrations (Table 5.1). DHT treatment did not influence serum LH or FSH levels (Table 
5.1). 
  
Chapter Five 
 220 
Figure 5.2 Estrous Cycling, Ovulation and Ovarian Phenotype 
 
Neuron but not granulosa cell AR signaling is required for the development of anovulation in the 
PCOS mouse model. Loss of extra-ovarian AR signaling ameliorates the development of acyclicity 
and anovulation in the PCOS mouse model. (A) Average number of full estrous cycles completed in a 
2-week period, confirming DHT-induced acyclicity in WT mice and showing no development of 
acyclicity in DHT-induced PCOS ARKO female mice. Data are the mean ± SEM. n = 5–9 per 
genotype/treatment group. (B) Average number of corpora lutea (CL) per ovary, showing no 
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development of anovulation in DHT-induced PCOS ARKO or NeurARKO female mice. Data are the 
mean ± SEM. n = 3–5 per genotype/treatment group. (C) Histological sections of representative 
ovaries from each treatment group, showing the maintenance of ovulations (indicated by the 
presence of corpora lutea) in DHT-induced PCOS ARKO and NeurARKO ovaries. (D) Percentage of 
cycling females in a 2-week period, showing no development of acyclicity in DHT-induced PCOS ARKO 
ovariectomized females transplanted with WT ovaries. (E) Histological sections of representative 
ovaries from each treatment group, showing corpora lutea in DHT-induced PCOS ARKO 
ovariectomized females transplanted with WT ovaries, indicative of recent ovulation. G, genotype; ns, 
no significant difference; T, DHT treatment; *, significant difference; star, corpora lutea; triangle, 
arrested antral follicle. (Magnification: 10x.) (*P < 0.05, two-way ANOVA). 
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Therefore, to conclusively test the hypothesis that extra-ovarian AR-signaling played a direct 
role in the development of the PCOS traits of irregular cycles and ovulatory dysfunction, we 
performed an independent experiment which investigated the effect of extra- and intra-
ovarian AR signaling on these PCOS traits separately. We undertook reciprocal ovary 
transplants between WT and ARKO females and then induced PCOS by long-term DHT 
treatment. All intact WT females treated with a blank implant cycled (8 of 8), while 100% of 
intact WT females treated with DHT were acyclic (0 of 8; P<0.01, Figure 5.2 D). Similarly, 
compared to intact control WT females with DHT treatment, 100% of WT hosts with either 
WT (0 of 5, P<0.01) or ARKO (0 of 6, P<0.01) transplanted ovaries failed to cycle, and their 
ovaries displayed no CL (Figure 5.2 D and E). This indicates that a functional AR in the ovary 
is not needed for the development of aberrant cycling in PCOS. However, 71% of ARKO hosts 
with WT transplanted ovaries (ie. with preserved AR signaling), cycled and their ovaries 
exhibited CL. This indicates that extra-ovarian AR actions are required for the development 
of the PCOS traits of aberrant estrous cycles and ovulatory dysfunction (Figure 5.2 D and E). 
Histologically, ovaries collected from all DHT treated WT (WT, NeurWT or GCWT) and GCARKO 
females displayed the classic polycystic appearance, while ARKO and NeurARKO ovaries did 
not display that phenotype (Figures 5.2 C and 5.3 C and D). Ovarian weight is increased in 
human PCOS but decreased in this rodent PCOS model (245,292). DHT treatment induced a 
significant decrease in ovary weight in all genotypes (P < 0.01) except for DHT-treated ARKO 
females which remained comparable to control ARKO ovaries (Figure 5.3 A). 
Atretic cyst-like follicles were not present in any of the control WT ovaries (WT, NeurWT or 
GCWT, Figures 5.2 C and 5.3 B and C), but after DHT-induced PCOS all females in these groups 
displayed a significant increase in the prevalence of cystic follicles (P < 0.05; Figures 5.2 C and 
5.3 B, C and D). Although non-DHT (blank implant) treated ARKO females exhibited a few 
cystic follicles, DHT treatment to induce PCOS did not increase the numbers, consistent with 
global AR inactivation preventing DHT-induced cyst development. Neuronal-specific loss of 
AR signaling significantly reduced (P<0.05) but did not fully protect against the development 
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of DHT-induced cystic follicles in NeurARKO ovaries, but was much less than that observed in 
DHT-treated WT and GCARKO ovaries (Figures 5.2 C and 5.3 B and C). 
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Table 5.1 Characterization of Hormone Profiles 
 
 
Serum concentrations of dihydrotestosterone (DHT), testosterone (T), dehydroepiandrosterone (DHEA), 5α-androstane-3α,17β-diol (3αdiol) and 5α-
androstane-3β,17β-diol (3βdiol), progesterone (P4) luteinizing hormone (LH) and follicle stimulating hormone (FSH). Data are the mean ± SEM. n = 4-9 per 
genotype/treatment group. * Significant difference compared with strain-matched wildtype (WT) control female mice.
Chapter Five 
 225 
Figure 5.3 Ovary Weight, Cysts and The Classic PCOS Ovarian Phenotype 
 
Global and neuron but not granulosa cell loss of AR signaling protects against the development of 
the classic polycystic ovarian phenotype in the PCOS mouse model. (A) Ovary weights confirming 
DHT-induced reduction in ovarian weight in WT mice, and showing no reduction in ovarian weight in 
DHT-induced PCOS ARKO female mice. Data are the mean ± SEM; n = 5–9 per genotype/treatment 
group. (B) Average number of atretic cyst-like follicles per ovary displaying no significant development 
of cysts in DHT-induced PCOS ARKO females. Data are the mean ± SEM; n = 4 ovaries per 
genotype/treatment group. (C) Histological sections of representative ovaries showing development 
of the classic PCOS ovarian phenotype in DHT-induced PCOS WT but not ARKO and NeurARKO ovaries. 
(D) Histological section of representative cyst found in all groups treated with DHT. Cysts display a 
thinned and discordant granulosa cell layer, a dispersed theca cell layer (arrow), and an oocyte with a 
fragmented nucleolus that has lost connection with most or all of its surrounding granulosa cells. 
G, genotype; ns, no significant difference; T, DHT treatment; *, significant difference. (Magnification: 
10x.) (*P < 0.05, two-way ANOVA) 
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Neuron but not granulosa cell AR signaling is required for the reduction in large antral 
follicle health in the PCOS mouse model. In agreement with previous studies using this PCOS 
mouse model (Chapter Three), antral follicle populations were not altered by DHT-induced 
PCOS in any treated groups (Figure S5.2). However, DHT treatment induced the PCOS trait of 
a significant increase in the proportion of morphologically unhealthy follicles in WT, NeurWT 
and GCWT females, at both the small (P < 0.01) and large (P < 0.05) antral developmental 
stages (Figure 5.4 A and B), whereas global AR insensitivity prevented the development of 
unhealthy antral follicles by DHT treatment of ARKO females (Figure 5.4 A and B). NeurARKO 
ovaries displayed a protection from DHT-induced increases in unhealthy large (Figure 5.4 B), 
but not small (P<0.01; Figure 5.4 A) antral follicles. However, a granulosa cell-specific loss of 
AR signaling did not protect against the DHT-induced increase in unhealthy small (P < 0.05) or 
large (P < 0.05) antral follicles in GCARKO ovaries (Figure 5.4 A and B).  
Large antral follicles in DHT treated WT, NeurWT and GCWT ovaries displayed a reduction in 
granulosa cell layer thickness (P < 0.01, Figure 5.4 C, E i and E ii) but a significant increase in 
theca cell layer area (P < 0.01, Figure 5.4 D, E iii and E iv). These features were fully prevented 
by a global loss of AR signaling (Figure 5.4 C and D). Granulosa cell specific loss of AR signaling 
inhibited the development of diminished granulosa cell layers, but not the increase in theca 
cell area (P < 0.05, Figure 5.4 C and D). Neuron-specific loss of AR signaling did not protect 
against DHT-induced diminished granulosa cell layers (P < 0.05), or an increase in theca cell 
layer area (P < 0.01) in NeurARKO antral follicles (Figure 5.4 C and D).  
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Figure 5.4 Follicle Health 
 
 
Global and neuron but not granulosa cell loss of AR signaling protects against the reduction on large 
antral follicle health in the PCOS mouse model. (A) Percentage of unhealthy small antral follicles per 
ovary, confirming DHT-induced increase in unhealthy small antral follicles in WT mice, and showing 
no significant decrease in small antral follicle health in DHT-induced PCOS ARKO ovaries. Data are the 
mean ± SEM; n = 4 ovaries per genotype/treatment group. (B) Percentage of unhealthy large antral 
follicles per ovary showing no significant decrease in large antral follicle health in DHT-induced PCOS 
ARKO or NeurARKO female mice. Data are the mean ± SEM; n = 4 ovaries per genotype/treatment 
group. (C) Average thickness of granulosa layer per follicle displaying no reduction in granulosa cell 
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layer thickness in DHT-induced PCOS ARKO or GCARKO ovaries. Data are the mean ± SEM; n = 7–24 
follicles per genotype/treatment group. (D) Average percentage theca area per follicle showing no 
significant increase in theca cell area in DHT-induced PCOS ARKO ovaries. Data are the mean ± SEM; n 
= 7–24 follicles per genotype/treatment group. (E) Histological sections representing the effects of 
DHT on granulosa cell layer thickness (ii, double-ended arrow) and percentage theca area (iv, white 
line) compared to controls (i and iii, respectively). G, genotype; ns, no significant difference; T, DHT 
treatment; *, significant difference. (Magnification: 10x.) (*P < 0.05, two-way ANOVA) 
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Neuron but not granulosa cell AR signaling is required for the development of obesity in the 
PCOS mouse model. All wild-types groups (WT, NeurWT or GCWT) that received DHT 
treatment exhibited a significant increase in body weight (P < 0.01, Figure 5.5 A) and 
parametrial (P < 0.01, Figure 5.5 B), retroperitoneal (P < 0.01), inguinal (P < 0.05) and 
mesenteric fat pad weights (P < 0.05). However, both global (ARKO) and neuron (NeurARKO) 
AR inactivation fully prevented this DHT-induced increase in body and fat pad weights (Figure 
5.5 A, B and C). In contrast, a granulosa cell specific loss of AR signaling did not inhibit the 
development of obesity with GCARKO females displaying a significant DHT-induced increase 
in body weight (P < 0.01) and parametrial (P < 0.01), retroperitoneal (P < 0.01), inguinal (P < 
0.05) and mesenteric (P < 0.05) fat pad weights (Figure 5.5 A and B). 
A loss of neuron but not granulosa cell AR signaling partially protects against the 
development of adipocyte hypertrophy in the PCOS mouse model. DHT treatment induced 
a significant decrease in serum adiponectin levels in all DHT-treated groups (P < 0.01, Figure 
5.6 A), except in global ARKO females where DHT did not change serum adiponectin levels 
(Figure 5.6 A). 
All WT groups exhibited a marked DHT-induced increase in adipocyte cell size (P < 0.01, Figure 
5.6 B and C), but this was fully prevented by global loss of AR signaling (Figure 5.6 B and C). 
DHT treatment also resulted in adipocyte hypertrophy in NeurARKO (P < 0.01) and GCARKO 
(P < 0.01) mice compared with genotype-matched control mice (Figure 5.6 B and C). However, 
the degree of adipocyte hypertrophy observed in DHT-treated NeurARKO females was 
significantly less than that exhibited in all DHT-treated WT (P < 0.01) and GCARKO (P < 0.01) 
parametrial fat pads (Figure 5.6 B and C).  
Fasting glucose levels were significantly increased in all WT mice (WT, NeurWT or GCWT) after 
DHT treatment (P < 0.05, Figure 5.6 D). Global loss of AR signaling eliminated this effect but 
DHT-treated NeurARKO (P < 0.01) and GCARKO (P < 0.01) mice still exhibited significantly 
raised fasting glucose levels (Figure 5.6 D). Similarly an effect of DHT treatment was apparent 
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with regards to overall glucose tolerance (2-way ANOVA main effect, P < 0.01; Figure 5.6 E), 
although DHT treatment had no effect on insulin tolerance (Figure S5.3). 
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Figure 5.5 Body Weight, Parametrial Fat Deposits and DEXA Scans 
 
 
Global and neuron but not granulosa cell loss of AR signaling protects against the development of 
obesity in the PCOS mouse model. (A) Body weight, confirming DHT-induced increased body weight 
in WT mice, and showing no significant increase in body weight in DHT-induced PCOS ARKO or 
NeurARKO female mice. Data are the mean ± SEM; n = 5–9 mice per genotype/treatment group. (B) 
Parametrial fat deposit weight showing no significant increase in adiposity in DHT-induced PCOS ARKO 
or NeurARKO female mice. Data are the mean ± SEM; n = 5–9 per genotype/treatment group. (C) 
Representative dual-energy X-ray absorptiometry (DEXA) images showing no development of obesity 
in DHT-induced PCOS ARKO female mice. G, genotype; ns, no significant difference; T, DHT treatment; 
*, significant difference. (*P < 0.05, two-way ANOVA)  
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Neuron but not granulosa cell AR signaling is required for the development of dyslipidemia 
in the PCOS mouse model. Increased cholesterol levels were present in all DHT-treated wild-
type groups (P < 0.01, Figure 5.7 A), but not in DHT-treated global and neuron-specific ARKO 
females. DHT-treated GCARKO mice still displayed the DHT-induced increase in serum 
cholesterol levels (Figure 5.7 A). DHT treatment had a significant effect on serum triglyceride 
levels (2-way ANOVA main effect, P < 0.01; Figure 5.7 B) with an increase in triglycerides in all 
three wild-type groups (WT, NeurWT or GCWT), whereas this effect was prevented in ARKO 
and NeurARKO, but not GCARKO female mice (Figure 5.7 B). These results suggest that DHT-
induced dyslipidemia requires a functional AR in neurons but not in granulosa cells. 
Systolic blood pressure was affected by DHT treatment alone (2-way ANOVA main effect, P < 
0.05), but this effect was independent of changes in AR genotype (Figure 5.7 C).  
Wild-type mice (WT, NeurWT or GCWT) treated with DHT displayed a 10- to 20-fold increase 
in hepatic lipid staining compared to controls (P < 0.01, Figure 5.7 D and E). Global loss of AR 
protected against the development of DHT-induced hepatic steatosis in ARKO females. 
GCARKO DHT-treated mice experienced a significant increase in lipid accumulation in the liver 
(P < 0.01). Loss of neuron AR partially protected against DHT-induced hepatic steatosis, as 
lipid accumulation in DHT-treated NeurARKO females was significantly less than that 
exhibited in all DHT-treated WT (P < 0.01) and GCARKO (P < 0.01) livers (Figure 5.7 D and E). 
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Figure 5.6 Adiponectin, Adipocyte Size, Fasting Glucose and Glucose Tolerance 
 
 
Global loss of AR signaling protects against the reduction in adiponectin levels, adipocyte 
hypertrophy and altered glucose homeostasis in the PCOS mouse model. (A) Serum levels of 
adiponectin, confirming DHT-induced suppression of serum adiponectin levels in WT mice and 
showing no significant reduction in adiponectin levels in DHT-induced PCOS ARKO female mice. Data 
are the mean ± SEM; n = 5–7 per genotype/treatment group. (B) Adipocyte size, showing no 
development of adipocyte hypertrophy in DHT-induced PCOS ARKO female mice. Data are the mean 
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± SEM; n = 3 sections per mouse, 3 mice per genotype/treatment group. (C) Histological sections of 
representative parametrial fat pads from each treatment group, showing no development of 
adipocyte hypertrophy in DHT-induced PCOS ARKO female mice. (D) Average fasting glucose levels 
showing no significant increase in glucose levels in DHT- induced PCOS ARKO female mice. Data are 
the mean ± SEM; n = 5–9 per genotype/treatment group. (E) Area under the curve (AUC) analysis of 
the oral glucose tolerance test, showing an overall effect of DHT treatment. Data are the mean ± SEM; 
n = 5–9 per genotype/treatment group. G, genotype; ns, no significant difference; T, DHT treatment; 
*, significant difference. (Magnification: 40×.) (*P < 0.05, two-way ANOVA.) 
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Figure 5.7 Serum Cholesterol and Triglycerides, Blood Pressure and Liver 
Adiposity 
 
 
Global and neuron but not granulosa cell loss of AR signaling ameliorates the development of 
dyslipidemia in the PCOS mouse model.  
(A) Serum cholesterol levels, confirming DHT-induced increased serum cholesterol in WT mice and 
showing no significant increase in cholesterol levels in DHT-induced PCOS ARKO or NeurARKO female 
mice. Data are the mean ± SEM; n = 5–7 per genotype/treatment group. (B) Serum triglyceride levels, 
showing an overall effect of DHT treatment and a nonsignificant trend to increased triglyceride levels 
in all DHT-treated groups, apart from DHT-induced PCOS ARKO and NeurARKO female mice. Data are 
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the mean ± SEM; n = 5–7 per genotype/treatment group. (C) Systolic blood pressure, displaying no 
significant difference between control and DHT-treated PCOS mice of any genotype. Data are the 
mean ± SEM; n = 5–9 per genotype/treatment group. (D) Analysis of liver steatosis by oil red O staining, 
showing no significant increase in the presence of steatosis in DHT-induced PCOS ARKO female mice. 
Data are the mean ± SEM; n = 3 sections per mouse, 3 mice per genotype/treatment group. (D) 
Histological sections of representative liver sections stained with oil red O, showing reduced lipid 
staining in DHT-induced PCOS ARKO livers. G, genotype; ns, no significant difference; T, DHT 
treatment; *, significant difference. (Magnification: 40×.) (*P < 0.05, two-way ANOVA.) 
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5.6 Discussion 
Although hyperandrogenism is a key trait of PCOS (652) and experimentally induces a range 
of reproductive, endocrine and metabolic PCOS characteristics in various animal models 
(411,470,604), the tissue or organ-specific mechanisms through which androgens elicit these 
key aspects of the PCOS phenotype remain unclear. In the current study we provide evidence 
that supports AR signaling as an important mediator in the development of features of 
experimental PCOS (Table 5.2). Our data demonstrates that, in particular, extra-ovarian 
neuroendocrine AR sites of androgen action are predominantly involved in the pathogenesis 
of  multiple key PCOS characteristics. This provides strong experimental support for recent 
GWAS findings that highlight the importance of gonadotropin action in the genetic origins of 
susceptibility to PCOS (334-336). In concert these findings suggest neuroendocrine AR 
signaling as a key target for the development of novel mechanism-based PCOS treatments. 
Our data shows that by combining a DHT-induced PCOS mouse model with global, tissue- and 
cell-specific ARKO mouse models, the induction of the PCOS traits of acyclicity and 
anovulation require AR signaling. These findings are in agreement with clinical evidence 
supporting a direct role for androgen actions in the development of dysfunctional menstrual 
cycling and ovulation in PCOS, as prolonged treatment with the AR antagonist flutamide is 
reported to restore menstrual cycle regularity and ovulation in some women with PCOS 
(585,586).  Interestingly, by contrast the treatment of women with PCOS with estrogen 
blockage, either by anti-estrogen (clomiphene citrate) or an aromatase inhibitor (letrozole) 
which increases FSH secretion, is rapidly effective at inducing ovulation (211). This infers that 
hypothalamic-pituitary feedback response in PCOS women is functional but that the longer 
time to effective treatment by androgen blockade may involve more complex, possibly multi-
step underlying mechanisms of androgen mediated effects, compared with the more direct 
mode of action of estrogen blockade. Importantly, our findings highlight the importance of 
extra-ovarian AR actions in the pathogenesis of ovulatory dysfunction in PCOS. We show that 
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females treated with DHT display aberrant ovulatory function when they have fully functional 
AR actions (intact WT females and ovariectomized WT females bearing WT ovary transplants) 
or a loss of AR signaling in the ovary only (GCARKO females and ovariectomized WT females 
bearing ARKO ovary transplants). However, females with an extra-ovarian loss of AR actions 
(NeurARKO females and ovariectomized ARKO females bearing WT ovary transplants) are 
protected against DHT-induced reduction in ovulation indicated by reduced numbers of 
corpora lutea. This suggests that hyperandrogenism-induced PCOS requires AR actions in 
neurons and that the AR in granulosa cells is less involved in the development of PCOS 
acyclicity. There was a discrepancy between the ovulatory function and cyclicity in NeurARKO, 
and a lack of an overall significant effect on serum P4 and LH, most likely due to all cycling 
mice being collected on the afternoon of diestrus, when serum P4 and LH levels are very low. 
Nevertheless, the presence of corpora lutea in NeurARKO ovaries conclusively confirms the 
occurrence of recent ovulations. In addition, by undertaking reciprocal ovary transplants 
between WT and ARKO females we decisively proved that extra-ovarian AR-signaling are 
crucial in the development of the PCOS traits of irregular cycles and ovulatory dysfunction. 
Taken together with the recent GWAS findings that implicates alterations in gonadotropin 
secretion in origins of PCOS (334-336), our findings support the previous hypothesis that 
hyperandrogenism may impair neuronal circuits in the brain, leading to a disruption in sex 
steroid feedback mechanisms and abnormal gonadotrophin secretion, and subsequent 
ovulatory dysfunction (263,657). Current evidence from a mouse PCOS model points to a role 
for androgen excess in promoting impaired progesterone-sensitive GABAergic input to GnRH 
neurons within the arcuate nucleus of the hypothalamus (263). Although species differences 
occur between humans and rodents in the site of action of positive estradiol feedback 
required to trigger the ovulatory LH surge (658), it is clear that alterations in GnRH pulse 
generation are present in women with PCOS (262). 
Classic PCOS multi-cystic ovaries were observed in all DHT-treated WT groups, whereas this 
was prevented by global and neuron loss of AR actions, confirming that AR-mediated 
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androgen action is required for the development of this key feature of PCOS. Similarly, the 
PCOS ovarian morphological features of reduced follicular health and antral follicle granulosa 
cell layer attenuation but theca cell layer hypertrophy were induced by DHT in all WT mice, 
but were not present in DHT-treated ARKO females. Furthermore, large antral follicle health 
was maintained in DHT-treated NeurARKO ovaries, while granulosa cell wall thickness was 
not attenuated in GCARKO females. This finding, together with the observation that a few 
DHT-treated GCARKO females display intermittent cycles and some CLs, implies that in 
addition to extra-ovarian androgen action, additional loci of ovarian AR actions are involved 
in mediating the PCOS reproductive phenotype. 
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Table 5.2 The Effects of Androgen Receptor Signaling Loss on The Development of PCOS Traits 
 
 
Summary of the effects of global (ARKO), neuronal-specific (NeurARKO), or granulosa cell-specific (GCARKO) loss of androgen receptor signaling compared to 
WT mice with DHT-induced PCOS. 
, clinical PCOS trait present; , clinical PCOS trait not present; partial, effect of DHT evident but not to the same extent seen in WT mice.  
*↑ In humans; ↓ in mice.†↑Cholesterol + clear trend toward ↑triglycerides.  
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Obesity is very common among women with PCOS and in turn leads to more severe 
hyperandrogenism (166,652). We observed significant increases in body and fat pad weights 
in all DHT-treated WT females, whereas global and neuron-specific disruption of AR signaling 
protected females from increased adiposity, implying that hyperandrogenism is directly 
involved in the high prevalence of obesity in women with PCOS. Supportive clinical evidence 
comes from findings that obese PCOS women consuming a hypocaloric diet together with an 
androgen antagonist (flutamide) exhibited additional favourable decreases in visceral fat 
compared with diet alone (659,660).  
Adipocyte dysfunction is also linked to PCOS pathogenesis (624,625). Adiponectin, postulated 
to be a beneficial adipokine due to its insulin sensitizing property and antiatherogenic action 
(661), is reduced in women with PCOS (376). Treatment with adiponectin in a rat model of 
PCOS ameliorates the PCOS phenotype by reversing acyclicity and PCOS ovarian features, and 
also improves glucose homeostasis (662). Serum adiponectin levels were reduced in our PCOS 
mouse model and this effect was protected by global loss of AR function, but not by neuron- 
or granulosa cell-specific loss of AR actions. Altered adipose structure has been reported in 
PCOS women (663), and is linked with androgen excess as prenatally androgenized females 
monkeys display impaired adipogenesis (664). Adipocyte hypertrophy and hepatic steatosis 
(resembling non-alcoholic fatty liver disease) were exhibited in all DHT-treated wild-type 
groups, but were absent in global ARKO females. Granulosa cell-specific loss of AR signaling 
did not protect against these lipid metabolic PCOS traits, but a neuron-specific loss of AR 
actions did offer partial protection, implying that other sites of AR signaling are required for 
full development of these traits. Although hypertrophic adipocytes are inherently insulin 
resistant, insulin resistance was not present in any of the DHT treated mice. Nevertheless, 
glucose homeostasis was consistently impaired with elevated fasting glucose levels observed 
in all DHT-treated wild-type groups as well as neuron- and granulosa cell-specific ARKO 
females, whereas global AR loss prevented the fasting hyperglycaemic effects of DHT 
treatment. Altered glucose homeostasis in conjunction with the increase in hepatic steatosis 
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observed in DHT-treated wild-type groups, indicates a significant role for AR signaling in 
regulating glycogenolysis. Dyslipidemia, a key risk factor for cardiovascular disease, was 
observed in all DHT-treated wild-type females. Global- or neuron-specific loss of AR signaling 
prevented DHT-induced dyslipidemia, as opposed to mice lacking granulosa cell AR which 
developed the condition. Further studies are needed to understand how central AR signaling, 
in particular, leads to the lipid metabolic disturbance of PCOS. However, the findings that 
increased subcutaneous fat mass and cholesterol levels induced by a high fat diet can be 
alleviated in ovariectomised female mice treated with DHT (665), indicates that a balance in 
direct AR actions is required to maintain normal metabolic function. 
By combining unique global and cell specific ARKO mouse models with a PCOS mouse model, 
we have revealed that hyperandrogenism, acting directly via the AR and independent of 
estrogenic effects, is required for the development of several key PCOS traits in an 
experimental mouse model. None of the inducible features of PCOS observed in WT mice 
were generated in mice with a global AR inactivation, indicating that AR-mediated androgen 
actions are critical in the pathogenesis of these traits. Our present findings extend our 
previous findings that global androgen insensitivity prevents the induction of experimental 
PCOS features in mature mice (Chapter Four). Moreover, we provide evidence to support a 
hypothesis that the development of many key PCOS traits do not require AR signaling in 
granulosa cells, but rather anovulation, impaired antral follicle health, obesity and lipid 
metabolic disturbance are all dependent on a functional neuronal AR signaling network. Yet 
neither NeurARKO or GCARKO mouse models fully protected against the development of all 
PCOS traits. This indicates that the development of some PCOS pathology require direct AR-
mediated androgen actions acting via other sites, or are a downstream response to the 
altered PCOS environment. These findings demonstrate the complexity of the mechanisms 
regulating PCOS pathogenesis, and support the notion that the development of PCOS involves 
hyperandrogenic actions acting within multiple tissues. Taken together our findings provide 
strong evidence that hyperandrogenism plays a direct pathogenic role involving a 
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neuroendocrine site of action in the development of key PCOS traits, and supports a more 
tissue and/or AR-mediated targeted approach in the development of novel therapeutic 
treatments. 
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5.7 Supporting Information 
Figure S5.1 Characterization of Estrous Cycle Patterns 
 
 
Estrous cycle pattern in representative females. D, diestrus; E, estrus; M, metestrus; P, proestrus. 
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Figure S5.2 Quantification of Antral Follicle Populations 
 
 
Average number of small antral (A) and large antral (B) follicles per ovary. Data are the mean ± SEM; 
n = 4 ovaries per genotype/treatment group. 
 
 
 
Figure S5.3 Characterization of Insulin Tolerance 
 
  
AUC analysis of insulin tolerance, showing an effect of genotype only (*P < 0.01, two-way ANOVA). 
Data are the mean ± SEM; n = 5–9 per genotype/treatment group.  
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Figure S5.4 Characterization of Global and Tissue-Specific ARKO Mice 
 
 
Representation of RT-PCR androgen receptor analyses using cDNA extracted from WT, ARKO, NeurWT, 
NeurARKO, GCWT, and GCARKO ovary, uterus, brain, and pituitary. The intact AR exon 3 PCR product 
is 288 bp long, whereas the excised AR exon 3 PCR product is 171 bp. Mouse β-actin was used as an 
internal control, with a PCR product of 431 bp. 
 
 
 
Table S5.1 Baseline Phenotypic Characteristics of the Different ARKO Mouse 
Models, Compared with Their Strain-Matched WT Controls 
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6.1 Final Discussion 
While the role and function of androgens in male physiology is well characterised, the 
importance of these classically male hormones in female reproductive physiology, particularly 
in normal and pathological ovarian function, is only recently coming to light (516,523,538). 
PCOS is the most common endocrinopathy in reproductive-aged women, affecting 5-15% of 
women worldwide today (143,292), and is the leading cause of anovulatory infertility in these 
women (666). PCOS encompasses a broad spectrum of reproductive symptoms including 
menstrual irregularities, ovulatory dysfunction and polycystic ovaries, aberrations to normal 
endocrine function such as hyperandrogenism, luteinising hormone hypersecretion and 
decreased P4, and metabolic abnormalities incorporating obesity, insulin resistance and 
T2DM, non-alcoholic fatty liver and an increased risk of cardiovascular disease (292,579).  
Despite the high prevalence of hyperandrogenism, the role of androgens in the 
etiopathogenesis of PCOS is not fully understood. Exposure to high levels of endogenous 
androgens has been well reported to cause symptoms similar to that of PCOS in congenital 
adrenal hyperplasia (551). The same is true of exogenous hyperandrogenism such as that seen 
in transsexuals undergoing a female-to-male transition with hormone replacement therapy 
(552). Furthermore, theca cells taken from the ovarian follicles of human PCOS ovaries have 
been shown to produce androgens at levels 20 times those taken from normal ovaries (584). 
Moreover, the effective use of androgen receptor antagonists, such as flutamide, to improve 
ovulatory dysfunction in some PCOS women lends great weight to the hypothesis that 
androgens play a critical, and causative role in the development of PCOS (585,586). 
The aim of this work was to unravel the role of androgen action in PCOS by employing a mouse 
model optimised to replicate an extensive range of human features of PCOS. The purpose of 
the first study (Chapter Three) was to generate such a model and comprehensively 
characterise the features produced by hyperandrogenism. Several rodent PCOS models have 
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been described in the literature, including treatment with androgens, estrogens, aromatase 
inhibitors and antiprogestins, as well as changes in light exposure and genetic alterations all 
being used to induce PCOS-like characteristics. As hyperandrogenism is a unifying feature of 
PCOS diagnoses, models utilising androgen treatment are favoured and have been shown to 
exhibit features such as acyclicity, anovulation, polycystic ovaries, hyperandrogenism and 
insulin resistance (462,466). However, when produced by exposure to the aromatizable 
androgen T and TP, it is difficult to differentiate between androgenic effects mediated via the 
AR and estrogenic actions by way of the ER. On the other hand, DHT cannot be aromatised to 
estrogens and provides the opportunity to limit the results to those facilitated solely by the 
AR. Rodent models employing a prenatal treatment with DHT have been reported to display 
irregular reproductive cycles and LH hypersecretion in addition to glucose intolerance 
independent of body weight (261,463,467). In mice, prenatal androgenisation with DHT has 
resulted in disrupted estrous cycles, delayed puberty and reduced fertility, as well as reduced 
CL numbers (468). Very few studies have utilised a postnatal DHT treatment in mice and a 
comprehensive analysis of the reproductive, endocrine and metabolic features present in this 
model is lacking. We have provided the first such analysis of this model, in addition to 
establishing the first letrozole and long-term DHEA mouse models of PCOS. Findings from this 
study show that long-term postnatal treatment with the potent bioactive androgen DHT, 
beginning at 3 weeks of age, replicates the most features in these mice that are consistent 
with those exhibited in human PCOS. Importantly, we have overcome the differences in 
strain-specific responses reported by others (615) by utilising a single strain of experimental 
mice.  
The second study contained within this work (Chapter Four) aimed to explore the popular 
theory that PCOS has its origins in fetal life (667), as well as confirming that the effects of 
androgens, as observed in our first study, are in fact androgenic in nature and mediated by 
the AR. A direct role for AR-mediated actions in normal and pathological female reproductive 
function has been proven by studies using AR knockout mouse models (ARKO) (571,572,575), 
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revealing the AR-mediated androgen actions are key in maintaining female fertility by 
optimizing ovarian follicle dynamics and ovulation (523,538,594). Additionally, aberrations in 
the CAG repeat polymorphism within the AR have been linked to the development of PCOS, 
strengthening the importance of AR signalling in the pathogenesis of PCOS. Results from this 
work solidify the importance of genomic AR signalling in the etiopathogeneis of PCOS. Using 
our prenatal model of PCOS generation via DHT treatment, combined with our unique model 
of global AR inactivation, we have shown that functional AR signalling is critical for the 
development of androgen-induced PCOS features. Prenatally androgenised WT mice 
displayed typical features of human PCOS including irregular cycles, oligo- or anovulation, the 
presence of atretic cystic follicles within the ovary and adipocyte hypertrophy. In contrast, 
homozygous ARKO mice displayed no hyperandrogenic features despite prenatal 
androgenisation. Interestingly, mice heterozygous for AR inactivation were also unaffected 
by androgen treatment, demonstrating that haploinsufficiency of the AR is enough to fully 
protect these mice from DHT-induced PCOS. As PCOS is often associated with dysregulation 
of feedback on the HPG axis (149), this study also investigated the effects of prenatal 
androgenisation on the E2-mediated negative feedback on the hypothalamus by way of 
quantifying the expression of several key neuropeptides (639). However, in the present study 
of WT mice, inhibition of LH secretion after E2 administration was maintained, expression of 
Kiss1, NKB, Dyn and their respective receptors were also unchanged following prenatal 
androgenisation. These results, combined with a lack of LH hypersecretion, suggest that in 
this prenatal mouse model of PCOS, the DHT-induced PCOS phenotype does not include 
disruption of GnRH secretion mediated by perturbations in negative feedback of the HPG axis. 
The final study (Chapter Five) was designed to elucidate the site of AR-mediated androgen 
actions in PCOS as the tissue or organ-specific mechanisms through which androgens elicit 
their effects have not yet been clarified. Because of this, current treatments for PCOS are 
systemic rather than targeted to the underlying mechanisms of disease. Without knowledge 
of androgen target tissues in PCOS, these mechanism-based treatments remain unachievable. 
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By combining our optimal DHT-induced model of PCOS with global, tissue- and cell-specific 
ARKO mouse models we have shown that the induction of PCOS by androgens requires 
functional AR signalling, as ARKO mice display no PCOS traits following long-term exposure to 
DHT. This is supported by clinical evidence showing that extended treatment with the AR 
antagonist flutamide is reported to restore menstrual cycle regularity and ovulation in some 
women with PCOS (585,586). In contrast, for the majority of PCOS traits, GCARKO mice were 
not protected from induction of PCOS by DHT, suggesting that intra-ovarian androgen actions, 
at least at the level of the granulosa cells, do not play an important role in the development 
of the PCOS phenotype. This was also supported by the transplantation of ARKO ovaries into 
WT hosts prior to PCOS induction, which was also not able to prevent the onset of 
reproductive PCOS symptoms (disrupted cycling and anovulation) in these mice.  
While an ovarian site of androgen action, outsides of the granulosa cells, cannot yet be 
completely discounted, characterisation of the theca cell androgen receptor knockout mouse 
(ThARKO) has revealed that functional AR signalling in the theca cells is not required to 
maintain normal reproductive function or ovarian development (578). However, under 
hyperandrogenic conditions (by way of exogenous DHT treatment), ThARKO mice 
experienced a partial rescue of reproductive function thanks to the lack of normal AR 
signalling in the ovarian theca cells, indicating that the AR within the theca cells may play an 
important role in pathological conditions such as PCOS and certainly warrants further 
investigation into the mechanisms behind these observations. Also pointing to the possible 
importance of theca cell androgen action in conditions such as PCOS is a recent study of a 
theca cell-specific knockout of phosphatase and tensin homolog (Pten) (668). Pten is an 
important mediator of the PI3K cell signalling pathway that regulates the cell cycle (669). Mice 
with this mutation (tPtenMT) displayed hyperandrogenemia and ovulatory dysfunction, two 
key characteristics of human PCOS, suggesting that Pten-mediated dysregulation of the cell 
cycle may be involved in the pathogenesis of PCOS (668).  
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Importantly, our findings revealed that it is extra-ovarian neuroendocrine AR-mediated 
actions that are key in the pathogenesis of PCOS. NeurARKO mice did not develop the majority 
of PCOS traits observed in their strain-matched WT littermates such as oligo- or anovulation, 
increases in unhealthy large antral follicles and fat accumulation. Additionally, supporting this 
is the finding that ARKO mice bearing ovaries transplanted from WT donors were also 
protected from the adverse effects of DHT treatment on cycling and ovulation due to their 
lack of functional extra-ovarian AR signalling. The idea that the site of androgen action in PCOS 
is neuroendocrine in nature is reinforced by the clinical use of the neurokinin-3 (NK3) receptor 
agonist AZD4901.  The ligand for the NK3 receptor, kisspeptin-neurokinin B (NKB), is a key 
regulator of GnRH secretion and therefore LH pulsatility (670,671). In a recent, randomized 
controlled trial AZD4901 was shown to reduce LH pulse frequency as well as serum LH and T 
concentrations in PCOS patients (672). This strongly supports the theory that targeting the 
neuroendocrine control of reproduction may prove an effective approach for the treatment 
of PCOS.  
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6.2 Future Directions of Study 
These studies have provided an extensive evaluation of a mouse model of human PCOS in 
which to study a wide range of features associated with this complex condition. Future studies 
utilising this model could investigate the role of androgen action in adipose tissue in the 
development of PCOS. The immerging evidence that adipose tissue functions as an endocrine 
organ capable of producing steroids (673), such as androgens, has highlighted adipose as a 
future target of examination into the tissue- or cell-specific sites of androgen action in PCOS. 
The recent establishment of an adipocyte cell-specific ARKO mouse line (fARKO) (674) will 
result in the ability to analyse the effects of adipose tissue AR inactivation on the pathogenesis 
of PCOS in our mouse model. 
Our mouse model of PCOS could also be used to study the improvement of treatments for 
infertility experienced with PCOS. Despite advances such as IVF and IVM, infertile women 
suffering from PCOS seeking fertility via ART achieve fewer pregnancies due to reduced 
conception and implantation and increased early miscarriage rates, reflecting suboptimal 
oocyte functional viability (675-678). The mouse provides the opportunity to recover multiple 
follicles and/or oocytes and may provide valuable insights into the improvement of in vitro 
culture systems as well as stimulation protocols and ART procedures. 
Now that this study has revealed that an extra-ovarian neuroendocrine site is involved in the 
androgen-induced pathogenesis of PCOS, a key direction of future study will be to pinpoint a 
more specific site within the brain in order to provide a realistic drug target for a more precise 
treatment in the future. Potential targets could include two subsets of neurons found within 
the arcuate nucleus of the hypothalamus, those expressing the agouti-related peptide (AgRP) 
or those expressing pro-opiomelanocortin stimulating hormone (POMC) (679). Both neuron 
types have been shown to be involved in regulating appetite with AgRP neurons playing a 
stimulatory role while POMC neurons involved in suppressing appetite (680). It is reasonable 
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to theorise that targeting these neuronal populations, either separately or in combination, 
for AR inactivation using cre recombinase enzymes specific to these cell types (681) may 
ameliorate the metabolic dysfunction seen in PCOS patients. If this were the case, it could 
provide an alternative to systemic treatments such as flutamide, confining the antiandrogen 
effects to the central nervous system and potentially reducing the side effects experienced 
by patients who are prescribed these medications for the management of their PCOS 
symptoms (679). 
Going forward, and based on the results of our work, future studies must focus on elucidating 
the underlying molecular mechanisms involved in androgen action in PCOS. It is by unravelling 
these fundamental mechanisms that a true understanding of this multifaceted syndrome can 
begin to be established. With this understanding development of tissue-specific, or even AR 
targeted, interventions can become the focus of future research and a potential cure for PCOS 
can be a realistic goal for the not too distant future. 
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6.3 Conclusion 
The work contained within this thesis has provided compelling evidence for the pivotal role 
of androgens in the etiopathogenesis of PCOS. We have developed an optimised mouse 
model of PCOS, with hyperandrogenism at its core, of which the future uses for further 
research are only limited by current methods of genetic manipulations and suitability of mice 
for the particular research area of interest. We have extensively characterised the effects of 
global androgen receptor inactivation on the PCOS phenotype as well as tissue- and cell 
specific inactivation in the brain and granulosa cells, respectively. Our findings have shown 
that extra-ovarian neuroendocrine AR-mediated androgen actions are key in the 
development of PCOS and provide realistic targets for the future development of novel 
treatments for PCOS. This work has provided important insights into and made significant 
progress in unravelling the role of androgens in Polycystic Ovary Syndrome. 
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Appendix One 
Genotyping of Mice and Model Validation 
PCR 
All PCR reagents (with the exception of PCR primers (Section 1.2.2)) were supplied by Bioline 
(Alexandria, NSW, Australia) unless otherwise stated. 
Cre PCR 
Reagents  Thermocycler Steps 
4µl 5x MyTaqTM Red Reaction Buffer  94°C for 3 minutes 
1µl MyTaqTM Red DNA Polymerase (5u/µl)  94°C for 1 minute 
0.5µl CRE-F forward primer (10µm)  68°C for 1 minute 
0.5µl CRE-R reverse primer (10µm)  72°C for 1 minute 
2µl DNA template for genotyping  Repeat steps 2-4 for a total of 30 cycles 
12µl Milli-Q water  72°C for 5 minutes 
Total volume = 20µl  Hold at 10°C 
 
ARflox PCR 
Reagents  Thermocycler Steps 
5µl 5x MangoTaqTM Reaction Buffer  94°C for 3 minutes 
0.125µl MangoTaqTM (5u/µl)  94°C for 1 minute 
0.5µl AREX3-F forward primer (10µm)  58°C for 1 minute 
0.5µl ARNeo-F forward primer (10µm)  72°C for 1 minute 
1µl ARIN3-R reverse primer (10µm)  Repeat steps 2-4 for a total of 30 cycles 
1µl MgCl2 (50µm)  72°C for 5 minutes 
2µl dNTP Mix (10mM)  Hold at 10°C 
2µl DNA template for genotyping   
12.875µl Milli-Q water   
Total volume = 25µl   
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ARCut PCR 
Reagents  Thermocycler Steps 
4µl 5x MyTaqTM Red Reaction Buffer  94°C for 3 minutes 
1µl MyTaqTM Red DNA Polymerase (5u/µl)  94°C for 1 minute 
0.5µl ARCut-F forward primer (10µm)  62°C for 1 minute 
1µl ARIN3-R reverse primer (10µm)  72°C for 1 minute 
2µl DNA template for genotyping  Repeat steps 2-4 for a total of 35 cycles 
11.5µl Milli-Q water  72°C for 5 minutes 
Total volume = 20µl  Hold at 10°C 
 
SRY PCR 
Reagents  Thermocycler Steps 
5µl 5x MangoTaqTM Reaction Buffer  94°C for 5 minutes 
0.2µl MangoTaqTM (5u/µl)  94°C for 1 minute 
0.5µl SRY-F forward primer (10µm)  66°C for 1 minute 
0.5µl SRY-F forward primer (10µm)  72°C for 1 minute 
1µl MgCl2 (50µm)  Repeat steps 2-4 for a total of 30 cycles 
2µl dNTP Mix (10mM)  72°C for 5 minutes 
2µl DNA template for genotyping  Hold at 10°C 
13.8µl Milli-Q water   
Total volume = 25µl   
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RNA Extraction 
1. During the collection of tissues, prior to snap freezing, cut the brain into four equal 
quarters. Keep uterus, ovaries and pituitary whole. Weigh each tissue. 
2. The following table provides the volumes of all reagents used which are proportionate 
to the average weight of the tissue from which RNA was being extracted.  
Tissue 
Average 
Weight 
(mg) 
TRI 
Reagent 
(ml) 
Chloroform 
(µl) 
Isopropanol 
(µl) 
80% 
ETOH 
(ml) 
Final 
Resuspension 
(RNase-free 
H2O - µl) 
Brain 100 1.5 350 750 1.5 100 
Uterus 65 1.0 225 500 1.0 50 
Ovary x2 10 0.5 125 250 0.5 10 
Pituitary 2 0.5 125 250 0.5 10 
 
3. Perform RNA extraction of each quarter of the brain separately. This will be pooled 
together after the final step. 
4. Prepared labelled, sterile 5ml tubes with the given volume of TRI Reagent, keeping the 
tubes on ice. Snap frozen tissues should be kept in liquid nitrogen until transferred to 
these tubes. 
5. Swiftly transfer snap frozen tissue into tubes containing Tri Reagent and homogenise 
using a handheld homogeniser. 
6. Clean the homogeniser between each tissue sample by running the homogeniser 
while submerged in two separate beakers of Milli-Q water followed by a beaker of 
80% ETOH. Allow the homogeniser to dry after cleaning. 
7.  Incubate the samples at RT for 5 minutes. 
8. Add the corresponding volume of chloroform to each tube. Cap the tubes tightly and 
shake vigorously for 15 seconds. Incubate at RT for 3 minutes. 
9. Transfer homogenate to 1.5ml RNase-free Eppendorf tubes. Brain and uterus samples 
will need to be split evenly between two tubes to allow the volume to fit. 
10. Centrifuge at 12,000 x g for 15 minutes at 4°C. 
11. Transfer the top aqueous phase into fresh 1.5ml RNase-free Eppendorf tubes. Samples 
that were split in step 9 can now be recombined. 
12. Add the appropriate volume of isopropanol and invert tubes gently to mix. Incubate 
at RT for 10 minutes. 
13. Centrifuge at 12,000 x g for 10 minutes at 4°C. 
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14. Discard the supernatant and wash the pellet by resuspending in 80% ETOH and 
centrifuging at 7,500 x g for 5 minutes at 4°C. Perform this wash step twice. 
15. Remove the final supernatant and allow the tubes to air dry to remove any remaining 
ETOH. Do not allow the pellet to over dry! 
16. Resuspend the final pellet in the volume of RNase-free water listed above. 
17. Combine all four brain samples for each genotype. 
18. Measure the concentration and purity of the RNA using a NanoDrop. RNA must be 
concentrated enough so that 2µg does not exceed 8µl (0.25µg/µl) for cDNA 
conversion. RNA that is too dilute can be concentrated using the method below. 
Concentrating Dilute RNA Samples (Pituitary RNA) 
1. Prepare 3M sodium acetate. 
a. Dissolve 24.609g into 100ml water. 
b. pH to 5.2 using 1M glacial acetic acid. 
2. In a 1.5ml RNase-free Eppendorf tube add: 
a. 10µl pituitary RNA 
b. 1µl 3M sodium acetate 
c. 10µl isopropanol 
3. Incubate at -20°C for 1 hour. 
4. Centrifuge at 20,000 x g for 15 minutes at 4°C. 
5. Remove supernatant and wash pellet with 70% ETOH. 
6. Centrifuge at 20,000 x g for 2 minutes at 4°C. 
7. Remove supernatant and allow pellet to air dry. Again, do not over dry! 
8. Resuspend pellet in 5µl RNase-free water and measure new concentration and purity 
using the NanoDrop. 
DNase Treatment and cDNA Conversion 
1. DNase Treatment 
a. In a sterile 0.5ml PCR Eppendorf tube add: 
i. 1µl 10x DNase I Reaction Buffer 
ii. 1µl DNase I 
iii. 2µg RNA (volume calculated using RNA concentration) 
iv. RNase-free water to bring total volume to 10µl 
b. Incubate at RT for 15 minutes. 
c. Add 1µl 25mM EDTA and run on the following thermocycler program: 
i. 65°C for 10 minutes 
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ii. 70°C for 5 minutes 
2. cDNA Conversion 
a. In a sterile 0.5ml PCR Eppendorf tube add: 
i. 1µl Random hexamers (50ng/µl) 
ii. 1µl Oligo(dT)20 (50µM) 
iii. 1µl 10mM dNTP mix 
iv. 1µg RNA 
v. DEPC-treated water to bring total volume to 10µl 
vi. Prepare a non-template control (NTC) by replacing RNA with water and 
a non-enzyme control (NEC) with RNA that will be used in the following 
steps. 
b. Incubate in thermocycler at 65°C for 5 minutes then on ice for 1 minute to stop 
the reaction. 
c. To each tube add: 
i. 2µl 10x RT buffer 
ii. 4µl 25mM MgCl2 
iii. 2µl 0.1M DTT 
iv. 1µl RNaseOUT 
v. 1µl SuperScript III RT (200U/µl) – do not add this to the NEC tube 
d. Run on the following thermocycler program: 
i. 25°C for 10 minutes 
ii. 50°C for 50 minutes 
iii. 85°C for 5 minutes 
e. Chill on ice for 1 minute. Add 1µl E.coli RNase-H (2U/µl) per tube and incubate 
in thermocycler at 37°C for 20 minutes. 
f. Dilute cDNA with 25µl RNase-free water and store at -20°C until use. 
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Model Validation PCR 
AR Exon 3 PCR 
Reagents  Thermocycler Steps 
4µl 5x MyTaqTM Red Reaction Buffer  94°C for 3 minutes 
1µl MyTaqTM Red DNA Polymerase (5u/µl)  94°C for 1 minute 
0.8µl AR_Exon3_F forward primer (10µm)  62°C for 1 minute 
0.8µl AR_Exon3_ R reverse primer (10µm)  72°C for 1 minute 
2µl DNA template for genotyping  Repeat steps 2-4 for a total of 35 cycles 
11.4µl Milli-Q water  72°C for 5 minutes 
Total volume = 20µl  Hold at 10°C 
 
b-actin PCR 
Reagents  Thermocycler Steps 
4µl 5x MyTaqTM Red Reaction Buffer  94°C for 3 minutes 
1µl MyTaqTM Red DNA Polymerase (5u/µl)  94°C for 1 minute 
1.2µl AR_Exon3_F forward primer (10µm)  62°C for 1 minute 
1.2µl AR_Exon3_ R reverse primer (10µm)  72°C for 1 minute 
2µl DNA template for genotyping  Repeat steps 2-4 for a total of 35 cycles 
10.6µl Milli-Q water  72°C for 5 minutes 
Total volume = 20µl  Hold at 10°C 
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Solutions 
0.5% Toluidine Blue 
• 5% stock solution 
o 5g Toluidine Blue O powder (Amresco, Ohio, USA, 0672-50g) 
o 100ml RO water 
® Dissolve toluidine powder in water by shaking vigorously. Allow to stand 
overnight. Shake vigorously and, again, leave to stand overnight. Filter solution 
through filter paper. 
• 0.5% working solution 
o 10ml 5% stock solution 
o 90ml RO water 
® Dilute stock solution 1:10 to achieve working concentration. 
30% Sucrose Solution v/v 
o 60g sucrose (Sigma-Aldrich, Missouri, USA, S0389) 
o 200ml RO water 
® Shake vigorously until dissolved. Store at 4°C. Make fresh once per month. 
4% Paraformaldehyde (PFA) 
o 4g paraformaldehyde powder (Merck, Darmstadt, Germany, 104005) 
o 50ml RO water 
o 1-3 drops 1M NaOH  
o 50ml Phosphate Buffer (mixed at ratio of 1 part Stock A to 5 parts Stock B) 
§ 0.2M Stock A (acidic) – 2.4g NaH2PO4 (Sigma-Aldrich, Missouri, USA, 
S8282) in 100ml RO water 
§ 0.2M Stock B (basic) – 2.8g Na2HPO4 (Sigma-Aldrich, Missouri, USA, 
S7907) in 100ml RO water 
® Store at 4°C for 1 month. 
® Add PFA powder and RO water to a glass bottle. Place on a heated magnetic 
stirrer (loose lid) and heat until it reaches 60°C. Do not let it boil. Add 1-3 drops 
1M NaOH until the solution clears. Remove from heat and add 50ml phosphate 
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buffer and tightly cap the bottle. Gently invert the bottle to mix. Allow to cool 
at RT before storing at 4°C for 1 week. 
1% Acid Alcohol 
o 5ml Hydrochloric acid (HCl) (Fronine, Thermo Fisher Scientific, VIC, Australia, 
FNN1736) 
o 495ml 70% EtOH 
® Carefully combine in HCl and EtOH, making sure to face all measuring cylinders 
and bottles away from you. Tightly cap the bottle and gently invert to mix. 
Alcoholic Eosin Y 
o Stock 1 
§ 0.575% Glacial acetic acid (Fronine, Thermo Fisher Scientific, VIC, 
Australia, AJA1) in water 
§ Dilute 5.75ml glacial acetic acid into 994.25ml RO water 
o Stock 2 
§ 0.82% Sodium acetate (Fronine, Thermo Fisher Scientific, VIC, 
Australia, AJA680) in water 
§ Dissolve 8.2g sodium acetate in 1L RO water 
o 5g Eosin Y powder (Sigma-Aldrich, Missouri, USA, E4009) 
® Dissolve Eosin Y powder into 295ml Stock 1 and 705ml Stock 2. Allow to 
dissolve overnight. Filter through filter paper and store at RT. 
Oil Red O Stain 
• Oil Red O stock solution 
o 1g Oil Red O Powder (Sigma-Aldrich, Missouri, USA, O0625) 
o 200ml Isopropanol 
® Dissolve the dye powder into the isopropanol by alternating gently shaking in 
a bottle and placing in a 37°C water bath until all powder is dissolved. 
• Working Oil Red O solution 
o 30ml Oil Red O stock solution 
o 20ml Milli-Q water 
® Combine by gentle inversion (do not shake vigorously) and allow to stand for 
10 minutes. Filter through filter paper and use immediately. This working 
solution does not keep and should be made fresh each time. 
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Histology 
Processing and Embedding of Tissues into Paraffin Wax 
Prior to use, tissues were transferred into Leica Jet II tissue processing cassettes (Leica 
Microsystems, Mt Waverley, VIC, Australia, 039441100). Smaller tissues, such as single 
ovaries, were protected by placing between two foam biopsy pads (ProSciTech, Kirwan, QLD, 
Australia, RM-476-1) within the cassette. Cassettes were submerged in 70% EtOH until 
processing began. 
Tissue were processed overnight in the Shandon™ Excelsior™ ES Tissue Processor (Thermo 
Fisher Scientific) through the following steps: 
• 75% EtOH   1 hour 
• 75% EtOH   1 hour 
• 100% EtOH   1 hour 
• 100% EtOH   1 hour 
• 100% EtOH   1 hour 
• 100% EtOH   1 hour 
• 100% EtOH   1 hour 
• Xylene    1 hour 
• Xylene    1 hour 
• Xylene    1 hour 
• Paraffin wax   1 hour and 20 minutes 
• Paraffin wax   1 hour and 20 minutes 
• Paraffin wax   1 hour and 20 minutes 
Tissues were then held in fresh paraffin wax until removed from the processor. 
Tissues were embedded in paraffin wax using the HistoStar™ Embedding Workstation 
(Thermo Fisher Scientific) and left to set before being stored at room temperature until use. 
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Processing and Embedding of Tissues into Methacrylate Resin 
Single ovaries were processed in glycol methanlacrylate acrylic resin (GMA) using the 
Tecknovit 7100 kit (Heraeus Kulzer, Wehrheim, Germany, 64709003) according to the 
manufacturer’s instructions. 
Paraformaldehyde-fixed ovaries were stored in 70% EtOH after fixation. Before processing 
they were transferred into fresh 70% EtOH for 1 hour followed by: 
• 100% EtOH  1 hour 
• 100% EtOH  1 hour 
• 100% EtOH  1 hour 
• Butanol  1 hour 
• Butanol  1 hour 
Whilst the ovaries were in the final butanol, fresh ‘infiltration solution’ was prepared by 
combining: 
• 100ml Technovit 7100 resin (2-hydroxyethyl methacrylate) 
• 1x 1g sachet Hardener I (benzoyl peroxide) 
Ovaries were incubated in a 50/50 mixture of ‘infiltration solution’ and 100% EtOH for 2 
hours. During this time, the ‘embedding solution’ was prepared by mixing: 
• 15ml ‘infiltration solution’ 
• 1ml Hardener II 
1-2ml of ‘embedding solution’ was carefully poured in each mould, taking care not to create 
any bubbles. The ovary was placed in the bottom centre of the mould and a metal block stump 
(labelled with sample ID) was placed on top. A few extra drops of ‘embedding solution’ were 
carefully added around the stump to ensure proper adhesion to the resin. Moulds were 
allowed to rest undisturbed for 2 hours to ensure that the ovaries remained in the centre of 
each mould. Resin blocks were left in the moulds to cure for 2 weeks at room temperature 
before being removed from the mould and allowed to cure for a further 2 weeks prior to use.  
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Haematoxylin and Eosin Staining 
• 100% Xylene (Fume hood)   10 min 
• 100% Xylene (Fume hood)   10 min 
• 100% EtOH     3 min 
• 100% EtOH     3 min 
• 95% EtOH     3 min 
• 70% EtOH     3 min 
• Tap water     Rinse 2x 2 min 
• Harris Haematoxylin (Filtered)  5 min 
• Tap water     Rinse until water is clear (approx. 5 min) 
• Acid Alcohol     Dip 5 times 
• Tap water     Rinse for 4 min 
• Scott’s Bluing Solution   Dip 6 times slowly 
• Tap water     Rinse for 4 min 
• Eosin Y Alcoholic    1 min 
• Tap water     Rinse for 1 min 
• 70% EtOH     3 min 
• 100% EtOH     3 min 
• 100% EtOH     3 min 
• 100% EtOH (Clean)    3 min 
Air dry slides overnight, covered in foil 
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Supplemental Material and Methods Provided for 
Chapter Three 
Methods and Validation of Steroid Assays for Mouse Serum  
A stable-isotope dilution LC–MS/MS method was established using atmospheric pressure 
photoionization to quantify testosterone (T), dihydrotestosterone (DHT), estradiol (E2), 3α-
diol, 3b-diol, dehydroepiandrosterone (DHEA), cortisol (CRS), corticosterone (CS), 17-
hydroxyprogesterone (17OHP4), 17hydroxypregnenolone (17OHP5), androstenedione 
(Adione), progesterone (P4), pregnenolone (P5), androsterone, androstenediol (Adiol), 
allopregnanolone (AlloP5), dihydroprogesterone (DHP) from serum. Sample preparation 
involved liquid–liquid extraction (LLE) with hexane: ethyl acetate (3:2) containing deuterated 
internal standards except for alloP5 and DHP for which deuterated isotopes were not 
available so that d4-P5 and d9-P4, respectively, were used instead. Accuracy was assessed by 
spiked recovery of serum pools, and imprecision by quality controls. 
Sample preparation 
Aliquots (100µL) of serum, standards or quality controls made up to 200µL with phosphate-
buffered saline (PBS) were transferred into 5ml glass tubes. To this, 1ml of hexane: 
ethylacetate (3:2 ratio containing deuterated steroid internal standards) was added, then 
vigorously mixed for 1 minute to extract steroids into the organic layer. Tubes were then 
covered and allowed to phase separate at 4°C for 1 hour and then placed in a -80°C freezer 
for 30 min to freeze the lower aqueous layer. The upper organic layer was then decanted into 
clean glass tubes and the solvent was allowed to evaporate in a fume hood overnight at 37°C. 
Dried samples were re-suspended in 500µl of 20% methanol in PBS (pH 7.4). Tubes were 
mixed for 1 minute and the volume was then transferred into a 96-well microwell plate. A 
425µl aliquot was injected onto the column for LC-MS/MS analysis. 
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Isotope Dilution and Liquid Chromatography – Tandem Mass Spectrometry 
(LC-MS/MS) 
Reconstituted liquid-liquid extract or diluted acetonitrile precipitated sample was injected 
(1mL) onto the column for LC–MS/MS analysis. Chromatographic separation was performed 
on a Shimadzu Prominence system (Shimadzu Scientific Instruments, Columbia, MD) with a 
Restek column, cat #9609312 (Ultra biphenyl, 100cm × 2.1mm, 3µm) with trident ultra-
biphenyl guard cartridge. The LC–MS/MS method is based on an online extraction of the 
injected sample followed by gradient elution of the 17 targeted steroids into the mass 
spectrometer. The solvents were; A H2O, B methanol, and C toluene (dopant). The injected 
sample (425µL) was initially washed with 10% B for 1 minute (1mL/min). The switching valve 
was then activated and the steroids were eluted using a water/methanol gradient 
(0.7 mL/min). The gradient was linear from 60% Solvent B (40% Solvent A) at 1.01 minutes to 
75% Solvent B (25% Solvent A) at 18.00 minutes and then to 100%B in 20 minutes. After this 
time the column was washed with 100% Solvent B for 2.0 minutes before the switching valve 
was returned to the original position, allowing equilibration before the next injection. The 
total run time was 24 minutes. 
Samples were kept at 10 °C and the column temperature held at 30 °C. An API-5000 triple-
quadrupole mass spectrometer (Applied Biosystems/MDS SCIEX, Ontario, Canada) equipped 
with an atmospheric pressure photoionization (APPI) source was operated in both positive 
and negative ion modes for the analysis. The APPI system consisted of a 10eV krypton 
discharge lamp with dopant (toluene) delivery set to 75µL/min. Nitrogen and zero grade air 
were supplied using a PEAK A320DR/NM20ZL unit (Peak Scientific Instruments, Renfrewshire, 
Scotland). Nitrogen was used as curtain gas (12 psi), ion source gas 1 (55 psi), ion source gas 
2 (50 psi) and collision gas (6 psi). Probe temperature was 500°C and the ion spray voltage 
was set to 750 V, and −750 V when in negative mode. Multiple reaction monitoring (MRM) 
was used to quantify the steroids. Settings for the various transitions were optimized by 
infusing pure steroid into the mass spectrometer. Unit mass resolution was used in both 
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mass-resolving quadrupoles Q1 and Q3. A dwell time of 200ms was used for the target 
analytes and 100ms for their corresponding isotopically-labelled internal standards. 
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Optimized Settings for MRM Transitions of Steroids Quantified Using APPI 
 Steroid Ionization mode 
RT 
(min) Ion fragmented 
MRM 
transition 
(Q1 → Q3) 
DP EP CE CXP 
1 E2 −APPI 8.66 [M − H]− 271 → 145 − 80 − 10 − 57 − 12 
 d4-E2 −APPI 8.66 [M − H]− 275 → 147 − 80 − 10 − 57 − 12 
2 T + APPI 14.55 [M + H]+ 289 → 109 80 10 35 12 
 d3-T + APPI 14.55 [M + H]+ 292 → 109 80 10 35 12 
3 DHT + APPI 16.38 [M − H2O + H]+ 273 → 123 80 10 31 12 
 d3-DHT + APPI 16.38 [M − H2O + H]+ 276 → 123 80 10 31 12 
4 3αDiol + APPI 12.01 [M − 2H2O + H]+ 257 → 161 80 10 28 12 
 d3-3αDiol + APPI 12.01 [M − 2H2O + H]+ 260 → 164 80 10 28 12 
5 3βDiol + APPI 11.20 [M − 2H2O + H]+ 257 → 161 80 10 28 12 
 d3-3βDiol + APPI 11.20 [M − 2H2O + H]+ 260 → 164 80 10 28 12 
6 DHEA + APPI 13.90 [M − 2H2O + H]+ 253.1→ 197.1 80 10 30 12 
 d2-DHEA + APPI 13.90 [M − 2H2O + H]+ 255.2→ 197.1 80 10 30 12 
7 Androstenedione + APPI 17.88 [M + H]+ 287.1 → 97.1 80 10 34 12 
 d3-Androstenedione + APPI 17.88 [M + H]+ 290.1 → 100.1 80 10 34 12 
8 Progesterone + APPI 21.25 [M + H]+ 315.3 → 97.1 80 10 34 12 
 d9-Progesterone + APPI 21.25 [M + H]+ 324.3 → 100.1 80 10 34 12 
9 Pregnenolone + APPI 18.94 [M − 2H2O + H]+ 281.1→ 171.1 80 10 35 12 
 d4-Pregnenolone + APPI 18.94 [M − 2H2O + H]+ 285.1→ 175.1 80 10 35 12 
10 17-hydroxyprenenolone + APPI 10.58 [M − 2H2O + H]+ 297.2→ 104.9 80 10 55 12 
 d3-17-hydroxyprenenolone + APPI 10.58 [M − 2H2O + H]+ 300.3→ 105.2 80 10 55 12 
11 17- hydroxyprogesterone + APPI 15.15 [M + H]+ 331.3 → 97.1 80 10 37 12 
 d8-17- hydroxyprogesterone + APPI 15.15 [M + H]+ 339.4 → 100.2 80 10 37 12 
12 Cortisol + APPI 6.35 [M + H]+ 363.2 → 121.3 80 10 35 12 
 d4-Cortisol + APPI 6.35 [M + H]+ 367.3 → 121.3 80 10 45 12 
13 Androsterone + APPI 15.87 [M − 2H2O + H]+ 255.3→ 199.1 80 10 29 12 
 d9-Androsterone + APPI 15.87 [M − 2H2O + H]+ 259.3→ 203.4 80 10 28 12 
14 Corticosterone + APPI 12.44 [M + H]+ 347.2 → 121.2 80 10 30 12 
 d8-Corticosterone + APPI 12.44 [M + H]+ 355.2 → 125.1 80 10 35 12 
*15 *Androstenediol + APPI 8.80 [M − 2H2O + H]+ 255.3→ 91.1 80 10 68 12 
 *d3-Androstenediol + APPI 8.80 [M − 2H2O + H]+ 258.3→ 91.1 80 10 61 12 
16 ** Dihydroxyprogesterone + APPI 21.70 [M + H]+ 317.3 → 123.2 80 10 32 12 
17 ** Allopregnenolone + APPI 19.83 [M − H2O + H]+ 305.5 → 135.2 80 10 28 12 
    [M − H2O + H]+ 305.5 → 283.4 80 10 22 12 
 
* androstenediol (+polarity) and estradiol (-polarity) cannot be measured in the same run as they elute 
at the same retention time but with different polarities and were difficult to separate under the 
current running conditions. 
 
** For dihydroxyprogesterone the internal standard of progesterone was used for quantitation and 
for allopregnenolone the internal standard of pregnenolone was used for quantitation as the 
respective deuterated internal standards for these 2 compounds were not available. 
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   Accuracy & Precision (%) 
 Sensitivity Recovery (%) Within-day (n=5) Between-day (n=15) 
Analytes* LOD LOQ Male Female Accuracy CV Accuracy CV 
Estradiol (E2) 1.0 pg/ml 2.5 pg/ml 81 81 103 8 98 10 
Cortisol(CRS) 0.25 ng/ml 1 ng/ml 79 83 110 11 107 12 
Corticosterone(CS) 0.1 ng/ml 0.25 ng/ml 91 88 86 9 92 10 
Testosterone(T) 10 pg/ml 25 pg/ml 92 96 108 5 100 5 
Dihydrotestosterone(DHT) 50 pg/ml 100 pg/ml 97 82 103 10 98 10 
17OH progesterone(17OHP4) 25 pg/ml 50 pg/ml 74 74 92 11 93 9 
17OH pregnenolone(17OHP5) 25 pg/ml 50 pg/ml 84 79 98 5 97 7 
3α-diol 50 pg/ml 100 pg/ml 89 97 109 8 103 7 
3b-diol 50 pg/ml 100 pg/ml 87 87 105 9 102 5 
DHEA 20 pg/ml 100 pg/ml 87 109 110 4 107 5 
Androstenedione(Adione) 12.5 pg/ml 25 pg/ml 96 91 107 6 97 7 
Progesterone (P4) 20 pg/ml 50 pg/ml 102 105 109 5 101 9 
Pregnenolone (P5) 50 pg/ml 100 pg/ml 92 104 102 9 97 8 
Androsterone 50 pg/ml 100 pg/ml 87 105 106 5 102 8 
Androstenediol (Adiol) 25 pg/ml 50 pg/ml 96 91 97 7 98 7 
Allopregnanolone(AlloP5) 50 pg/ml 100 pg/ml 81 80 96 6 93 7 
Dihydroprogesterone(DHP) 50 pg/ml 100 pg/ml 90 83 93 5 94 8 
 
* All steroids analysed in positive ionization mode except for estradiol which was analysed in negative 
mode 
LOQ is defined as the lowest concentration estimated with a CV<20%. 
LOD is defined as the lowest concentration distinguishable from background based on a signal:noise 
ratio of 3  
Recovery is the estimate of % of known spiked steroid concentration added to mouse serum that is 
measured 
Accuracy and precision are the averages of 3 QC samples (low, mid and high range) in each run  
 
  
 
 
 
 
 
 
